Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Dec. 29, 2013 | Feb. 20, 2014 | Jun. 28, 2013 | |
Document and Entity Information [Abstract] | ' | ' | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Entity Registrant Name | 'PERKINELMER INC | ' | ' |
Entity Central Index Key | '0000031791 | ' | ' |
Current Fiscal Year End Date | '--12-29 | ' | ' |
Document Period End Date | 29-Dec-13 | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 112,851,324 | ' |
Entity Well-known Seasoned Issuer | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Public Float | ' | ' | $3,604,263,522 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Revenue | ' | ' | ' |
Product revenue | $1,498,070 | $1,474,674 | $1,319,510 |
Service revenue | 668,162 | 640,531 | 598,998 |
Total revenue | 2,166,232 | 2,115,205 | 1,918,508 |
Cost of product revenue | 783,584 | 762,989 | 686,812 |
Cost of service revenue | 405,674 | 389,010 | 383,896 |
Selling, general and administrative expenses | 585,850 | 632,734 | 624,393 |
Research and development expenses | 133,023 | 132,639 | 115,821 |
Restructuring and contract termination charges, net | 33,928 | 25,137 | 13,452 |
Asset impairment | 6,731 | 74,153 | 3,006 |
Operating income from continuing operations | 217,442 | 98,543 | 91,128 |
Interest and other expense (income), net | 64,110 | 47,956 | 26,774 |
Income from continuing operations before income taxes | 153,332 | 50,587 | 64,354 |
Provision for income taxes | -14,592 | -17,854 | 63,182 |
Income from continuing operations | 167,924 | 68,441 | 1,172 |
Gain (loss) on disposition of discontinued operations before income taxes | -1,810 | 2,405 | 1,999 |
(Benefit from) provision for income taxes on discontinued operations and dispositions | -1,098 | 906 | -4,484 |
Net income from discontinued operations and dispositions | -712 | 1,499 | 6,483 |
Net income | $167,212 | $69,940 | $7,655 |
Basic earnings per share: | ' | ' | ' |
Continuing operations | $1.50 | $0.60 | $0.01 |
Discontinued operations | ($0.01) | $0.01 | $0.06 |
Net Income | $1.49 | $0.61 | $0.07 |
Diluted earnings per share: | ' | ' | ' |
Continuing operations | $1.48 | $0.60 | $0.01 |
Discontinued operations | ($0.01) | $0.01 | $0.06 |
Net income | $1.47 | $0.61 | $0.07 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Income (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Net income | $167,212 | $69,940 | $7,655 |
Other comprehensive income (loss) | ' | ' | ' |
Foreign currency translation adjustments, net of tax | 8,756 | 11,363 | 1,814 |
Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service (Cost) Credit, Net of Tax | -658 | -82 | 107 |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | 2,892 | 1,196 | 1,196 |
Unrealized (losses) gains on securities, net of tax | 8 | 30 | -59 |
Other comprehensive income (loss) | 10,998 | 12,507 | 3,058 |
Comprehensive income | $178,210 | $82,447 | $10,713 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Thousands, unless otherwise specified | ||
Current assets: | ' | ' |
Cash and cash equivalents | $173,242 | $171,444 |
Accounts receivable, net | 470,028 | 457,011 |
Inventories, net | 261,036 | 247,688 |
Other current assets | 140,532 | 95,611 |
Total current assets | 1,044,838 | 971,754 |
Property, plant and equipment, net | 185,373 | 210,516 |
Marketable securities and investments | 1,319 | 1,149 |
Intangible assets, net | 460,430 | 529,901 |
Goodwill | 2,143,120 | 2,122,788 |
Other assets, net | 111,632 | 65,654 |
Total assets | 3,946,712 | 3,901,762 |
Current liabilities: | ' | ' |
Short-term debt | 2,624 | 1,772 |
Accounts payable | 167,196 | 168,943 |
Accrued restructuring | 26,374 | 21,364 |
Accrued expenses and other current liabilities | 404,064 | 388,026 |
Current liabilities of discontinued operations | 2,538 | 995 |
Total current liabilities | 602,796 | 581,100 |
Long-term debt | 932,104 | 938,824 |
Long-term liabilities | 417,325 | 442,026 |
Total liabilities | 1,952,225 | 1,961,950 |
Commitments and contingencies (see Note 18) | ' | ' |
Stockholders' equity: | ' | ' |
Preferred stock-$1 par value per share, authorized 1,000,000 shares; none issued or outstanding | 0 | 0 |
Common stock-$1 par value per share, authorized 300,000,000 shares; issued and outstanding 112,626,000 shares and 115,036,000 shares at December 29, 2013 and December 30, 2012, respectively | 112,626 | 115,036 |
Capital in excess of par value | 119,906 | 209,610 |
Retained earnings | 1,684,364 | 1,548,573 |
Accumulated other comprehensive income | 77,591 | 66,593 |
Total stockholders' equity | 1,994,487 | 1,939,812 |
Total liabilities and stockholders' equity | $3,946,712 | $3,901,762 |
Consolidated_Balance_Sheet_Par
Consolidated Balance Sheet Parenthetical (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
Balance Sheet Parenthetical [Abstract] | ' | ' |
Preferred stock, par value | $1 | $1 |
Preferred stock, authorized | 1,000,000 | 1,000,000 |
Preferred stock, issued | 0 | 0 |
Preferred stock, outstanding | 0 | 0 |
Common stock, par value | $1 | $1 |
Common stock, authorized | 300,000,000 | 300,000,000 |
Common stock, issued | 112,626,000 | 115,036,000 |
Common stock, outstanding | 112,626,000 | 115,036,000 |
Consolidated_Statements_of_Sto
Consolidated Statements of Stockholders' Equity (USD $) | Total | Common Stock Amount [Member] | Capital In Excess of Par Value [Member] | Retained Earnings [Member] | Accumulated Other Comprehensive Income (Loss) [Member] |
In Thousands | |||||
Beginning Balance at Jan. 02, 2011 | $1,925,391 | $115,715 | $224,013 | $1,534,635 | $51,028 |
Net income (as adjusted) | 7,655 | ' | ' | 7,655 | ' |
Other comprehensive income (loss) (as adjusted) | 3,058 | ' | ' | ' | 3,058 |
Dividends | -31,607 | ' | ' | -31,607 | ' |
Exercise of employee stock options and related income tax benefits | 32,334 | 1,138 | 31,196 | ' | ' |
Issuance of common stock for employee benefit plans | 2,197 | 103 | 2,094 | ' | ' |
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 110,005 | 4,084 | 105,921 | ' | ' |
Issuance of common stock for long-term incentive program | 8,657 | 285 | 8,372 | ' | ' |
Stock compensation | 4,536 | 0 | 4,536 | 0 | 0 |
Ending Balance at Jan. 01, 2012 | 1,842,216 | 113,157 | 164,290 | 1,510,683 | 54,086 |
Net income (as adjusted) | 69,940 | ' | ' | 69,940 | ' |
Other comprehensive income (loss) (as adjusted) | 12,507 | ' | ' | ' | 12,507 |
Dividends | -32,050 | ' | ' | -32,050 | 0 |
Exercise of employee stock options and related income tax benefits | 34,006 | 1,611 | 32,395 | ' | ' |
Issuance of common stock for employee benefit plans | 1,323 | 54 | 1,269 | ' | ' |
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 2,104 | 82 | 2,022 | ' | ' |
Issuance of common stock for long-term incentive program | 8,955 | 296 | 8,659 | ' | ' |
Stock compensation | 5,019 | 0 | 5,019 | 0 | 0 |
Ending Balance at Dec. 30, 2012 | 1,939,812 | 115,036 | 209,610 | 1,548,573 | 66,593 |
Net income (as adjusted) | 167,212 | ' | ' | 167,212 | ' |
Other comprehensive income (loss) (as adjusted) | 10,998 | ' | ' | ' | 10,998 |
Dividends | -31,421 | ' | ' | -31,421 | ' |
Exercise of employee stock options and related income tax benefits | 19,842 | 947 | 18,895 | ' | ' |
Issuance of common stock for employee benefit plans | 2,732 | 90 | 2,642 | ' | ' |
Cost of Repurchased Common Shares, Repurchase Plan and Amount for Statutory Tax Withholding Obligations | 127,398 | 3,728 | 123,670 | ' | ' |
Issuance of common stock for long-term incentive program | 8,257 | 281 | 7,976 | ' | ' |
Stock compensation | 4,453 | 0 | 4,453 | 0 | 0 |
Ending Balance at Dec. 29, 2013 | $1,994,487 | $112,626 | $119,906 | $1,684,364 | $77,591 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Operating activities: | ' | ' | ' |
Net income | $167,212 | $69,940 | $7,655 |
Add: net income from discontinued operations and dispositions | 712 | -1,499 | -6,483 |
Income from continuing operations | 167,924 | 68,441 | 1,172 |
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations: | ' | ' | ' |
Restructuring and contract termination charges, net | 33,928 | 25,137 | 13,452 |
Depreciation and amortization | 128,471 | 126,865 | 110,921 |
Stock-based compensation | 14,053 | 21,031 | 15,482 |
Pension and other postretirement expense | -18,176 | 35,336 | 74,974 |
Deferred taxes | -29,907 | -65,551 | -289 |
Contingencies and prior year tax matters | -34,455 | 1,382 | 5,482 |
Amortization of deferred debt issuance costs, interest rate hedge and accretion of discounts | 6,502 | 3,517 | 5,651 |
Losses (gains) on step acquisitions and dispositions, net | -1,566 | 0 | 113 |
Amortization of acquired inventory revaluation | 203 | 5,214 | 4,092 |
Asset impairment | 6,731 | 74,153 | 3,006 |
Changes in assets and liabilities which (used) provided cash, excluding effects from companies purchased and divested: | ' | ' | ' |
Accounts receivable, net | -14,440 | -44,626 | -20,597 |
Inventories, net | -13,851 | -8,213 | -2,200 |
Accounts payable | -1,800 | -7,876 | -1,776 |
Excess tax benefit from exercise of common stock options | 0 | -1,767 | -9,321 |
Accrued expenses and other | -85,564 | -79,468 | 33,841 |
Net cash provided by operating activities of continuing operations | 158,053 | 153,575 | 234,003 |
Net cash (used in) provided by operating activities of discontinued operations | 538 | -1,405 | -9,129 |
Net cash provided by operating activities | 158,591 | 152,170 | 224,874 |
Investing activities: | ' | ' | ' |
Capital expenditures | -38,991 | -42,408 | -30,592 |
Proceeds from dispositions of property, plant and equipment, net | 52,202 | 0 | 456 |
Changes in restricted cash balances | 0 | 487 | 1,250 |
Proceeds from surrender of life insurance policies | 783 | 0 | 814 |
Payments for acquisitions and investments, net of cash and cash equivalents acquired | -15,699 | -40,858 | -914,041 |
Net cash used in investing activities of continuing operations | -1,705 | -82,779 | -942,113 |
Net cash provided by (used in) investing activities of discontinued operations | 494 | 2,470 | 32,252 |
Net cash (used in) provided by investing activities | -1,211 | -80,309 | -909,861 |
Financing activities: | ' | ' | ' |
Payments on revolving credit facility | -538,000 | -435,850 | -763,000 |
Proceeds from revolving credit facility | 677,000 | 395,000 | 787,000 |
Early Repayment of Senior Debt | -150,000 | 0 | 0 |
Payments of Debt Extinguishment Costs | -11,119 | 0 | 0 |
Proceeds from sale of senior debt | 0 | 0 | 496,860 |
Payments of debt issuance costs | 0 | -416 | -10,531 |
Payments on other credit facilities | 5,281 | 5,274 | -2,303 |
Payments for (Proceeds from) Hedge, Financing Activities | 1,363 | 4,050 | 0 |
Payments for acquisition-related contingent consideration | 0 | -12,459 | -137 |
Excess tax benefit from exercise of common stock options | 0 | 1,767 | 9,321 |
Proceeds from issuance of common stock under stock plans | 20,313 | 32,478 | 23,736 |
Purchases of common stock | -127,398 | -2,104 | -110,005 |
Dividends paid | -31,600 | -31,903 | -31,829 |
Net cash provided by (used in) financing activities of continuing operations | -154,160 | -44,163 | 399,112 |
Net cash used in financing activities of discontinued operations | 0 | 0 | -1,908 |
Net cash provided by (used in) financing activities | -154,160 | -44,163 | 397,204 |
Effect of exchange rate changes on cash and cash equivalents | -1,422 | 1,404 | 10,039 |
Net (decrease) increase in cash and cash equivalents | 1,798 | 29,102 | -277,744 |
Cash and cash equivalents at beginning of year | 171,444 | 142,342 | 420,086 |
Cash and cash equivalents at end of year | 173,242 | 171,444 | 142,342 |
Supplemental disclosures of cash flow information | ' | ' | ' |
Interest | 39,904 | 40,447 | 12,184 |
Income taxes | $36,675 | $53,281 | $41,644 |
Nature_of_Operations_and_Accou
Nature of Operations and Accounting Policies | 12 Months Ended |
Dec. 29, 2013 | |
Accounting Policies [Abstract] | ' |
Nature of Operations and Accounting Policies | ' |
Nature of Operations and Accounting Policies | |
Nature of Operations: PerkinElmer, Inc. is a leading provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its advanced technologies, solutions and services, critical issues are addressed that help to improve the health and safety of people and their environment. The results are reported within two reporting segments: Human Health and Environmental Health. | |
The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. | |
The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. | |
The Company realigned its organization at the beginning of fiscal year 2013. The Company's Informatics business, as well as its field service on products previously sold by the Company's former Bio-discovery business, were moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2013 reflect this new alignment of the Company's operating segments. Financial information relating to fiscal years 2012 and 2011 has been retrospectively adjusted to reflect the changes to the operating segments. | |
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. Each of the fiscal years ended December 29, 2013, December 30, 2012 and January 1, 2012 included 52 weeks. The fiscal year ending December 28, 2014 will also include 52 weeks. | |
The Company has evaluated subsequent events from December 29, 2013 through the date of the issuance of these consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. | |
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. | |
Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. | |
In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, such as cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. | |
Revenue from software licenses and services was 5% of the Company's total revenue for fiscal year 2013, 3% of the Company's total revenue for fiscal year 2012, and 2% of the Company's total revenue for fiscal year 2011. The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved. | |
The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. | |
The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers. | |
Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service and storage contracts are recognized over the contract period. | |
Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. | |
Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. | |
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. | |
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. | |
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details. | |
Property, Plant and Equipment: The Company depreciates plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. | |
Asset Retirement Obligations: The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset-retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as an operating expense. The amounts recorded in the consolidated financial statements are not material to any year presented. | |
Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds. | |
Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net, and were not material. | |
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. All changes that do not qualify as measurement period adjustments are included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. | |
Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of certain trademarks and trade names that are not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. | |
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details. | |
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected forfeiture rate, life of the option and the expected price volatility of the underlying stock. The Company estimates the expected forfeiture and expected life assumptions based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below. | |
Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. | |
Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. | |
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. | |
Research and Development: Research and development costs are expensed as incurred. The fair value of acquired in-process research and development ("IPR&D") costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. | |
Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the alignment with the Company’s growth strategy, the impact of acquisitions, divestitures and the integration of its business units. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. | |
Comprehensive Income: In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending December 29, 2013, December 30, 2012 and January 1, 2012. See Note 19 for additional details. | |
Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. | |
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. | |
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. As of December 29, 2013, the Company had no outstanding cash flow hedges, and as of December 30, 2012, the Company had two outstanding cash flow hedges with Euro denominated notional amounts of €50.0 million. The Company also has entered into foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into net earnings on the consolidated financial statements. | |
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective dates. The Company believes that the impact of recently issued pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows or do not apply to the Company's operations. |
Business_Combinations_and_Asse
Business Combinations and Asset Purchases | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Business Combinations [Abstract] | ' | |||||||
Business Combinations and Asset Purchases | ' | |||||||
Business Combinations | ||||||||
Acquisitions in fiscal year 2013 | ||||||||
The Company completed the acquisition of four businesses for total consideration of $11.4 million, in cash. As of the closing dates, the Company potentially had to pay additional contingent consideration for the four acquired businesses of up to $2.2 million, which at closing had an estimated fair value of $1.1 million. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Company's operations from the acquisition dates. As of December 29, 2013, the purchase accounting allocations related to these acquisitions were preliminary. | ||||||||
Acquisition in fiscal year 2012 | ||||||||
Acquisition of Haoyuan Biotech Co., Ltd. In November 2012, the Company acquired all outstanding stock of Shanghai Haoyuan Biotech Co., Ltd. ("Haoyuan"). Haoyuan is a provider of nucleic acid-based blood screening solutions for the blood banking and clinical diagnostics markets. The Company expects this acquisition to extend the Company's capabilities into nucleic acid blood screening, as well as deepen its position in the growing molecular clinical diagnostics market in China. The Company paid the shareholders of Haoyuan $38.0 million in cash for the stock of Haoyuan. The Company recorded a receivable of $2.7 million from the shareholders of Haoyuan as a reduction of purchase price for the settlement of certain contingencies. This receivable was collected in fiscal year 2013. As of the closing date, the Company potentially had to pay the shareholders additional contingent consideration of up to $30.0 million, which at closing had an estimated fair value of $1.9 million. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date. | ||||||||
The total purchase price has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: | ||||||||
Haoyuan | ||||||||
(In thousands) | ||||||||
Fair value of business combination: | ||||||||
Cash payments | $ | 38,000 | ||||||
Contingent consideration | 1,900 | |||||||
Working capital and other adjustments | (2,729 | ) | ||||||
Less: cash acquired | (175 | ) | ||||||
Total | $ | 36,996 | ||||||
Identifiable assets acquired and liabilities assumed: | ||||||||
Current assets | $ | 2,389 | ||||||
Property, plant and equipment | 2,906 | |||||||
Identifiable intangible assets: | ||||||||
Core technology | 17,700 | |||||||
Trade names | 400 | |||||||
IPR&D | 300 | |||||||
Goodwill | 19,682 | |||||||
Deferred taxes | (2,656 | ) | ||||||
Liabilities assumed | (3,725 | ) | ||||||
Total | $ | 36,996 | ||||||
The weighted average amortization periods of identifiable definite-lived intangible assets for core technology and trade names were 8 years. | ||||||||
Acquisitions in fiscal year 2011 | ||||||||
Acquisition of Caliper Life Sciences, Inc. In November 2011, the Company acquired all of the outstanding stock of Caliper Life Sciences, Inc. ("Caliper"). Caliper is a provider of imaging and detection solutions for life sciences research, diagnostics and environmental markets. Caliper develops and sells integrated systems, consisting of instruments, software, reagents, laboratory automation tools, and assay development and discovery services, primarily to pharmaceutical, biotechnology, and diagnostics companies, and government and other not-for-profit research institutions. The Company paid the shareholders of Caliper $646.3 million in cash for the stock of Caliper. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Human Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, licenses, customer relationships, and trade names, acquired as part of this acquisitions had weighted average amortization periods of 5 years for core technology, 6 years for licenses, 7 years for customer relationships, and 7 years for trade names. | ||||||||
In addition to the Caliper acquisition, the Company completed the acquisition of seven businesses in fiscal year 2011 for total consideration of $333.6 million, in cash. As of the closing dates, the Company potentially had to pay additional contingent consideration for the seven acquired businesses of up to $50.8 million, which at closing had an estimated fair value of $20.1 million. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, of which $4.7 million is tax deductible. The Company reported the operations for these acquisitions within the results of the operations from the acquisition dates. Identifiable definite-lived intangible assets, such as customer relationships, core technology, IPR&D, licenses, and trade names, acquired as part of these acquisitions had weighted average amortization periods between 7 years and 11 years. | ||||||||
The total purchase price for the acquisitions in fiscal year 2011 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: | ||||||||
Caliper | Other | |||||||
(In thousands) | ||||||||
Fair value of business combination: | ||||||||
Cash payments | $ | 646,317 | $ | 333,581 | ||||
Contingent consideration | — | 20,124 | ||||||
Working capital and other adjustments | — | 32 | ||||||
Less: cash acquired | (43,576 | ) | (26,923 | ) | ||||
Total | $ | 602,741 | $ | 326,814 | ||||
Identifiable assets acquired and liabilities assumed: | ||||||||
Current assets | $ | 55,027 | $ | 16,857 | ||||
Property, plant and equipment | 14,580 | 1,661 | ||||||
Identifiable intangible assets: | ||||||||
Core technology | 52,000 | 35,724 | ||||||
Trade names | 14,200 | 3,374 | ||||||
Licenses | 18,000 | 3,000 | ||||||
Customer relationships | 93,000 | 96,910 | ||||||
IPR&D | — | 3,839 | ||||||
Goodwill | 353,103 | 236,573 | ||||||
Deferred taxes | 52,472 | (45,017 | ) | |||||
Deferred revenue | (6,554 | ) | (10,496 | ) | ||||
Liabilities assumed | (43,087 | ) | (15,611 | ) | ||||
Total | $ | 602,741 | $ | 326,814 | ||||
Caliper's revenue and pre-tax loss from continuing operations for the period from the acquisition date to January 1, 2012 were $29.3 million and $3.0 million, respectively. The following unaudited pro forma information presents the combined financial results for the Company and Caliper as if the acquisition of Caliper had been completed at the beginning of fiscal year 2011: | ||||||||
January 1, | ||||||||
2012 | ||||||||
(In thousands) | ||||||||
Pro Forma Statement of Operations Information (Unaudited): | ||||||||
Revenue | $ | 2,042,730 | ||||||
Loss from continuing operations | (25,854 | ) | ||||||
Basic loss per share: | ||||||||
Continuing operations | $ | (0.23 | ) | |||||
Diluted loss per share: | ||||||||
Continuing operations | $ | (0.23 | ) | |||||
The unaudited pro forma information for fiscal year 2011 has been calculated after applying the Company's accounting policies and the impact of acquisition date fair value adjustments. The fiscal year 2011 unaudited pro forma loss from continuing operations was adjusted to exclude approximately $18.1 million of acquisition-related transaction costs. In addition, the fiscal year 2011 unaudited pro forma loss from continuing operations was adjusted to exclude nonrecurring expenses related to the fair value adjustments associated with the acquisition of Caliper that were recorded by the Company related to the completion of this acquisition. The pro forma condensed consolidated financial results have been prepared for comparative purposes only and include certain adjustments, such as fair value adjustment to inventory and deferred revenue, increased interest expense on debt obtained to finance the transaction, and increased amortization for the fair value of acquired intangible assets. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of fiscal year 2011, or of future results of the consolidated entities. | ||||||||
The Company does not consider the acquisitions completed during fiscal years 2013, 2012, and 2011, with the exception of the Caliper acquisition, to be material to its consolidated results of operations; therefore, the Company is only presenting pro forma financial information of operations for the Caliper acquisition. The aggregate revenue and results of operations for the acquisitions completed during fiscal years 2013 and 2012 for the period from their respective acquisition dates to December 29, 2013 and December 30, 2012 were minimal. The aggregate revenue for the acquisitions, with the exception of Caliper, completed during fiscal year 2011 for the period from their respective acquisition dates to January 1, 2012 was $32.4 million and the results of operations were minimal. The Company has also determined that the presentation of the results of operations for each of those acquisitions, from the date of acquisition, is impracticable due to the integration of the operations upon acquisition. | ||||||||
As of December 29, 2013 the purchase price allocations for acquisitions completed in fiscal years 2012 and 2011 were final. The preliminary allocation of the purchase price for acquisitions completed in fiscal year 2013 were based upon an initial valuation. The Company's estimates and assumptions underlying the initial valuation are subject to change within the measurement period, which is up to one year from the acquisition date. The primary areas of the preliminary purchase price allocation that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition date during the measurement period. During the measurement period, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of those assets and liabilities as of that date. Adjustments to the preliminary allocation of the purchase price during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocation of the purchase price made during the measurement period would be as if the adjustments had been completed on the acquisition date. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement period are included in current period earnings. | ||||||||
Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $31.3 million as of December 29, 2013. As of December 29, 2013, the Company has recorded contingent consideration obligations relating to its acquisitions of Dexela Limited, Haoyuan and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $4.9 million. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets, or the recognition of additional consideration which would be expensed. | ||||||||
In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of deferred revenue assumed with its acquisitions. The estimated fair value of deferred revenue is determined by the legal performance obligation at the date of acquisition, and is generally based on the nature of the activities to be performed and the related costs to be incurred after the acquisition date. The fair value of an assumed liability related to deferred revenue is estimated based on the current market cost of fulfilling the obligation, plus a normal profit margin thereon. The estimated costs to fulfill the deferred revenue are based on the historical direct costs related to providing the services. The Company does not include any costs associated with selling effort, research and development, or the related fulfillment margins on these costs. In most acquisitions, profit associated with selling effort is excluded because the acquired businesses would have concluded the selling effort on the support contracts prior to the acquisition date. The estimated research and development costs are not included in the fair value determination, as these costs are not deemed to represent a legal obligation at the time of acquisition. The sum of the costs and operating income approximates, in theory, the amount that the Company would be required to pay a third-party to assume the obligation. | ||||||||
Total transaction costs related to acquisition activities for fiscal years 2013, 2012, and 2011 were $0.1 million, $1.2 million and $10.7 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's consolidated statements of operations. |
Discontinued_Operations
Discontinued Operations | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | ' | |||||||||||
Discontinued Operations | ' | |||||||||||
Discontinued Operations | ||||||||||||
As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining liabilities of these businesses have been presented separately, and are reflected within liabilities from discontinued operations in the accompanying consolidated balance sheets as of December 29, 2013 and December 30, 2012. | ||||||||||||
The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Gain (loss) on disposition of Photoflash business | $ | 493 | $ | 2,459 | $ | (134 | ) | |||||
Loss on disposition of Technical Services business | (2,100 | ) | — | — | ||||||||
Net (loss) gain on disposition of other discontinued operations | (203 | ) | (54 | ) | 2,133 | |||||||
Net (loss) gain on disposition of discontinued operations before income taxes | $ | (1,810 | ) | $ | 2,405 | $ | 1,999 | |||||
In June 2010, the Company sold its Photoflash business, which was included in the Company's Environmental Health segment, for $13.5 million, including an adjustment for net working capital, plus potential additional contingent consideration. The Company recognized a pre-tax gain of $0.5 million in fiscal year 2013 and a pre-tax gain of $2.5 million in fiscal year 2012 for contingent consideration related to this sale. | ||||||||||||
In August 1999, the Company sold the assets of its Technical Service business for approximately $250.0 million in cash and the assumption by the buyer of certain liabilities of the Technical Services business. During fiscal year 2013, the Company recorded a pre-tax loss of $2.1 million for a contingency related to this business. | ||||||||||||
During fiscal years 2013, 2012, and 2011, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized a pre-tax gain of $2.1 million in fiscal year 2011. The fiscal year 2011 pre-tax gain included a $4.0 million gain for contingent consideration related to the sale of the Company's semiconductor business in fiscal year 2006, which was partially offset by a pre-tax loss of $1.8 million related to updating the net working capital adjustment associated with the sale of the Company's Illumination and Detection Solutions ("IDS") business in fiscal year 2010. | ||||||||||||
The Company recognized a tax benefit of $1.1 million on discontinued operations in fiscal year 2013, a tax provision of $0.9 million on discontinued operations in fiscal year 2012 and a tax benefit of $4.5 million in fiscal year 2011 on discontinued operations. The recognition of $4.5 million income tax benefit in fiscal year 2011 was primarily the result of a change in estimate related to the federal income tax liability associated with the repatriation of the unremitted earnings of the IDS and Photoflash businesses, as further described in Note 6, below, partially offset by the tax provision on the contingent consideration received in fiscal year 2011 related to the sale of the Company's semiconductor business in fiscal year 2006. |
Restructuring_and_Contract_Ter
Restructuring and Contract Termination Charges, Net | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||
Restructuring and Contract Termination Charges, Net | ' | |||||||||||
Restructuring and Contract Termination Charges, Net | ||||||||||||
The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with the Company’s growth strategy and the integration of its business units. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges, and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges and are included as a component of operating expenses from continuing operations. | ||||||||||||
The restructuring plans for the fourth and third quarters of fiscal year 2013 were principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions. The restructuring plan for the first quarter of fiscal year 2013 was principally intended to focus resources on higher growth end markets. The restructuring plan for the fourth quarter of fiscal year 2012 was principally intended to shift resources to higher growth geographic regions and end markets. The restructuring plan for the third quarter of fiscal year 2012 was principally intended to shift certain of the Company's operations into a newly established shared service center. The restructuring plans for the first and second quarters of fiscal year 2012 were principally intended to realign operations, research and development resources and production resources as a result of previous acquisitions. | ||||||||||||
A description of the restructuring plans and the activity recorded are as follows: | ||||||||||||
Q4 2013 Restructuring Plan | ||||||||||||
During the fourth quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q4 2013 Plan”). As a result of the Q4 2013 Plan, the Company recognized a $8.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $3.0 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2013 Plan, the Company reduced headcount by 74 employees. All employees were notified of termination under the Q4 2013 Plan by December 29, 2013. | ||||||||||||
The following table summarizes the Q4 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 3,912 | $ | 7,271 | $ | 11,183 | ||||||
Amounts paid and foreign currency translation | (1,924 | ) | (417 | ) | (2,341 | ) | ||||||
Balance at December 29, 2013 | $ | 1,988 | $ | 6,854 | $ | 8,842 | ||||||
The Company anticipates that the remaining severance payments of $2.0 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $6.9 million, net of estimated sublease income, for the closure of the excess facility space will be paid through fiscal year 2019, in accordance with the terms of the applicable leases. | ||||||||||||
Q3 2013 Restructuring Plan | ||||||||||||
During the third quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q3 2013 Plan”). As a result of the Q3 2013 Plan, the Company recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, the Company reduced headcount by 30 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013. | ||||||||||||
The following table summarizes the Q3 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 394 | $ | 138 | $ | 532 | ||||||
Amounts paid and foreign currency translation | (257 | ) | (138 | ) | (395 | ) | ||||||
Balance at December 29, 2013 | $ | 137 | $ | — | $ | 137 | ||||||
The Company anticipates that the remaining severance payments of $0.1 million for workforce reductions will be completed by the end of the second quarter of fiscal year 2014. The closure of the facility space will not require any additional payments. | ||||||||||||
Q2 2013 Restructuring Plan | ||||||||||||
During the second quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2013 Plan”). As a result of the Q2 2013 Plan, the Company initially recognized a $9.9 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space, and recognized a $8.8 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. Subsequent to the initial charge, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for services that were provided for one-time benefits in which the employee was required to render service beyond the legal notification period. As part of the Q2 2013 Plan, the Company reduced headcount by 265 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013. | ||||||||||||
The following table summarizes the Q2 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 18,746 | $ | 572 | $ | 19,318 | ||||||
Amounts paid and foreign currency translation | (5,996 | ) | (572 | ) | (6,568 | ) | ||||||
Balance at December 29, 2013 | $ | 12,750 | $ | — | $ | 12,750 | ||||||
The Company anticipates that the remaining severance payments of $12.8 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014. The closure of the facility space will not require any additional payments. | ||||||||||||
Q1 2013 Restructuring Plan | ||||||||||||
During the first quarter of fiscal year 2013, the Company’s management approved a plan to focus resources on higher growth end markets (the “Q1 2013 Plan”). As a result of the Q1 2013 Plan, the Company recognized a $2.3 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q1 2013 Plan, the Company reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013. | ||||||||||||
The following table summarizes the Q1 2013 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 2,585 | ||||||||||
Amounts paid and foreign currency translation | (2,377 | ) | ||||||||||
Balance at December 29, 2013 | $ | 208 | ||||||||||
The Company anticipates that the remaining severance payments of $0.2 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. | ||||||||||||
Q4 2012 Restructuring Plan | ||||||||||||
During the fourth quarter of fiscal year 2012, the Company’s management approved a plan to shift resources to higher growth geographic regions and end markets (the “Q4 2012 Plan”). As a result of the Q4 2012 Plan, the Company recognized a $0.6 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $2.4 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2012 Plan, the Company reduced headcount by 54 employees. All employees were notified of termination under the Q4 2012 Plan by December 30, 2012. | ||||||||||||
The following table summarizes the Q4 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 2,936 | ||||||||||
Amounts paid and foreign currency translation | (254 | ) | ||||||||||
Balance at December 30, 2012 | 2,682 | |||||||||||
Amounts paid and foreign currency translation | (2,089 | ) | ||||||||||
Balance at December 29, 2013 | $ | 593 | ||||||||||
The Company anticipates that the remaining severance payments of $0.6 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2014. | ||||||||||||
Q3 2012 Restructuring Plan | ||||||||||||
During the third quarter of fiscal year 2012, the Company’s management approved a plan to shift certain of the Company's operations into a newly established shared service center (the “Q3 2012 Plan”). As a result of the Q3 2012 Plan, and during fiscal year 2012, the Company recognized $3.9 million pre-tax restructuring charges in each of the Human Health and Environmental Health segments related to a workforce reduction from reorganization activities. During fiscal year 2013, the Company recorded a pre-tax restructuring reversal of $0.3 million in each of the Human Health and Environmental Health segments due to lower than expected costs associated with remaining severance payments. As part of the Q3 2012 Plan, the Company reduced headcount by 66 employees. All employees were notified of termination under the Q3 2012 Plan by September 30, 2012. | ||||||||||||
The following table summarizes the Q3 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 7,446 | ||||||||||
Change in estimate | 326 | |||||||||||
Amounts paid and foreign currency translation | (219 | ) | ||||||||||
Balance at December 30, 2012 | 7,553 | |||||||||||
Change in estimate | (524 | ) | ||||||||||
Amounts paid and foreign currency translation | (3,271 | ) | ||||||||||
Balance at December 29, 2013 | $ | 3,758 | ||||||||||
The Company anticipates that the remaining severance payments of $3.8 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014. | ||||||||||||
Q2 2012 Restructuring Plan | ||||||||||||
During the second quarter of fiscal year 2012, the Company’s management approved a plan to realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2012 Plan”). As a result of the Q2 2012 Plan, and during fiscal year 2012, the Company recognized a $7.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and recognized a $0.2 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. During fiscal year 2013, the Company recorded an additional $2.1 million pre-tax restructuring charge in the Human Health segment for services that were provided for one-time benefits in which the employee was required to render service beyond the legal notification period. In addition during fiscal year 2013, the Company recorded a pre-tax restructuring reversal of $0.3 million due to lower than expected costs associated with remaining severance payments. The Company expects to recognize an additional $0.1 million of incremental restructuring expense in future periods as services are provided for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits. This expense will be recognized ratably over the required service period. As part of the Q2 2012 Plan, the Company will reduce headcount by 203 employees. All employees were notified of termination under the Q2 2012 Plan by July 1, 2012. | ||||||||||||
The following table summarizes the Q2 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 7,422 | ||||||||||
Amounts paid and foreign currency translation | (2,836 | ) | ||||||||||
Balance at December 30, 2012 | 4,586 | |||||||||||
Provision | 2,115 | |||||||||||
Change in estimate | (294 | ) | ||||||||||
Amounts paid and foreign currency translation | (5,072 | ) | ||||||||||
Balance at December 29, 2013 | $ | 1,335 | ||||||||||
The Company anticipates that the remaining severance payments of $1.3 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. | ||||||||||||
Q1 2012 Restructuring Plan | ||||||||||||
During the first quarter of fiscal year 2012, the Company’s management approved a plan to realign operations and production resources as a result of previous acquisitions (the “Q1 2012 Plan”). As a result of the Q1 2012 Plan, and during fiscal year 2012, the Company recognized a $5.4 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $1.0 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. During fiscal year 2013, the Company recorded a pre-tax restructuring reversal of $0.4 million in the Human Health segment and a pre-tax restructuring reversal of $0.1 million in the Environmental Health segment due to lower than expected costs associated with remaining severance payments. As part of the Q1 2012 Plan, the Company reduced headcount by 112 employees. All employees were notified of termination and the Company completed all actions related to the closure of excess facility space under the Q1 2012 Plan by April 1, 2012. | ||||||||||||
The following table summarizes the Q1 2012 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 6,315 | $ | 79 | $ | 6,394 | ||||||
Amounts paid and foreign currency translation | (5,034 | ) | (79 | ) | (5,113 | ) | ||||||
Balance at December 30, 2012 | 1,281 | — | 1,281 | |||||||||
Change in estimate | (537 | ) | — | (537 | ) | |||||||
Amounts paid and foreign currency translation | (619 | ) | — | (619 | ) | |||||||
Balance at December 29, 2013 | $ | 125 | $ | — | $ | 125 | ||||||
The Company anticipates that the remaining severance payments of $0.1 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. The closure of the excess facility space will not require any additional payments. | ||||||||||||
Previous Restructuring and Integration Plans | ||||||||||||
The principal actions of the restructuring and integration plans from fiscal years 2001 through 2011 were workforce reductions related to the integration of the Company’s businesses in order to reduce costs and achieve operational efficiencies as well as workforce reductions in both the Human Health and Environmental Health segments by shifting resources into geographic regions and end markets that are more consistent with the Company’s growth strategy. During fiscal year 2013, the Company paid $2.4 million related to these plans and recorded a reversal of $1.1 million primarily related to lower than expected costs associated with workforce reductions within both the Human Health and the Environmental Health segments. As of December 29, 2013, the Company had $7.5 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. The Company expects to make payments for these leases, the terms of which vary in length, through fiscal year 2022. | ||||||||||||
Contract Termination Charges | ||||||||||||
The Company has terminated various contractual commitments in connection with certain disposal activities and have recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded an additional pre-tax charge of $0.7 million in fiscal year 2013, a pre-tax charge of $1.5 million in fiscal year 2012 and a pre-tax charge of $2.0 million in fiscal year 2011, primarily as a result of terminating various contractual commitments in the Environmental Health segment. The Company made payments for these obligations of $1.0 million during fiscal year 2013, $2.9 million during fiscal year 2012, and $0.4 million during fiscal year 2011. The remaining balance of these accruals as of December 29, 2013 was $0.3 million. |
Interest_and_Other_Expense_Inc
Interest and Other Expense (Income), Net | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Other Income and Expenses [Abstract] | ' | |||||||||||
Interest and Other Expense (Income), Net | ' | |||||||||||
Interest and Other Expense, Net | ||||||||||||
Interest and other expense, net, consisted of the following for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Interest income | $ | (650 | ) | $ | (747 | ) | $ | (1,884 | ) | |||
Interest expense | 49,924 | 45,787 | 24,783 | |||||||||
Other expense, net | 14,836 | 2,916 | 3,875 | |||||||||
Total interest and other expense, net | $ | 64,110 | $ | 47,956 | $ | 26,774 | ||||||
In December 2013, the Company redeemed all of its 6% senior unsecured notes due in 2015 (the “2015 Notes”) for a redemption price that included the outstanding principal amount of $150.0 million and a prepayment premium of $11.1 million, which is included in other expense, net. The transaction also resulted in the write-off of $2.8 million for the remaining unamortized derivative losses for previously settled cash flow hedges and the write-off of $0.2 million for the remaining deferred debt issuance costs. Both of these amounts are included in interest expense. |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Income Taxes | ' | |||||||||||
Income Taxes | ||||||||||||
The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position. | ||||||||||||
The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Unrecognized tax benefits, beginning of period | $ | 58,110 | $ | 51,740 | $ | 39,226 | ||||||
Gross increases—tax positions in prior period | 325 | 10,653 | 2,753 | |||||||||
Gross decreases—tax positions in prior period | (10,539 | ) | (4,665 | ) | (4,729 | ) | ||||||
Gross increases—current-period tax positions | 2,222 | 3,343 | 2,451 | |||||||||
Gross increases—related to acquisitions | — | — | 14,412 | |||||||||
Settlements | (3,643 | ) | (2,822 | ) | (430 | ) | ||||||
Lapse of statute of limitations | (6,495 | ) | (595 | ) | (2,224 | ) | ||||||
Foreign currency translation adjustments | (570 | ) | 456 | 281 | ||||||||
Unrecognized tax benefits, end of period | $ | 39,410 | $ | 58,110 | $ | 51,740 | ||||||
The Company classifies interest and penalties as a component of income tax expense. At December 29, 2013, the Company had accrued interest and penalties of approximately $4.0 million and $0.4 million, respectively. During fiscal year 2013, the Company recognized a benefit of approximately $3.9 million for interest and a benefit of $3.7 million for penalties in its total tax provision primarily due to settlements and statues that had lapsed. During fiscal year 2012, the Company recognized a charge of approximately $1.1 million for interest and a benefit of $2.2 million for penalties in its total tax provision. During fiscal year 2011, the Company recognized interest and penalties of approximately $0.5 million and zero, respectively, in its total tax provision. At December 29, 2013, the Company had gross tax effected unrecognized tax benefits of $39.4 million, of which $33.4 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations. | ||||||||||||
The Company believes that it is reasonably possible that approximately $4.0 million of its uncertain tax positions at December 29, 2013, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statues of limitations and potential settlements. Various tax years after 2006 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction. | ||||||||||||
During fiscal year 2013, the Company recorded net discrete income tax benefits of $24.0 million primarily for reversals of uncertain tax position reserves and resolution of other tax matters. | ||||||||||||
The components of (loss) income from continuing operations before income taxes were as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
U.S. | $ | (82,253 | ) | $ | (118,546 | ) | $ | (145,298 | ) | |||
Non-U.S. | 235,585 | 169,133 | 209,652 | |||||||||
Total | $ | 153,332 | $ | 50,587 | $ | 64,354 | ||||||
On a U. S. income tax basis, the Company has reported significant taxable income over the three year period ended December 29, 2013. The Company has utilized tax attributes to minimize cash taxes paid on that taxable income. | ||||||||||||
The components of the provision for (benefit from) income taxes for continuing operations were as follows: | ||||||||||||
Current Expense (Benefit) | Deferred Expense | Total | ||||||||||
(Benefit) | ||||||||||||
(In thousands) | ||||||||||||
Fiscal year ended December 29, 2013 | ||||||||||||
Federal | $ | (1,292 | ) | $ | (29,961 | ) | $ | (31,253 | ) | |||
State | 1,582 | (2,147 | ) | (565 | ) | |||||||
Non-U.S. | 15,025 | 2,201 | 17,226 | |||||||||
Total | $ | 15,315 | $ | (29,907 | ) | $ | (14,592 | ) | ||||
Fiscal year ended December 30, 2012 | ||||||||||||
Federal | $ | (5,234 | ) | $ | (34,920 | ) | $ | (40,154 | ) | |||
State | 2,617 | (2,794 | ) | (177 | ) | |||||||
Non-U.S. | 50,314 | (27,837 | ) | 22,477 | ||||||||
Total | $ | 47,697 | $ | (65,551 | ) | $ | (17,854 | ) | ||||
Fiscal year ended January 1, 2012 | ||||||||||||
Federal | $ | 18,309 | $ | 8,615 | $ | 26,924 | ||||||
State | 3,397 | (4,583 | ) | (1,186 | ) | |||||||
Non-U.S. | 41,765 | (4,321 | ) | 37,444 | ||||||||
Total | $ | 63,471 | $ | (289 | ) | $ | 63,182 | |||||
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Continuing operations | $ | (14,592 | ) | $ | (17,854 | ) | $ | 63,182 | ||||
Discontinued operations | (1,098 | ) | 906 | (4,484 | ) | |||||||
Total | $ | (15,690 | ) | $ | (16,948 | ) | $ | 58,698 | ||||
A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision (benefit) is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Tax at statutory rate | $ | 53,663 | $ | 17,708 | $ | 22,526 | ||||||
Non-U.S. rate differential, net | (36,377 | ) | (26,652 | ) | (37,797 | ) | ||||||
U.S. taxation of multinational operations | 3,658 | 1,727 | 1,487 | |||||||||
State income taxes, net | (2,145 | ) | 3,265 | (5,536 | ) | |||||||
Prior year tax matters | (23,534 | ) | 3,389 | (9,079 | ) | |||||||
Estimated taxes on repatriation | — | — | 79,662 | |||||||||
Federal tax credits | (5,452 | ) | (1,657 | ) | (1,509 | ) | ||||||
Change in valuation allowance | (4,675 | ) | (14,446 | ) | 11,364 | |||||||
Other, net | 270 | (1,188 | ) | 2,064 | ||||||||
Total | $ | (14,592 | ) | $ | (17,854 | ) | $ | 63,182 | ||||
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 29, 2013 and December 30, 2012 were as follows: | ||||||||||||
December 29, | December 30, | |||||||||||
2013 | 2012 | |||||||||||
(In thousands) | ||||||||||||
Deferred tax assets: | ||||||||||||
Inventory | $ | 9,850 | $ | 9,893 | ||||||||
Reserves and accruals | 30,269 | 19,845 | ||||||||||
Accrued compensation | 15,920 | 15,803 | ||||||||||
Net operating loss and credit carryforwards | 132,710 | 165,274 | ||||||||||
Accrued pension | 23,353 | 34,016 | ||||||||||
Restructuring reserve | 6,853 | 7,951 | ||||||||||
Deferred revenue | 42,687 | 42,054 | ||||||||||
All other, net | 1,666 | 1,432 | ||||||||||
Total deferred tax assets | 263,308 | 296,268 | ||||||||||
Deferred tax liabilities: | ||||||||||||
Postretirement health benefits | (3,894 | ) | (3,472 | ) | ||||||||
Depreciation and amortization | (163,269 | ) | (191,075 | ) | ||||||||
Repatriation accrual | — | (31,447 | ) | |||||||||
Total deferred tax liabilities | (167,163 | ) | (225,994 | ) | ||||||||
Valuation allowance | (63,139 | ) | (67,814 | ) | ||||||||
Net deferred tax assets | $ | 33,006 | $ | 2,460 | ||||||||
At December 29, 2013, the Company had state net operating loss carryforwards of $275.0 million, foreign net operating loss carryforwards of $177.2 million, state tax credit carryforwards of $11.9 million, general business tax credit carryforwards of $29.6 million, and foreign tax credit carryforwards of $5.0 million. These are subject to expiration in years ranging from 2014 to 2032, and without expiration for certain foreign net operating loss carryforwards and certain state credit carryforwards. At December 29, 2013, the Company also had U.S. federal net operating loss carryforwards of $113.4 million as a result of acquisitions. The Company acquired estimated utilizable U.S. federal loss carryforwards of $223.4 million as a result of the Caliper acquisition during fiscal year 2011, of which $88.8 million remain at December 29, 2013. The utilization of these losses and credits is subject to annual limitations based on Section 382 of the Internal Revenue Code of 1986, as amended. These federal losses and credits will expire in fiscal years 2014 through 2030. | ||||||||||||
Valuation allowances take into consideration limitations imposed upon the use of the tax attributes and reduce the value of such items to the likely net realizable amount. The Company regularly evaluates positive and negative evidence available to determine if valuation allowances are required or if existing valuation allowances are no longer required. Valuation allowances have been provided on state net operating loss and state tax credit carryforwards and on certain foreign tax attributes that the Company has determined are not more likely than not to be realized. There were $10.4 million of valuation allowances provided on acquired tax attributes in connection with business combinations occurring in fiscal year 2011. The decrease in the valuation allowance in fiscal year 2013 is primarily due to the anticipated utilization of attributes in certain foreign jurisdictions. The change in the Company's valuation allowance during fiscal year 2012 was primarily due to the reversal of valuation allowances for two of the Company’s non-U.S. subsidiaries when it became more likely than not that the subsidiaries’ deferred tax assets would be realized. | ||||||||||||
Current deferred tax assets of $78.3 million and $34.9 million were included in other current assets at December 29, 2013 and December 30, 2012, respectively. Long-term deferred tax liabilities of $45.3 million and $32.4 million were included in other long-term liabilities at December 29, 2013 and December 30, 2012, respectively. | ||||||||||||
The components of net deferred tax assets (liabilities) as of December 29, 2013 and December 30, 2012 were as follows: | ||||||||||||
December 29, | December 30, | |||||||||||
2013 | 2012 | |||||||||||
(In thousands) | ||||||||||||
U.S. | $ | 22,565 | $ | (10,919 | ) | |||||||
Non-U.S. | 10,441 | 13,379 | ||||||||||
Total | $ | 33,006 | $ | 2,460 | ||||||||
As a result of the sale of the IDS and Photoflash businesses in fiscal year 2010, the Company concluded that the remaining operations within those foreign subsidiaries previously containing IDS and Photoflash operations did not require the same level of capital as previously required, and therefore the Company planned to repatriate approximately $250.0 million of previously unremitted earnings and provided for the estimated taxes on the repatriation of those earnings. The impact of this tax provision in fiscal year 2010 was an increase to the Company’s tax provision of $65.8 million in discontinued operations. The Company utilized existing tax attributes to minimize the cash taxes paid on the repatriation. As of January 1, 2012, the Company had completed the repatriation of the previously unremitted earnings of the IDS and Photoflash businesses, and reduced the recorded estimated tax liability associated with the repatriation by $6.7 million. This change in estimate was recorded as a credit to discontinued operations during fiscal year 2011. | ||||||||||||
As a result of the Caliper acquisition, the Company concluded in fiscal year 2011 that certain foreign operations did not require the same level of capital as previously expected, and therefore the Company planned to repatriate approximately $350.0 million of previously unremitted earnings and has provided for the estimated taxes on the repatriation of those earnings. As a result of the planned repatriation, the Company recorded an increase to the Company’s tax provision of $79.7 million in continuing operations in fiscal year 2011. The Company utilized tax attributes, primarily those acquired in the Caliper acquisition, to minimize the cash taxes paid on the repatriation. As of December 29, 2013, the Company had completed the repatriation of the $350.0 million of foreign earnings. | ||||||||||||
Taxes have not been provided on unremitted earnings of international subsidiaries that the Company considers indefinitely reinvested because the Company plans to keep these amounts indefinitely reinvested overseas except for instances where the Company can remit such earnings to the U.S. without an associated net tax cost. The Company's indefinite reinvestment determination is based on the future operational and capital requirements. As of December 29, 2013, the amount of foreign earnings that the Company has the intent and ability to keep invested outside the U.S. indefinitely and for which no U.S. tax cost has been provided was approximately $607.0 million. It is not practical to calculate the unrecognized deferred tax liability on those earnings. |
Earnings_Per_Share
Earnings Per Share | 12 Months Ended | ||||||||
Dec. 29, 2013 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Earnings Per Share | ' | ||||||||
Earnings Per Share | |||||||||
Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: | |||||||||
December 29, | December 30, | January 1, | |||||||
2013 | 2012 | 2012 | |||||||
(In thousands) | |||||||||
Number of common shares—basic | 112,254 | 113,728 | 112,976 | ||||||
Effect of dilutive securities: | |||||||||
Stock options | 982 | 847 | 739 | ||||||
Restricted stock awards | 267 | 285 | 149 | ||||||
Number of common shares—diluted | 113,503 | 114,860 | 113,864 | ||||||
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 485 | 1,288 | 2,281 | ||||||
Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future. |
Accounts_Receivable_Net
Accounts Receivable, Net | 12 Months Ended |
Dec. 29, 2013 | |
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | ' |
Accounts Receivable, Net | ' |
Accounts Receivable, Net | |
Accounts receivable were net of reserves for doubtful accounts of $30.2 million and $23.4 million as of December 29, 2013 and December 30, 2012, respectively. |
Inventories_Net
Inventories, Net | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Inventory Disclosure [Abstract] | ' | |||||||
Inventories, Net | ' | |||||||
Inventories, Net | ||||||||
Inventories as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Raw materials | $ | 92,891 | $ | 74,924 | ||||
Work in progress | 15,505 | 12,768 | ||||||
Finished goods | 152,640 | 159,996 | ||||||
Total inventories, net | $ | 261,036 | $ | 247,688 | ||||
Property_Plant_and_Equipment_N
Property, Plant and Equipment, Net | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Property, Plant and Equipment, Net [Abstract] | ' | |||||||
Property, Plant and Equipment, Net | ' | |||||||
Property, Plant and Equipment, Net | ||||||||
Property, plant and equipment, at cost, as of December 29, 2013 and December 30, 2012, consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Land | $ | 1,779 | $ | 8,050 | ||||
Building and leasehold improvements | 174,449 | 180,821 | ||||||
Machinery and equipment | 327,956 | 324,608 | ||||||
Total property, plant and equipment | 504,184 | 513,479 | ||||||
Accumulated depreciation | (318,811 | ) | (302,963 | ) | ||||
Total property, plant and equipment, net | $ | 185,373 | $ | 210,516 | ||||
Depreciation expense on property, plant and equipment for the fiscal years ended December 29, 2013, December 30, 2012 and January 1, 2012 was $38.1 million, $35.6 million and $30.9 million, respectively. |
Marketable_Securities_and_Inve
Marketable Securities and Investments | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Marketable Securities [Abstract] | ' | |||||||||||||||
Marketable Securities and Investments | ' | |||||||||||||||
Marketable Securities and Investments | ||||||||||||||||
Investments as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||||||||||
December 29, | December 30, | |||||||||||||||
2013 | 2012 | |||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,319 | $ | 1,149 | ||||||||||||
Marketable securities include equity and fixed-income securities held to meet obligations associated with the Company’s supplemental executive retirement plan and other deferred compensation plans. The Company has, accordingly, classified these securities as long-term. | ||||||||||||||||
The net unrealized holding gain and loss on marketable securities, net of deferred income taxes, reported as a component of other comprehensive income in stockholders’ equity, was a $0.01 million gain in fiscal year 2013 and $0.03 million gain in fiscal year 2012. The proceeds from the sales of securities and the related gains and losses are not material for any period presented. | ||||||||||||||||
Marketable securities classified as available for sale as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||||||||||
Market | Gross Unrealized Holding | |||||||||||||||
Value | Cost | Gains | (Losses) | |||||||||||||
(In thousands) | ||||||||||||||||
December 29, 2013 | ||||||||||||||||
Equity securities | $ | 740 | $ | 871 | $ | — | $ | (131 | ) | |||||||
Fixed-income securities | 308 | 308 | — | — | ||||||||||||
Other | 271 | 334 | — | (63 | ) | |||||||||||
$ | 1,319 | $ | 1,513 | $ | — | $ | (194 | ) | ||||||||
December 30, 2012 | ||||||||||||||||
Equity securities | $ | 657 | $ | 804 | $ | — | $ | (147 | ) | |||||||
Fixed-income securities | 294 | 294 | — | — | ||||||||||||
Other | 198 | 261 | — | (63 | ) | |||||||||||
$ | 1,149 | $ | 1,359 | $ | — | $ | (210 | ) | ||||||||
Goodwill_and_Intangible_Assets
Goodwill and Intangible Assets, Net | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||
Goodwill and Intangible Assets, Net | ' | |||||||||||
Goodwill and Intangible Assets, Net | ||||||||||||
The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets. | ||||||||||||
As discussed in Note 23, the Company realigned its organization at the beginning of fiscal year 2013, which resulted in a change in the composition of the Company's reporting units and reportable segments. The Company's Informatics business, as well as its field service on products previously sold by the Company's former Bio-discovery business, were moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2013 reflect this new alignment of the Company's operating segments. Financial information relating to fiscal years 2012 and 2011 has been retrospectively adjusted to reflect the changes to the operating segments. As a result of the realignment, the Company reallocated goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the businesses within the historical Environmental Health segment. The change resulted in $215.7 million of goodwill being allocated from the Environmental Health segment to the Human Health segment. | ||||||||||||
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2013, its annual impairment date for fiscal year 2013, which was based on the change in the reporting structure. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 30.0% for each reporting unit. | ||||||||||||
The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rate and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The long-term terminal growth rates for the Company’s reporting units ranged from 4.5% to 6.0% for the fiscal year 2013 impairment analysis. The range for the discount rates for the reporting units was 10.5% to 12.0%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill. | ||||||||||||
The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company currently evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2013, and concluded that there was no impairment of non-amortizing intangible assets. | ||||||||||||
As part of integrating the Company's recent acquisitions, in the fourth quarter of fiscal year 2012, the Company decided that prospectively it would primarily focus on the PerkinElmer trade name. Accordingly, the Company undertook a review of certain of its trade names within its portfolio as part of a realignment of its marketing strategy. The process resulted in the Company determining that the lives of certain trade names that it intends to phase out should be shortened, and in certain cases non-amortizing trade names were determined to no longer be indefinite-lived. Accordingly, the Company tested the recoverability of these identified indefinite-lived and definite-lived intangibles and concluded that the fair values of certain trade name intangible assets were less than the carrying amounts of those assets. For non-amortizing trade names the Company compared the fair values, which was determined using a relief from royalty method, to the carrying values, considering the revised useful lives. For amortizing trade names, the Company first determined if the undiscounted cash flows associated with the intangibles exceeded the carrying values. If the undiscounted cash flows did not exceed the carrying values, the Company determined the fair values of the trade names using a relief from royalty method, considering the revised useful lives. As a result, the remaining adjusted fair values of $6.1 million for trade names are being amortized over the period of time until the trade names are expected to be phased out, having weighted average remaining useful lives of 3 years. | ||||||||||||
Additionally during fiscal year 2012, the Company recorded an intangible asset impairment charge of $74.2 million which was equal to the excess of the carrying amounts of the intangible assets over the fair value of such assets. The Company recognized $73.4 million pre-tax impairment charges in the Human Health segment and also recognized $0.7 million pre-tax impairment charges in the Environmental Health segment. | ||||||||||||
An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. During fiscal year 2013, the Company recorded a charge of $6.7 million for the impairment of certain long-lived assets within the Human Health segment, as the carrying amounts of the long-lived assets were not recoverable and exceeded their fair value. The Company recorded a charge of $3.0 million for the impairment of intangible assets during fiscal year 2011 within the Human Health segment for the full impairment of license agreements that the Company no longer intends to use. These non-cash impairments of long-lived assets, including intangible assets, have been recorded as a separate component of operating expenses. | ||||||||||||
The changes in the carrying amount of goodwill for fiscal years 2013 and 2012 are as follows (the January 1, 2012 and December 30, 2012 balances have been retrospectively adjusted to reflect the realignment of the Company, see Note 23): | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(In thousands) | ||||||||||||
Adjusted balance at January 1, 2012 | $ | 1,606,913 | $ | 487,322 | $ | 2,094,235 | ||||||
Foreign currency translation | 5,892 | 2,979 | 8,871 | |||||||||
Acquisitions, earnouts and other | 19,682 | — | 19,682 | |||||||||
Adjusted balance at December 30, 2012 | 1,632,487 | 490,301 | 2,122,788 | |||||||||
Foreign currency translation | 12,867 | 2,300 | 15,167 | |||||||||
Acquisitions, earnouts and other | 2,978 | 2,187 | 5,165 | |||||||||
Balance at December 29, 2013 | $ | 1,648,332 | $ | 494,788 | $ | 2,143,120 | ||||||
Identifiable intangible asset balances at December 29, 2013 by category and by business segment were as follows: | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(In thousands) | ||||||||||||
Patents | $ | 36,791 | $ | 2,800 | $ | 39,591 | ||||||
Less: Accumulated amortization | (22,205 | ) | (2,002 | ) | (24,207 | ) | ||||||
Net patents | 14,586 | 798 | 15,384 | |||||||||
Trade names and trademarks | 35,972 | 86 | 36,058 | |||||||||
Less: Accumulated amortization | (16,371 | ) | (86 | ) | (16,457 | ) | ||||||
Net trade names and trademarks | 19,601 | — | 19,601 | |||||||||
Licenses | 71,580 | 7,600 | 79,180 | |||||||||
Less: Accumulated amortization | (45,835 | ) | (7,095 | ) | (52,930 | ) | ||||||
Net licenses | 25,745 | 505 | 26,250 | |||||||||
Core technology | 187,387 | 114,683 | 302,070 | |||||||||
Less: Accumulated amortization | (88,811 | ) | (80,515 | ) | (169,326 | ) | ||||||
Net core technology | 98,576 | 34,168 | 132,744 | |||||||||
Customer relationships | 305,038 | 16,357 | 321,395 | |||||||||
Less: Accumulated amortization | (127,397 | ) | (5,436 | ) | (132,833 | ) | ||||||
Net customer relationships | 177,641 | 10,921 | 188,562 | |||||||||
IPR&D | 4,257 | 5,226 | 9,483 | |||||||||
Less: Accumulated amortization | (695 | ) | (1,483 | ) | (2,178 | ) | ||||||
Net IPR&D | 3,562 | 3,743 | 7,305 | |||||||||
Net amortizable intangible assets | 339,711 | 50,135 | 389,846 | |||||||||
Non-amortizable intangible assets: | ||||||||||||
Trade names and trademarks | — | 70,584 | 70,584 | |||||||||
Total | $ | 339,711 | $ | 120,719 | $ | 460,430 | ||||||
Identifiable intangible asset balances at December 30, 2012 by category and business segment were as follows: | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(As adjusted) | ||||||||||||
(In thousands) | ||||||||||||
Patents | $ | 91,948 | $ | 16,021 | $ | 107,969 | ||||||
Less: Accumulated amortization | (74,831 | ) | (15,123 | ) | (89,954 | ) | ||||||
Net patents | 17,117 | 898 | 18,015 | |||||||||
Trade names and trademarks | 37,511 | 183 | 37,694 | |||||||||
Less: Accumulated amortization | (13,707 | ) | (179 | ) | (13,886 | ) | ||||||
Net trade names and trademarks | 23,804 | 4 | 23,808 | |||||||||
Licenses | 72,674 | 7,933 | 80,607 | |||||||||
Less: Accumulated amortization | (41,493 | ) | (5,875 | ) | (47,368 | ) | ||||||
Net licenses | 31,181 | 2,058 | 33,239 | |||||||||
Core technology | 268,902 | 138,643 | 407,545 | |||||||||
Less: Accumulated amortization | (146,662 | ) | (101,848 | ) | (248,510 | ) | ||||||
Net core technology | 122,240 | 36,795 | 159,035 | |||||||||
Customer relationships | 321,732 | 5,905 | 327,637 | |||||||||
Less: Accumulated amortization | (105,764 | ) | (2,620 | ) | (108,384 | ) | ||||||
Net customer relationships | 215,968 | 3,285 | 219,253 | |||||||||
IPR&D | 4,163 | 3,300 | 7,463 | |||||||||
Less: Accumulated amortization | (376 | ) | (1,120 | ) | (1,496 | ) | ||||||
Net IPR&D | 3,787 | 2,180 | 5,967 | |||||||||
Net amortizable intangible assets | 414,097 | 45,220 | 459,317 | |||||||||
Non-amortizable intangible assets: | ||||||||||||
Trade names and trademarks | — | 70,584 | 70,584 | |||||||||
Total | $ | 414,097 | $ | 115,804 | $ | 529,901 | ||||||
Total amortization expense related to definite-lived intangible assets was $90.4 million in fiscal year 2013, $91.2 million in fiscal year 2012 and $80.0 million in fiscal year 2011. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $83.2 million in fiscal year 2014, $69.2 million in fiscal year 2015, $60.2 million in fiscal year 2016, $50.7 million in fiscal year 2017, and $39.1 million in fiscal year 2018. | ||||||||||||
The Company entered into a strategic agreement in fiscal year 2012 under which it acquired certain intangible assets and received a license to certain core technology for an analytics and data discovery platform, as well as the exclusive right to distribute the platform in certain scientific research and development markets. During fiscal year 2012, the Company paid $6.8 million for net intangible assets and $25.0 million for prepaid royalties. During fiscal year 2013, the Company extended the existing agreement for an additional year. In addition, the Company entered into a new agreement to expand the distribution rights to the clinical and other related markets and acquired additional intangible assets. During fiscal year 2013, the Company paid $7.0 million for net intangible assets and $40.3 million for prepaid royalties. The prepaid royalties have been recorded primarily as other long-term assets. The Company does not expect to pay any additional prepaid royalties within the next twelve months. The Company expenses royalties as revenue is recognized. These intangible assets are being amortized over their estimated useful lives. The Company has reported the amortization of these intangible assets within the results of the Company's Human Health segment from the execution date. |
Debt
Debt | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Debt Disclosure [Abstract] | ' | |||||||||||||||
Debt | ' | |||||||||||||||
Debt | ||||||||||||||||
Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under the senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The Company's former senior unsecured revolving credit facility provided for $700.0 million of revolving loans and had an initial maturity of December 16, 2016. As of December 29, 2013, undrawn letters of credit in the aggregate amount of $12.0 million were treated as issued and outstanding under the former senior unsecured revolving credit facility. As of December 29, 2013, the Company had $291.0 million available for additional borrowing under the former facility. The interest rates under the former senior unsecured revolving credit facility were based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate was the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by Bank of America, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. The Eurocurrency margin as of December 29, 2013 was 130 basis points. The weighted average Eurocurrency interest rate as of December 29, 2013 was 0.17%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.47%, which was the interest applicable to borrowings outstanding under the Eurocurrency rate as of December 29, 2013. At December 29, 2013 and December 30, 2012, the Company had $397.0 million and $258.0 million, respectively of borrowings in U.S. Dollars outstanding under the former senior unsecured revolving credit facility with interest based primarily on the above described Eurocurrency rate. The credit agreement for the former facility contained affirmative, negative and financial covenants and events of default similar to those contained in the Company's new credit facility. | ||||||||||||||||
The new senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. The interest rates under the new senior unsecured revolving credit facility will be based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate will be the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JPMorgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. The new credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the Company's credit agreement for its previous facility. The financial covenants in the Company's new senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. The Company uses the senior unsecured revolving credit facilities for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. | ||||||||||||||||
6% Senior Unsecured Notes due in 2015. On May 30, 2008, the Company issued $150.0 million aggregate principal amount of senior unsecured notes due in 2015 in a private placement and received $150.0 million of proceeds from the issuance. The 2015 Notes were scheduled to mature in May 2015 and paid interest at an annual rate of 6%. Interest on the 2015 Notes was payable semi-annually on May 30th and November 30th of each year. The Company had the option to redeem some or all of the 2015 Notes at a make-whole redemption price plus accrued and unpaid interest. In December 2013, the Company redeemed all of the 2015 Notes for a redemption price that included the outstanding principal amount of $150.0 million and a prepayment premium of $11.1 million, which is included in other expense, net. The transaction also resulted in the write-off of $2.8 million for the remaining unamortized derivative losses for previously settled cash flow hedges and the write-off of $0.2 million for the remaining deferred debt issuance costs. Both of these amounts are included in interest expense. | ||||||||||||||||
5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of December 29, 2013, the 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest. | ||||||||||||||||
Financing Lease Obligations. In September 2012, the Company entered into agreements with the lessors of buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, which resulted in the Company being considered the owner of the buildings during the construction period. At the end of the construction period, the Company will not be reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases will qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At December 29, 2013, the Company had $40.3 million recorded for these financing lease obligations, of which $2.6 million was recorded as short-term debt and $37.7 million was recorded as long-term debt. At December 30, 2012, the Company had $34.6 million recorded for these financing lease obligations, of which $1.7 million was recorded as short-term debt and $32.9 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other. | ||||||||||||||||
The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2013: | ||||||||||||||||
Sr. Unsecured | 5.0% Sr. Notes | Financing Lease Obligations | Total | |||||||||||||
Revolving | Maturing 2021 | |||||||||||||||
Credit Facility | ||||||||||||||||
Maturing 2016(1) | ||||||||||||||||
(In thousands) | ||||||||||||||||
2014 | $ | — | $ | — | $ | 2,624 | $ | 2,624 | ||||||||
2015 | — | — | 2,632 | 2,632 | ||||||||||||
2016 | 397,000 | — | 2,641 | 399,641 | ||||||||||||
2017 | — | — | 2,649 | 2,649 | ||||||||||||
2018 | — | — | 2,802 | 2,802 | ||||||||||||
2019 and thereafter | — | 500,000 | 26,948 | 526,948 | ||||||||||||
Total before unamortized discount | 397,000 | 500,000 | 40,296 | 937,296 | ||||||||||||
Unamortized discount | — | (2,568 | ) | — | (2,568 | ) | ||||||||||
Total | $ | 397,000 | $ | 497,432 | $ | 40,296 | $ | 934,728 | ||||||||
___________________________ | ||||||||||||||||
-1 | On January 8, 2014, the Company refinanced its debt held under the senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility, with an initial maturity of January 8, 2019. |
Accrued_Expenses_and_Other_Cur
Accrued Expenses and Other Current Liabilities | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Accounts Payable and Accrued Liabilities, Current [Abstract] | ' | |||||||
Accrued Expenses and Other Current Liabilities | ' | |||||||
Accrued Expenses and Other Current Liabilities | ||||||||
Accrued expenses and other current liabilities as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Payroll and incentives | $ | 53,049 | $ | 55,342 | ||||
Employee benefits | 41,019 | 42,485 | ||||||
Deferred revenue | 164,723 | 154,247 | ||||||
Federal, non-U.S. and state income taxes | 11,783 | 16,091 | ||||||
Other accrued operating expenses | 133,490 | 119,861 | ||||||
Total accrued expenses and other current liabilities | $ | 404,064 | $ | 388,026 | ||||
Employee_Benefit_Plans
Employee Benefit Plans | 12 Months Ended | |||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | |||||||||||||||||
Employee Benefit Plans | ' | |||||||||||||||||
Employee Benefit Plans | ||||||||||||||||||
Savings Plan: The Company has a 401(k) Savings Plan for the benefit of all qualified U.S. employees, with such employees receiving matching contributions in the amount equal to 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits. Such matching contributions have been in effect since February 1, 2011 for all employees except former employees of Caliper, who received matching contributions of 50.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits until December 31, 2012, and received matching contributions of 100.0% of the first 5.0% of eligible compensation up to applicable Internal Revenue Service limits after December 31, 2012. Savings plan expense was $12.8 million in fiscal year 2013, $12.3 million in fiscal year 2012 and $10.6 million in fiscal year 2011. | ||||||||||||||||||
Pension Plans: The Company has a defined benefit pension plan covering certain U.S. employees and non-U.S. pension plans for certain non-U.S. employees. The principal U.S. defined benefit pension plan was closed to new hires effective January 31, 2001, and benefits for those employed by the Company’s former Life Sciences businesses were frozen as of that date. Plan benefits were frozen as of March 2003 for those employed by the Company’s former Analytical Instruments business and corporate employees. Plan benefits were frozen as of January 31, 2011 for all remaining employees that were still actively accruing in the plan. The plans provide benefits that are based on an employee’s years of service and compensation near retirement. | ||||||||||||||||||
Net periodic pension (credit) cost for U.S. and non-U.S. plans included the following components for fiscal years ended: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Service cost | $ | 3,664 | $ | 3,852 | $ | 3,880 | ||||||||||||
Interest cost | 21,334 | 23,164 | 25,169 | |||||||||||||||
Expected return on plan assets | (25,106 | ) | (20,768 | ) | (22,534 | ) | ||||||||||||
Actuarial (gain) loss | (16,464 | ) | 28,355 | 64,005 | ||||||||||||||
Amortization of prior service cost | (267 | ) | (242 | ) | (221 | ) | ||||||||||||
Net periodic pension (credit) cost | $ | (16,839 | ) | $ | 34,361 | $ | 70,299 | |||||||||||
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2013 and December 30, 2012. | ||||||||||||||||||
December 29, 2013 | December 30, 2012 | |||||||||||||||||
Non-U.S. | U.S. | Non-U.S. | U.S. | |||||||||||||||
(In thousands) | ||||||||||||||||||
Actuarial present value of benefit obligations: | ||||||||||||||||||
Accumulated benefit obligations | $ | 277,125 | $ | 279,299 | $ | 271,153 | $ | 301,770 | ||||||||||
Change in benefit obligations: | ||||||||||||||||||
Projected benefit obligations at beginning of year | $ | 278,707 | $ | 301,770 | $ | 231,325 | $ | 297,001 | ||||||||||
Service cost | 2,589 | 1,075 | 2,502 | 1,350 | ||||||||||||||
Interest cost | 9,834 | 11,500 | 11,235 | 11,929 | ||||||||||||||
Benefits paid and plan expenses | (11,218 | ) | (17,817 | ) | (10,625 | ) | (17,568 | ) | ||||||||||
Participants’ contributions | 391 | — | 432 | — | ||||||||||||||
Plan settlement | (918 | ) | — | — | — | |||||||||||||
Actuarial loss (gain) | 1,678 | (17,229 | ) | 38,541 | 9,058 | |||||||||||||
Effect of exchange rate changes | 7,153 | — | 5,297 | — | ||||||||||||||
Projected benefit obligations at end of year | $ | 288,216 | $ | 279,299 | $ | 278,707 | $ | 301,770 | ||||||||||
Change in plan assets: | ||||||||||||||||||
Fair value of plan assets at beginning of year | $ | 114,515 | $ | 221,755 | $ | 97,836 | $ | 195,022 | ||||||||||
Actual return on plan assets | 17,201 | 8,818 | 12,710 | 27,301 | ||||||||||||||
Benefits paid and plan expenses | (11,218 | ) | (17,817 | ) | (10,625 | ) | (17,568 | ) | ||||||||||
Employer’s contributions | 20,200 | 37,000 | 10,882 | 17,000 | ||||||||||||||
Participants’ contributions | 391 | — | 432 | — | ||||||||||||||
Plan settlement | (918 | ) | — | — | — | |||||||||||||
Effect of exchange rate changes | 3,533 | — | 3,280 | — | ||||||||||||||
Fair value of plan assets at end of year | 143,704 | 249,756 | 114,515 | 221,755 | ||||||||||||||
Net liabilities recognized in the consolidated balance sheets | $ | (144,512 | ) | $ | (29,543 | ) | $ | (164,192 | ) | $ | (80,015 | ) | ||||||
Net amounts recognized in the consolidated balance sheets consist of: | ||||||||||||||||||
Noncurrent assets | $ | 6,879 | $ | — | $ | — | $ | — | ||||||||||
Current liabilities | (7,360 | ) | — | (7,398 | ) | — | ||||||||||||
Noncurrent liabilities | (144,031 | ) | (29,543 | ) | (156,794 | ) | (80,015 | ) | ||||||||||
Net liabilities recognized in the consolidated balance sheets | $ | (144,512 | ) | $ | (29,543 | ) | $ | (164,192 | ) | $ | (80,015 | ) | ||||||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||||||||||||||||
Prior service cost | $ | (1,745 | ) | $ | — | $ | (2,048 | ) | $ | — | ||||||||
Net amounts recognized in accumulated other comprehensive income | $ | (1,745 | ) | $ | — | $ | (2,048 | ) | $ | — | ||||||||
Actuarial assumptions as of the year-end measurement date: | ||||||||||||||||||
Discount rate | 3.77 | % | 4.77 | % | 3.62 | % | 3.92 | % | ||||||||||
Rate of compensation increase | 3.23 | % | None | 2.88 | % | None | ||||||||||||
Actuarial assumptions used to determine net periodic pension cost during the year were as follows: | ||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | ||||||||||||||||
Non-U.S. | U.S. | Non-U.S. | U.S. | Non-U.S. | U.S. | |||||||||||||
Discount rate | 3.62 | % | 3.92 | % | 4.91 | % | 4.1 | % | 5.14 | % | 5.3 | % | ||||||
Rate of compensation increase | 2.88 | % | None | 3.22 | % | 3.5 | % | 3.42 | % | 3.5 | % | |||||||
Expected rate of return on assets | 5.5 | % | 7.5 | % | 5.4 | % | 7.75 | % | 6.7 | % | 8.1 | % | ||||||
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: | ||||||||||||||||||
December 29, | December 30, | |||||||||||||||||
2013 | 2012 | |||||||||||||||||
(In thousands) | ||||||||||||||||||
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets | ||||||||||||||||||
Projected benefit obligations | $ | 151,391 | $ | 278,707 | ||||||||||||||
Fair value of plan assets | — | 114,515 | ||||||||||||||||
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets | ||||||||||||||||||
Accumulated benefit obligations | $ | 148,235 | $ | 271,153 | ||||||||||||||
Fair value of plan assets | — | 114,515 | ||||||||||||||||
Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2013 and December 30, 2012, and target asset allocations for fiscal year 2014 are as follows: | ||||||||||||||||||
Target Allocation | Percentage of Plan Assets at | |||||||||||||||||
December 28, 2014 | December 29, 2013 | December 30, 2012 | ||||||||||||||||
Asset Category | Non-U.S. | U.S. | Non-U.S. | U.S. | Non-U.S. | U.S. | ||||||||||||
Equity securities | 45-55% | 40-50% | 51 | % | 43 | % | 71 | % | 55 | % | ||||||||
Debt securities | 45-55% | 50-60% | 48 | % | 57 | % | 29 | % | 39 | % | ||||||||
Other | 0-5% | 0-5% | 1 | % | 0 | % | 0 | % | 6 | % | ||||||||
Total | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | ||||||
The Company maintains target allocation percentages among various asset classes based on investment policies established for the pension plans which are designed to maximize the total rate of return (income and appreciation) after inflation within the limits of prudent risk taking, while providing for adequate near-term liquidity for benefit payments. | ||||||||||||||||||
The Company’s expected returns on assets assumptions are derived from management’s estimates, as well as other information compiled by management, including studies that utilize customary procedures and techniques. The studies include a review of anticipated future long-term performance of individual asset classes and consideration of the appropriate asset allocation strategy given the anticipated requirements of the plans to determine the average rate of earnings expected on the funds invested to provide for the pension plans benefits. While the study gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term, prospective rate. | ||||||||||||||||||
The Company's discount rate assumptions are derived from a range of factors, including a yield curve composed of the rates of return on high-quality fixed-income corporate bonds available at the measurement date and the related expected duration for the obligations. | ||||||||||||||||||
The target allocations for plan assets are listed in the above table. Equity securities primarily include investments in large-cap and mid-cap companies located in the United States and abroad, and equity index funds. Debt securities include corporate bonds of companies from diversified industries, high-yield bonds, and U.S. government securities. Other types of investments include investments in non-U.S. government index linked bonds, multi-strategy hedge funds and venture capital funds that follow several different strategies. | ||||||||||||||||||
The fair values of the Company’s pension plan assets as of December 29, 2013 and December 30, 2012 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: | ||||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 29, 2013 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 4,458 | $ | 4,458 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 34,127 | 34,127 | — | — | ||||||||||||||
International large-cap value | 27,595 | 27,595 | — | — | ||||||||||||||
Emerging markets growth | 12,517 | 12,517 | — | — | ||||||||||||||
Equity index funds | 73,796 | — | 73,796 | — | ||||||||||||||
Domestic real estate funds | 2,471 | 2,471 | — | — | ||||||||||||||
Commodity funds | 8,179 | 8,179 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Non-U.S. Treasury Securities | 18,344 | — | 18,344 | — | ||||||||||||||
Corporate and U.S. debt instruments | 132,828 | 45,215 | 87,613 | — | ||||||||||||||
Corporate bonds | 22,619 | — | 22,619 | — | ||||||||||||||
High yield bond funds | 6,170 | 6,170 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 22,689 | — | — | 22,689 | ||||||||||||||
Venture capital funds | 8 | — | — | 8 | ||||||||||||||
Non-U.S. government index linked bonds | 27,659 | — | 27,659 | — | ||||||||||||||
Total assets measured at fair value | $ | 393,460 | $ | 140,732 | $ | 230,031 | $ | 22,697 | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 30, 2012 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 13,940 | $ | 13,940 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 37,674 | 37,674 | — | — | ||||||||||||||
International large-cap value | 37,239 | 37,239 | — | — | ||||||||||||||
U.S. small-cap | 3,567 | 3,567 | — | — | ||||||||||||||
Emerging markets growth | 12,390 | 12,390 | — | — | ||||||||||||||
Equity index funds | 80,999 | — | 80,999 | — | ||||||||||||||
Domestic real estate funds | 2,235 | 2,235 | — | — | ||||||||||||||
Commodity funds | 8,940 | 8,940 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 565 | — | 565 | — | ||||||||||||||
Corporate and U.S. debt instruments | 73,362 | 18,985 | 54,377 | — | ||||||||||||||
Corporate bonds | 22,497 | — | 22,497 | — | ||||||||||||||
High yield bond funds | 11,624 | 11,624 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 20,262 | — | — | 20,262 | ||||||||||||||
Venture capital funds | 7 | — | — | 7 | ||||||||||||||
Private funds | 162 | — | — | 162 | ||||||||||||||
Non-U.S. government index linked bonds | 10,807 | — | 10,807 | — | ||||||||||||||
Total assets measured at fair value | $ | 336,270 | $ | 146,594 | $ | 169,245 | $ | 20,431 | ||||||||||
Valuation Techniques: Valuation techniques utilized need to maximize the use of observable inputs and minimize the use of unobservable inputs. There have been no changes in the methodologies utilized at December 29, 2013 compared to December 30, 2012. The following is a description of the valuation techniques utilized to measure the fair value of the assets shown in the table above. | ||||||||||||||||||
Equity Securities: Shares of registered investment companies that are publicly traded are categorized as Level 1 assets; they are valued at quoted market prices that represent the net asset value of the fund. These instruments have active markets. | ||||||||||||||||||
Equity index funds are mutual funds that are not publicly traded and are comprised primarily of underlying equity securities that are publicly traded on exchanges. Price quotes for the assets held by these funds are readily observable and available. Equity index funds are categorized as Level 2 assets. | ||||||||||||||||||
Fixed Income Securities: Fixed income mutual funds that are publicly traded are valued at quoted market prices that represent the net asset value of securities held by the fund and are categorized as Level 1 assets. | ||||||||||||||||||
Fixed income index funds that are not publicly traded are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments and are categorized as Level 2 assets. | ||||||||||||||||||
Individual fixed income bonds are categorized as Level 2 assets except where sufficient quoted prices exist in active markets, in which case such securities are categorized as Level 1 assets. These securities are valued using third-party pricing services. These services may use, for example, model-based pricing methods that utilize observable market data as inputs. Broker dealer bids or quotes of securities with similar characteristics may also be used. | ||||||||||||||||||
Other Types of Investments: Non-U.S. government index link bond funds are not publicly traded and are stated at net asset value as determined by the issuer of the fund based on the fair value of the underlying investments. Underlying investments consist of bonds in which payment of income on the principal is related to a specific price index and are categorized as Level 2 assets. | ||||||||||||||||||
Hedge funds, private equity funds and venture capital funds are valued at fair value by using the net asset values provided by the investment managers and are updated, if necessary, using analytical procedures, appraisals, public market data and/or inquiry of the investment managers. The net asset values are determined based upon the fair values of the underlying investments in the funds. These other investments invest primarily in readily available marketable securities and allocate gains, losses, and expense to the investor based on the ownership percentage as described in the fund agreements. They are categorized as Level 3 assets. | ||||||||||||||||||
The Company's policy is to recognize significant transfers between levels at the actual date of the event. | ||||||||||||||||||
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2013, 2012, and 2011 is as follows: | ||||||||||||||||||
Fair Value Measurements Using | ||||||||||||||||||
Significant Unobservable Inputs | ||||||||||||||||||
(Level 3): | ||||||||||||||||||
Common | Venture | Multi-strategy | Total | |||||||||||||||
Collective | Capital | Hedge | ||||||||||||||||
Trusts/Private Funds | Funds | Funds | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Balance at January 2, 2011 | $ | — | $ | 14 | $ | 20,073 | $ | 20,087 | ||||||||||
Realized losses | — | — | (84 | ) | (84 | ) | ||||||||||||
Unrealized losses | — | (7 | ) | (704 | ) | (711 | ) | |||||||||||
Balance at January 1, 2012 | — | 7 | 19,285 | 19,292 | ||||||||||||||
Realized gains | 1,162 | — | — | 1,162 | ||||||||||||||
Unrealized gains | 19 | — | 977 | 996 | ||||||||||||||
Purchases | 9,448 | — | — | 9,448 | ||||||||||||||
Issuances, Sales and Settlements | (10,467 | ) | — | — | (10,467 | ) | ||||||||||||
Balance at December 30, 2012 | 162 | 7 | 20,262 | 20,431 | ||||||||||||||
Realized gains | 7 | — | — | 7 | ||||||||||||||
Unrealized (losses) gains | (19 | ) | 1 | 2,427 | 2,409 | |||||||||||||
Issuances, Sales and Settlements | (150 | ) | — | — | (150 | ) | ||||||||||||
Balance at December 29, 2013 | $ | — | $ | 8 | $ | 22,689 | $ | 22,697 | ||||||||||
With respect to plans outside of the United States, the Company expects to contribute $11.1 million in the aggregate during fiscal year 2014. During fiscal year 2013, the Company made contributions of $37.0 million for the 2012 plan year to its defined benefit pension plan in the United States. During fiscal year 2013, the Company contributed $20.2 million, in the aggregate, to plans outside of the United States, which includes an additional contribution of $10.0 million to its defined benefit pension plan in the United Kingdom. During fiscal year 2012, the Company contributed $17.0 million for the 2011 plan year to its defined benefit pension plans in the United States, and $10.9 million in the aggregate to its defined benefit pension plans outside of the United States. | ||||||||||||||||||
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: | ||||||||||||||||||
Non-U.S. | U.S. | |||||||||||||||||
(In thousands) | ||||||||||||||||||
2014 | $ | 11,878 | $ | 17,836 | ||||||||||||||
2015 | 12,931 | 17,848 | ||||||||||||||||
2016 | 13,312 | 17,916 | ||||||||||||||||
2017 | 13,627 | 17,990 | ||||||||||||||||
2018 | 14,156 | 18,219 | ||||||||||||||||
2019-2023 | 77,736 | 91,400 | ||||||||||||||||
The Company also sponsors a supplemental executive retirement plan to provide senior management with benefits in excess of normal pension benefits. Effective July 31, 2000, this plan was closed to new entrants. At December 29, 2013 and December 30, 2012, the projected benefit obligations were $21.1 million and $23.2 million, respectively. Assets with a fair value of $0.3 million and $0.2 million, segregated in a trust (which is included in marketable securities and investments on the consolidated balance sheets), were available to meet this obligation as of December 29, 2013 and December 30, 2012, respectively. Pension income and expenses for this plan was approximately income of $0.4 million in fiscal year 2013, expense of $2.5 million in fiscal year 2012 and expense of $4.9 million in fiscal year 2011. | ||||||||||||||||||
Postretirement Medical Plans: The Company provides healthcare benefits for eligible retired U.S. employees under a comprehensive major medical plan or under health maintenance organizations where available. Eligible U.S. employees qualify for retiree health benefits if they retire directly from the Company and have at least ten years of service. Generally, the major medical plan pays stated percentages of covered expenses after a deductible is met and takes into consideration payments by other group coverage and by Medicare. The plan requires retiree contributions under most circumstances and has provisions for cost-sharing charges. Effective January 1, 2000, this plan was closed to new hires. For employees retiring after 1991, the Company has capped its medical premium contribution based on employees’ years of service. The Company funds the amount allowable under a 401(h) provision in the Company’s defined benefit pension plan. Assets of the plan are primarily equity and debt securities and are available only to pay retiree health benefits. | ||||||||||||||||||
Net periodic postretirement medical benefit credit included the following components for the fiscal years ended: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Service cost | $ | 106 | $ | 106 | $ | 85 | ||||||||||||
Interest cost | 135 | 144 | 163 | |||||||||||||||
Expected return on plan assets | (965 | ) | (877 | ) | (884 | ) | ||||||||||||
Actuarial (gain) loss | (182 | ) | (929 | ) | 705 | |||||||||||||
Amortization of prior service cost | — | — | (253 | ) | ||||||||||||||
Net periodic postretirement medical benefit credit | $ | (906 | ) | $ | (1,556 | ) | $ | (184 | ) | |||||||||
The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2013 and December 30, 2012. | ||||||||||||||||||
December 29, | December 30, | |||||||||||||||||
2013 | 2012 | |||||||||||||||||
(In thousands) | ||||||||||||||||||
Actuarial present value of benefit obligations: | ||||||||||||||||||
Retirees | $ | 1,331 | $ | 1,475 | ||||||||||||||
Active employees eligible to retire | 470 | 431 | ||||||||||||||||
Other active employees | 2,009 | 1,913 | ||||||||||||||||
Accumulated benefit obligations at beginning of year | 3,810 | 3,819 | ||||||||||||||||
Service cost | 106 | 106 | ||||||||||||||||
Interest cost | 135 | 144 | ||||||||||||||||
Benefits paid | (189 | ) | (205 | ) | ||||||||||||||
Actuarial (gain) loss | (520 | ) | (54 | ) | ||||||||||||||
Change in accumulated benefit obligations during the year | (468 | ) | (9 | ) | ||||||||||||||
Retirees | 1,159 | 1,331 | ||||||||||||||||
Active employees eligible to retire | 388 | 470 | ||||||||||||||||
Other active employees | 1,795 | 2,009 | ||||||||||||||||
Accumulated benefit obligations at end of year | 3,342 | 3,810 | ||||||||||||||||
Change in plan assets: | ||||||||||||||||||
Fair value of plan assets at beginning of year | 12,958 | 11,411 | ||||||||||||||||
Actual return on plan assets | 438 | 1,547 | ||||||||||||||||
Fair value of plan assets at end of year | 13,396 | 12,958 | ||||||||||||||||
Net assets recognized in the consolidated balance sheets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net amounts recognized in the consolidated balance sheets consist of: | ||||||||||||||||||
Noncurrent assets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net assets recognized in the consolidated balance sheets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||||||||||||||||
Prior service cost | $ | — | $ | — | ||||||||||||||
Net amounts recognized in accumulated other comprehensive income | $ | — | $ | — | ||||||||||||||
Actuarial assumptions as of the year-end measurement date: | ||||||||||||||||||
Discount rate | 4.77 | % | 3.86 | % | ||||||||||||||
Actuarial assumptions used to determine net cost during the year are as follows: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
Discount rate | 3.86 | % | 4 | % | 5.3 | % | ||||||||||||
Expected rate of return on assets | 7.5 | % | 7.75 | % | 8.1 | % | ||||||||||||
The Company maintains a master trust for plan assets related to the U.S. defined benefit plans and the U.S. postretirement medical plan. Accordingly, investment policies, target asset allocations and actual asset allocations are the same as those disclosed for the U.S. defined benefit plans. | ||||||||||||||||||
The fair values of the Company’s plan assets at December 29, 2013 and December 30, 2012 by asset category, classified in the three levels of inputs described in Note 21, are as follows: | ||||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 29, 2013 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 167 | $ | 167 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 1,831 | 1,831 | — | — | ||||||||||||||
International large-cap value | 1,480 | 1,480 | — | — | ||||||||||||||
Emerging markets growth | 672 | 672 | — | — | ||||||||||||||
Domestic real estate funds | 133 | 133 | — | — | ||||||||||||||
Commodity funds | 439 | 439 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 7,126 | 2,426 | 4,700 | — | ||||||||||||||
High yield bond funds | 331 | 331 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 1,217 | — | — | 1,217 | ||||||||||||||
Total assets measured at fair value | $ | 13,396 | $ | 7,479 | $ | 4,700 | $ | 1,217 | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 30, 2012 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 798 | $ | 798 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S large-cap | 2,202 | 2,202 | — | — | ||||||||||||||
International large-cap value | 2,177 | 2,177 | — | — | ||||||||||||||
U.S. small-cap | 209 | 209 | — | — | ||||||||||||||
Emerging markets growth | 724 | 724 | — | — | ||||||||||||||
Domestic real estate funds | 131 | 131 | — | — | ||||||||||||||
Commodity funds | 523 | 523 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 33 | — | 33 | — | ||||||||||||||
Corporate and U.S. debt instruments | 4,288 | 1,110 | 3,178 | — | ||||||||||||||
High yield bond funds | 679 | 679 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 1,184 | — | — | 1,184 | ||||||||||||||
Private funds | 9 | — | — | 9 | ||||||||||||||
Venture capital funds | 1 | — | — | 1 | ||||||||||||||
Total assets measured at fair value | $ | 12,958 | $ | 8,553 | $ | 3,211 | $ | 1,194 | ||||||||||
Valuation Techniques: Valuation techniques are the same as those disclosed for the U.S. defined benefit plans above. | ||||||||||||||||||
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2013, 2012, and 2011 is as follows: | ||||||||||||||||||
Fair Value Measurements Using | ||||||||||||||||||
Significant Unobservable Inputs | ||||||||||||||||||
(Level 3): | ||||||||||||||||||
Common | Venture | Multi-strategy | Total | |||||||||||||||
Collective | Capital | Hedge | ||||||||||||||||
Trusts/Private Funds | Funds | Funds | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Balance at January 2, 2011 | $ | — | $ | 1 | $ | 1,086 | $ | 1,087 | ||||||||||
Realized gains | — | — | 84 | 84 | ||||||||||||||
Unrealized losses | — | — | (41 | ) | (41 | ) | ||||||||||||
Purchases | — | — | — | — | ||||||||||||||
Issuances, Sales and Settlements | — | — | — | — | ||||||||||||||
Balance at January 1, 2012 | — | 1 | 1,129 | 1,130 | ||||||||||||||
Realized gains | 68 | — | — | 68 | ||||||||||||||
Unrealized gains | 1 | — | 55 | 56 | ||||||||||||||
Purchases | 552 | — | — | 552 | ||||||||||||||
Issuances, Sales and Settlements | (612 | ) | — | — | (612 | ) | ||||||||||||
Balance at December 30, 2012 | 9 | 1 | 1,184 | 1,194 | ||||||||||||||
Realized gains | — | — | — | — | ||||||||||||||
Unrealized (losses) gains | (1 | ) | (1 | ) | 33 | 31 | ||||||||||||
Purchases | — | — | — | — | ||||||||||||||
Issuances, Sales and Settlements | (8 | ) | — | — | (8 | ) | ||||||||||||
Balance at December 29, 2013 | $ | — | $ | — | $ | 1,217 | $ | 1,217 | ||||||||||
The Company does not expect to make any contributions to the postretirement medical plan during fiscal year 2014. | ||||||||||||||||||
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: | ||||||||||||||||||
Postretirement Medical Plan | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
2014 | $ | 202 | ||||||||||||||||
2015 | 205 | |||||||||||||||||
2016 | 210 | |||||||||||||||||
2017 | 217 | |||||||||||||||||
2018 | 224 | |||||||||||||||||
2019-2023 | 1,227 | |||||||||||||||||
Deferred Compensation Plans: During fiscal year 1998, the Company implemented a nonqualified deferred compensation plan that provides benefits payable to officers and certain key employees or their designated beneficiaries at specified future dates, or upon retirement or death. The plan was amended to eliminate deferral elections from participants for plan years beginning January 1, 2011. Benefit payments under the plan are funded by contributions from participants, and for certain participants, contributions are funded by the Company. The obligations related to the deferred compensation plan totaled $1.0 million and $0.9 million at December 29, 2013 and December 30, 2012, respectively. |
Contingencies
Contingencies | 12 Months Ended |
Dec. 29, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Contingencies | ' |
Contingencies | |
The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. During fiscal year 2013, the Company accrued an additional $5.7 million related to a particular site for increased monitoring and mitigation activities. The Company has accrued $13.5 million as of December 29, 2013, which represents management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. This amount is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded. | |
Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint dated October 23, 2002 in the United States District Court for the Southern District of New York, Civil Action No. 02-8448, seeking injunctive and monetary relief against Amersham plc, Amersham BioSciences, PerkinElmer, Inc., PerkinElmer Life Sciences, Inc., Sigma-Aldrich Corporation, Sigma Chemical Company, Inc., Molecular Probes, Inc., and Orchid BioSciences, Inc. The complaint alleges that the Company breached its distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology, separately and together with the other defendants. The Company filed an answer and a counterclaim alleging that Enzo's patents are invalid. In 2007, after the court issued a decision in 2006 regarding the construction of the claims in Enzo's patents that effectively limited the coverage of certain of those claims and, the Company believes, excluded certain of the Company's products from the coverage of Enzo's patents, summary judgment motions were filed by the defendants. The case was assigned to a new district court judge in January 2009 and in March 2009, the new judge denied the pending summary judgment motions without prejudice and ordered a stay of the case until the federal appellate court decided Enzo's appeal of the judgment of the United States District Court for the District of Connecticut in Enzo Biochem vs. Applera Corp. and Tropix, Inc. (the “Connecticut Case”), which involved a number of the same patents and which could materially affect the scope of Enzo's case against the Company. In March 2010, the United States Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part the judgment in the Connecticut Case. The district court permitted the Company and the other defendants to jointly file a motion for summary judgment on certain patent and other issues common to all of the defendants. On September 12, 2012, the court granted in part and denied in part the Company's motion for summary judgment of non-infringement. On December 21, 2012, the Company filed a second motion for summary judgment on claims that were not addressed in the first motion, which the court also granted in part and denied in part. The case is expected to go to trial in March 2014. | |
The Company believes it has meritorious defenses to the matter described above, and it is contesting the action vigorously. While this matter is subject to uncertainty, in the opinion of the Company’s management, based on its review of the information available at this time, the resolution of this matter will not have a material adverse effect on the Company’s consolidated financial statements. | |
The Company is also subject to various other claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these other contingencies at December 29, 2013 should not have a material adverse effect on the Company’s consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company. |
Warranty_Reserves
Warranty Reserves | 12 Months Ended | |||
Dec. 29, 2013 | ||||
Product Warranties Disclosures [Abstract] | ' | |||
Warranty Reserves | ' | |||
Warranty Reserves | ||||
The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the consolidated balance sheets. | ||||
A summary of warranty reserve activity for the fiscal years ended December 29, 2013, December 30, 2012 and January 1, 2012 is as follows: | ||||
(In thousands) | ||||
Balance at January 2, 2011 | $ | 8,250 | ||
Provision charged to income | 15,001 | |||
Payments | (15,154 | ) | ||
Adjustments to previously provided warranties, net | 926 | |||
Foreign currency translation and acquisitions | 1,389 | |||
Balance at January 1, 2012 | 10,412 | |||
Provision charged to income | 17,750 | |||
Payments | (18,022 | ) | ||
Adjustments to previously provided warranties, net | 801 | |||
Foreign currency translation and acquisitions | 62 | |||
Balance at December 30, 2012 | 11,003 | |||
Provision charged to income | 17,291 | |||
Payments | (17,116 | ) | ||
Adjustments to previously provided warranties, net | (693 | ) | ||
Foreign currency translation and acquisitions | 49 | |||
Balance at December 29, 2013 | $ | 10,534 | ||
Stock_Plans
Stock Plans | 12 Months Ended | ||||||||||||||||||||
Dec. 29, 2013 | |||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||||||||||
Stock Plans | ' | ||||||||||||||||||||
Stock Plans | |||||||||||||||||||||
Stock-Based Compensation: | |||||||||||||||||||||
In addition to the Company’s Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, which includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued, 10.7 million shares of the Company’s common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. | |||||||||||||||||||||
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2013, 2012, and 2011: | |||||||||||||||||||||
December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | |||||||||||||||||||
(In thousands) | |||||||||||||||||||||
Cost of product and service revenue | $ | 1,304 | $ | 1,276 | $ | 1,139 | |||||||||||||||
Research and development expenses | 853 | 769 | 583 | ||||||||||||||||||
Selling, general and administrative expenses | 11,896 | 18,986 | 13,760 | ||||||||||||||||||
Total stock-based compensation expense | $ | 14,053 | $ | 21,031 | $ | 15,482 | |||||||||||||||
The total income tax benefit recognized in the consolidated statements of operations for stock-based compensation was $4.4 million in fiscal year 2013, $6.8 million in fiscal year 2012 and $5.1 million in fiscal year 2011. Stock-based compensation costs capitalized as part of inventory were $0.4 million and $0.3 million as of December 29, 2013 and December 30, 2012, respectively. The excess tax benefit recognized from stock awards, classified as a financing cash activity, was zero in fiscal year 2013, $1.8 million in fiscal year 2012 and $9.3 million in fiscal year 2011. | |||||||||||||||||||||
Stock Options: The Company has granted options to purchase common shares at prices equal to the market price of the common shares on the date the option is granted. Conditions of vesting are determined at the time of grant. Options are generally exercisable in equal annual installments over a period of three years, and will generally expire seven years after the date of grant. Options replaced in association with business combination transactions are generally issued with the same terms of the respective plans under which they were originally issued. | |||||||||||||||||||||
The fair value of each option grant is estimated using the Black-Scholes option pricing model. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated primarily based on the historical volatility of the Company’s stock. The average expected life was based on the contractual term of the option and historic exercise experience. The risk-free interest rate is based on United States Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as an analysis of actual option forfeitures. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: | |||||||||||||||||||||
December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | |||||||||||||||||||
Risk-free interest rate | 0.9 | % | 0.6 | % | 1.9 | % | |||||||||||||||
Expected dividend yield | 0.8 | % | 1.2 | % | 1.1 | % | |||||||||||||||
Expected lives | 5 years | 4 years | 4 years | ||||||||||||||||||
Expected stock volatility | 38.5 | % | 38.7 | % | 38.1 | % | |||||||||||||||
The following table summarizes stock option activity for the three fiscal years ended December 29, 2013: | |||||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | |||||||||||||||||||
Number | Weighted- | Number | Weighted- | Number | Weighted- | ||||||||||||||||
of | Average | of | Average | of | Average | ||||||||||||||||
Shares | Price | Shares | Price | Shares | Price | ||||||||||||||||
(Shares in thousands) | |||||||||||||||||||||
Outstanding at beginning of year | 4,266 | $ | 21.64 | 5,346 | $ | 20.57 | 6,983 | $ | 21.86 | ||||||||||||
Granted | 518 | 33.62 | 756 | 26.28 | 847 | 24.2 | |||||||||||||||
Exercised | (947 | ) | 21.45 | (1,611 | ) | 20.16 | (1,138 | ) | 20.86 | ||||||||||||
Canceled | (8 | ) | 22.88 | (210 | ) | 22.34 | (1,237 | ) | 30.29 | ||||||||||||
Forfeited | (335 | ) | 23.04 | (15 | ) | 21.98 | (109 | ) | 18.27 | ||||||||||||
Outstanding at end of year | 3,494 | $ | 23.34 | 4,266 | $ | 21.64 | 5,346 | $ | 20.57 | ||||||||||||
Exercisable at end of year | 2,392 | $ | 20.66 | 2,677 | $ | 20 | 3,549 | $ | 20.74 | ||||||||||||
The aggregate intrinsic value for stock options outstanding at December 29, 2013 was $51.7 million with a weighted-average remaining contractual term of 3.5 years. The aggregate intrinsic value for stock options exercisable at December 29, 2013 was $41.8 million with a weighted-average remaining contractual term of 2.7 years. At December 29, 2013, there were 3.4 million stock options that were vested, and expected to vest in the future, with an aggregate intrinsic value of $51.3 million and a weighted-average remaining contractual term of 3.5 years. | |||||||||||||||||||||
The weighted-average per-share grant-date fair value of options granted during fiscal years 2013, 2012, and 2011 was $10.82, $7.36, and $7.03, respectively. The total intrinsic value of options exercised during fiscal years 2013, 2012, and 2011 was $13.8 million, $13.1 million, and $6.9 million, respectively. Cash received from option exercises for fiscal years 2013, 2012, and 2011 was $20.3 million, $32.5 million, and $23.7 million, respectively. The total compensation expense recognized related to the Company’s outstanding options was $4.4 million in fiscal year 2013, $5.1 million in fiscal year 2012 and $4.5 million in fiscal year 2011. | |||||||||||||||||||||
There was $5.6 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of December 29, 2013. This cost is expected to be recognized over a weighted-average period of 1.7 years, and will be adjusted for any future changes in estimated forfeitures. | |||||||||||||||||||||
Restricted Stock Awards: The Company has awarded shares of restricted stock and restricted stock units to certain employees at no cost to them, which cannot be sold, assigned, transferred or pledged during the restriction period. The restricted stock and restricted stock units vest through the passage of time, assuming continued employment. The fair value of the award at the time of the grant is expensed on a straight line basis primarily in selling, general and administrative expenses over the vesting period, which is generally three years. These awards were granted under the Company’s 2009 Plan, 2005 Incentive Plan and 2001 Incentive Plan. Recipients of the restricted stock have the right to vote such shares and receive dividends. | |||||||||||||||||||||
The following table summarizes restricted stock award activity for the three fiscal years ended December 29, 2013: | |||||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | |||||||||||||||||||
Number | Weighted- | Number | Weighted- | Number | Weighted- | ||||||||||||||||
of | Average | of | Average | of | Average | ||||||||||||||||
Shares | Grant- | Shares | Grant- | Shares | Grant- | ||||||||||||||||
Date Fair | Date Fair | Date Fair | |||||||||||||||||||
Value | Value | Value | |||||||||||||||||||
(Shares in thousands) | |||||||||||||||||||||
Nonvested at beginning of year | 781 | $ | 24.71 | 672 | $ | 23.62 | 578 | $ | 22 | ||||||||||||
Granted | 289 | 33.87 | 358 | 25.86 | 460 | 26.31 | |||||||||||||||
Vested | (346 | ) | 22.98 | (184 | ) | 23.19 | (272 | ) | 23.96 | ||||||||||||
Forfeited | (75 | ) | 28.76 | (65 | ) | 24.03 | (94 | ) | 24.58 | ||||||||||||
Nonvested at end of year | 649 | $ | 29.24 | 781 | $ | 24.71 | 672 | $ | 23.62 | ||||||||||||
The fair value of restricted stock awards vested during fiscal years 2013, 2012, and 2011 was $8.0 million, $4.3 million, and $6.5 million, respectively. The total compensation expense recognized related to the restricted stock awards was $7.5 million in fiscal year 2013, $8.2 million in fiscal year 2012 and $6.5 million in fiscal year 2011. | |||||||||||||||||||||
As of December 29, 2013, there was $9.0 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.2 fiscal years. | |||||||||||||||||||||
Performance Units: The Company’s performance unit program provides a cash award based on the achievement of specific performance criteria. A target number of units are granted at the beginning of a three-year performance period. The number of units earned at the end of the performance period is determined by multiplying the number of units granted by a performance factor ranging from 0% to 200%. Awards are determined by multiplying the number of units earned by the stock price at the end of the performance period, and are paid in cash and accounted for as a liability based award. The compensation expense associated with these units is recognized over the period that the performance targets are expected to be achieved. The Company granted 98,056 performance units, 122,675 performance units, and 89,828 performance units during fiscal years 2013, 2012, and 2011, respectively. The weighted-average per-share grant-date fair value of performance units granted during fiscal years 2013, 2012, and 2011 was $34.06, $26.18, and $26.71, respectively. The total compensation expense related to these performance units was $1.4 million, $7.1 million, and $3.7 million for fiscal years 2013, 2012, and 2011, respectively. As of December 29, 2013, there were 282,044 performance units outstanding subject to forfeiture, with a corresponding liability of $4.8 million recorded in accrued expenses and long-term liabilities. | |||||||||||||||||||||
Stock Awards: The Company’s stock award program provides non-employee Directors an annual equity award. For fiscal years 2013, 2012, and 2011 the award equaled the number of shares of the Company’s common stock which has an aggregate fair market value of $100,000 on the date of the award. The stock award is prorated for non-employee Directors who serve for only a portion of the year. The compensation expense associated with these stock awards is recognized when the stock award is granted. In fiscal years 2013, 2012, and 2011, each non-employee Director was awarded 3,263 shares, 3,580 shares, and 3,544 shares, respectively. The Company also granted 955 shares to a new non-employee Director during fiscal year 2012. The weighted-average per-share grant-date fair value of stock awards granted during fiscal years 2013, 2012, and 2011 was $30.65, $27.87, and $28.22, respectively. In fiscal years 2013, 2012, and 2011, the total compensation expense recognized related to these stock awards was $0.7 million, $0.7 million and $0.8 million, respectively. | |||||||||||||||||||||
Employee Stock Purchase Plan: In April 1999, the Company’s shareholders approved the 1998 Employee Stock Purchase Plan. In April 2005, the Compensation and Benefits Committee of the Board voted to amend the Employee Stock Purchase Plan, effective July 1, 2005, whereby participating employees have the right to purchase common stock at a price equal to 95% of the closing price on the last day of each six-month offering period. The number of shares which an employee may purchase, subject to certain aggregate limits, is determined by the employee’s voluntary contribution, which may not exceed 10% of the employee’s base compensation. During fiscal year 2013, the Company issued 89,521 shares of common stock under the Company’s Employee Stock Purchase Plan at a weighted-average price of $30.51 per share. During fiscal year 2012, the Company issued 53,961 shares under this plan at a weighted-average price of $24.51 per share. During fiscal year 2011, the Company issued 102,970 shares under this plan at a weighted-average price of $21.33 per share. At December 29, 2013 there remains available for sale to employees an aggregate of 1.1 million shares of the Company’s common stock out of the 5.0 million shares authorized by shareholders for issuance under this plan. |
Stockholders_Equity
Stockholders' Equity | 12 Months Ended | |||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||||||
Stockholders' Equity | ' | |||||||||||||||||||
Stockholders’ Equity | ||||||||||||||||||||
Comprehensive Income: | ||||||||||||||||||||
The components of accumulated other comprehensive income consisted of the following: | ||||||||||||||||||||
Foreign | Unrecognized | Unrealized | Unrealized and Realized (Losses) Gains on Derivatives, net of tax | Accumulated | ||||||||||||||||
Currency | Prior Service | (Losses) | Other | |||||||||||||||||
Translation | Costs, net of | Gains on | Comprehensive | |||||||||||||||||
Adjustment, | tax | Securities, | Income | |||||||||||||||||
net of tax | net of tax | |||||||||||||||||||
(In thousands) | ||||||||||||||||||||
Balance, January 2, 2011 | $ | 54,350 | $ | 2,062 | $ | (100 | ) | $ | (5,284 | ) | $ | 51,028 | ||||||||
Current year change | 1,814 | 107 | (59 | ) | 1,196 | 3,058 | ||||||||||||||
Balance, January 1, 2012 | 56,164 | 2,169 | (159 | ) | (4,088 | ) | 54,086 | |||||||||||||
Current year change | 11,363 | (82 | ) | 30 | 1,196 | 12,507 | ||||||||||||||
Balance, December 30, 2012 | 67,527 | 2,087 | (129 | ) | (2,892 | ) | 66,593 | |||||||||||||
Current year change | 8,756 | (658 | ) | 8 | 2,892 | 10,998 | ||||||||||||||
Balance, December 29, 2013 | $ | 76,283 | $ | 1,429 | $ | (121 | ) | $ | — | $ | 77,591 | |||||||||
During fiscal year 2013, pre-tax losses of $4.8 million were reclassified from accumulated other comprehensive income into interest and other expense, net, related to previously settled cash flow hedges, which includes $2.8 million for the remaining unamortized derivative losses that were reclassified when the Company redeemed all of its 2015 Notes. The Company recognized a tax provision of $1.9 million related to these amounts reclassified out of accumulated other comprehensive income for fiscal year 2013. During both fiscal years 2012 and 2011, pre-tax losses of $2.0 million were reclassified from accumulated other comprehensive income into interest and other expense, net related to previously settled cash flow hedges. The Company recognized a tax provision of $0.8 million related to these amounts reclassified out of accumulated other comprehensive income in both fiscal years 2012 and 2011. During fiscal years 2013, 2012, and 2011, pre-tax expense of $0.7 million, pre-tax expense of $0.1 million, and pre-tax income of $0.1 million, respectively, were reclassified from accumulated other comprehensive income into selling, general and administrative expenses as a component of net periodic benefit cost. | ||||||||||||||||||||
Stock Repurchase Program: | ||||||||||||||||||||
On October 24, 2012, the Board of Directors (the "Board") authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 24, 2014 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During fiscal year 2013, the Company repurchased approximately 3.6 million shares of common stock in the open market at an aggregate cost of $123.0 million, including commissions, under the Repurchase Program. During fiscal year 2012, the Company did not repurchase any shares of common stock under any stock repurchase program. During fiscal year 2011, the Company repurchased approximately 4.0 million shares of common stock in the open market at an aggregate cost of $107.8 million, including commissions. The repurchases made during fiscal year 2011 were made pursuant to the Company's stock repurchase program originally announced in October 2008 that expired in October 2012. As of December 29, 2013, approximately 2.4 million shares authorized by the Board under the Repurchase Program remained available for repurchase. | ||||||||||||||||||||
The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans. During fiscal year 2013, the Company repurchased 127,544 shares of common stock for this purpose at an aggregate cost of $4.4 million. During fiscal year 2012, the Company repurchased 82,186 shares of common stock for this purpose at an aggregate cost of $2.1 million. During fiscal year 2011, the Company repurchased 84,243 shares of common stock for this purpose at an aggregate cost of $2.2 million. | ||||||||||||||||||||
The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value. | ||||||||||||||||||||
Dividends: | ||||||||||||||||||||
The Board declared a regular quarterly cash dividend of $0.07 per share in each quarter of fiscal years 2013 and 2012. At December 29, 2013, the Company has accrued $7.9 million for dividends declared on October 24, 2013 for the fourth quarter of fiscal year 2013 payable in February 2014. On January 24, 2014, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the first quarter of fiscal year 2014 that will be payable in May 2014. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources. |
Derivatives_And_Hedging_Activi
Derivatives And Hedging Activities | 12 Months Ended |
Dec. 29, 2013 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' |
Derivatives and Hedging Activities | ' |
Derivatives and Hedging Activities | |
The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures. | |
In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings. | |
Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as fair value hedges, with U.S. equivalent notional amounts totaling $138.4 million at December 29, 2013, $64.3 million at December 30, 2012, and $268.9 million at January 1, 2012, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during fiscal years 2013, 2012, and 2011. | |
As of December 29, 2013, the Company had no cash flow hedges outstanding, and as of December 30, 2012, the Company had two outstanding cash flow hedges. During fiscal year 2012, the Company entered into two forward foreign exchange contracts with settlement dates in fiscal year 2013 and combined Euro denominated notional amounts of €50.0 million, designated as cash flow hedges. During fiscal year 2013 the Company settled these Euro denominated forward foreign exchange contracts. The derivative gains were amortized into interest and other expense, net when the hedged exposures affected interest and other expense, net. Such amounts were not material for fiscal year 2013. | |
In May 2008, the Company settled forward interest rate contracts with notional amounts totaling $150.0 million upon the issuance of its 2015 Notes, and recognized $8.4 million, net of taxes of $5.4 million, of accumulated derivative losses in other comprehensive income. During each of fiscal years 2013, 2012, and 2011, the Company amortized a pre-tax loss of $2.0 million into interest and other expense, net. In addition, during fiscal year 2013, the Company redeemed all of its 2015 Notes and recognized a pre-tax loss of $2.8 million for the remaining unamortized derivative losses into interest and other expense, net. | |
The Company does not expect any pre-tax losses to be reclassified from accumulated other comprehensive income into interest and other expense, net within the next twelve months. |
Fair_Value_Measurements
Fair Value Measurements | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||
Fair Value Measurements | ' | |||||||||||||||
Fair Value Measurements | ||||||||||||||||
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of December 29, 2013. | ||||||||||||||||
The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during fiscal years 2013 and 2012. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value. | ||||||||||||||||
Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. | ||||||||||||||||
The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2013 and December 30, 2012 classified in one of the three classifications described above: | ||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable Inputs | |||||||||||||
December 29, | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
2013 | ||||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,319 | $ | 1,319 | $ | — | $ | — | ||||||||
Foreign exchange derivative assets | 293 | — | 293 | — | ||||||||||||
Foreign exchange derivative liabilities | (396 | ) | — | (396 | ) | — | ||||||||||
Contingent consideration | (4,926 | ) | — | — | (4,926 | ) | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable Inputs | |||||||||||||
December 30, | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,149 | $ | 1,149 | $ | — | $ | — | ||||||||
Foreign exchange derivative assets | 274 | — | 274 | — | ||||||||||||
Foreign exchange derivative liabilities, net | (294 | ) | — | (294 | ) | — | ||||||||||
Contingent consideration | (3,017 | ) | — | — | (3,017 | ) | ||||||||||
Valuation Techniques: The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices, and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities. | ||||||||||||||||
Marketable securities: Include equity and fixed-income securities measured at fair value using the quoted market prices at the reporting date. | ||||||||||||||||
Foreign exchange derivative assets and liabilities: Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. | ||||||||||||||||
Valuation Techniques: The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities. | ||||||||||||||||
Contingent consideration: The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $31.3 million as of December 29, 2013. As of December 29, 2013, the Company has recorded contingent consideration obligations relating to its acquisitions of Dexela Limited, Haoyuan and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $4.9 million. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date, and the remaining weighted average earnout period at December 29, 2013 was two years. | ||||||||||||||||
A reconciliation of the beginning and ending Level 3 net liabilities is as follows: | ||||||||||||||||
(In thousands) | ||||||||||||||||
Balance at January 2, 2011 | $ | (1,731 | ) | |||||||||||||
Additions | (20,131 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 1,908 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | (344 | ) | ||||||||||||||
Balance at January 1, 2012 | (20,298 | ) | ||||||||||||||
Additions | (1,900 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 17,433 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | 1,748 | |||||||||||||||
Balance at December 30, 2012 | (3,017 | ) | ||||||||||||||
Additions | (1,100 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 135 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | (944 | ) | ||||||||||||||
Balance at December 29, 2013 | $ | (4,926 | ) | |||||||||||||
During the fourth quarter of fiscal year 2012, the Company recorded $74.2 million of pre-tax intangible asset impairment charges related to certain trade names. A description of these impairment charges is included within Note 12. The fair value measurements were determined using a relief from royalty method, which incorporates unobservable inputs, thereby classifying the fair value measurements as a Level 3 measurement within the fair value hierarchy. The primary inputs used in the relief from royalty method, an income-based approach, included estimated prospective cash flows considering the revised useful lives and an estimated royalty rate that would be used by a market participant. The royalty rates ranged from 0.5% to 1.0%, the discount rates ranged from 11.0% to 12.0%, and the useful lives ranged from 1 to 8 years. The identified indefinite-lived intangibles related to the above impairment charges, had a carrying value of $76.4 million and a fair value of $4.5 million as of the impairment date, resulting in an impairment loss of $71.9 million. The identified definite-lived intangibles related to the above impairment charges, had a carrying value of $3.8 million and a fair value of $1.5 million as of the impairment date, resulting in an impairment loss of $2.3 million. | ||||||||||||||||
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1. | ||||||||||||||||
The Company’s senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $397.0 million and $258.0 million as of December 29, 2013 and December 30, 2012, respectively. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during fiscal year 2013. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2. | ||||||||||||||||
The Company’s 2015 Notes, with a face value of $150.0 million, had an aggregate carrying value of $150.0 million and a fair value of $165.4 million as of December 30, 2012. The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $513.0 million as of December 29, 2013. The 2021 Notes had an aggregate carrying value of $497.2 million, net of $2.8 million of unamortized original issue discount, and a fair value of $558.3 million as of December 30, 2012. The fair value of the 2021 Notes is estimated using market quotes from brokers and are based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $40.3 million and $34.6 million as of December 29, 2013 and December 30, 2012, respectively, and approximated the fair value as there has been minimal change in the Company's incremental borrowing rate. As of December 29, 2013, the 2021 Notes and financing lease obligations were classified as Level 2. | ||||||||||||||||
As of December 29, 2013, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks. |
Leases
Leases | 12 Months Ended |
Dec. 29, 2013 | |
Leases [Abstract] | ' |
Leases | ' |
Leases | |
The Company leases certain property and equipment under operating leases. Rental expense charged to continuing operations for fiscal years 2013, 2012, and 2011 amounted to $52.7 million, $60.3 million, and $49.1 million, respectively. Minimum rental commitments under noncancelable operating leases are as follows: $56.5 million in fiscal year 2014, $39.1 million in fiscal year 2015, $27.2 million in fiscal year 2016, $22.5 million in fiscal year 2017, $19.5 million in fiscal year 2018 and $91.5 million in fiscal year 2019 and thereafter. | |
On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and the Company has deferred $26.5 million of gains which will be amortized in operating expenses over the initial lease term of 15 years. During fiscal year 2013, the Company amortized $0.6 million of deferred gains related to the lease. At December 29, 2013, $25.9 million of these deferred gains remained to be amortized, recorded in long-term liabilities. |
Industry_Segment_and_Geographi
Industry Segment and Geographic Area Information | 12 Months Ended | |||||||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||||||
Industry Segment Information | ' | |||||||||||||||||||||||
Industry Segment and Geographic Area Information | ||||||||||||||||||||||||
The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1. | ||||||||||||||||||||||||
The Company realigned its organization at the beginning of fiscal year 2013. The Company's Informatics business, as well as its field service on products previously sold by the Company's former Bio-discovery business, were moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2013 reflect this new alignment of the Company's operating segments. Financial information relating to fiscal years 2012 and 2011 has been retrospectively adjusted to reflect the changes to the operating segments. The principal products and services of these two operating segments are: | ||||||||||||||||||||||||
• | Human Health. Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets. | |||||||||||||||||||||||
• | Environmental Health. Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. | |||||||||||||||||||||||
The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments. | ||||||||||||||||||||||||
Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below for the fiscal years ended: | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(As adjusted) | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
Human Health | ||||||||||||||||||||||||
Product revenue | $ | 957,022 | $ | 926,733 | $ | 761,665 | ||||||||||||||||||
Service revenue | 252,734 | 247,909 | 216,227 | |||||||||||||||||||||
Total revenue | 1,209,756 | 1,174,642 | 977,892 | |||||||||||||||||||||
Operating income from continuing operations(1) | 146,100 | 59,196 | 89,725 | |||||||||||||||||||||
Environmental Health | ||||||||||||||||||||||||
Product revenue | 541,048 | 547,941 | 557,845 | |||||||||||||||||||||
Service revenue | 415,428 | 392,622 | 382,771 | |||||||||||||||||||||
Total revenue | 956,476 | 940,563 | 940,616 | |||||||||||||||||||||
Operating income from continuing operations(1) | 97,052 | 111,844 | 108,922 | |||||||||||||||||||||
Corporate | ||||||||||||||||||||||||
Operating loss from continuing operations(2) | (25,710 | ) | (72,497 | ) | (107,519 | ) | ||||||||||||||||||
Continuing Operations | ||||||||||||||||||||||||
Product revenue | $ | 1,498,070 | $ | 1,474,674 | $ | 1,319,510 | ||||||||||||||||||
Service revenue | 668,162 | 640,531 | 598,998 | |||||||||||||||||||||
Total revenue | 2,166,232 | 2,115,205 | 1,918,508 | |||||||||||||||||||||
Operating income from continuing operations | 217,442 | 98,543 | 91,128 | |||||||||||||||||||||
Interest and other expense, net (see Note 5) | 64,110 | 47,956 | 26,774 | |||||||||||||||||||||
Income from continuing operations before income taxes | $ | 153,332 | $ | 50,587 | $ | 64,354 | ||||||||||||||||||
____________________________ | ||||||||||||||||||||||||
(1) | Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company recognized a $6.7 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012. The Company recognized a $3.0 million pre-tax impairment charge in the Human Health segment in fiscal year 2011. | |||||||||||||||||||||||
(2) | Activity related to the mark-to-market adjustment on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted pre-tax income of $17.6 million in fiscal year 2013, a pre-tax loss of $31.8 million in fiscal year 2012, and a pre-tax loss of $67.9 million in fiscal year 2011. | |||||||||||||||||||||||
Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 29, 2013: | ||||||||||||||||||||||||
Depreciation and Amortization | Capital Expenditures | |||||||||||||||||||||||
Expense | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | 2013 | 2012 | 2012 | |||||||||||||||||||
(As adjusted) | (As adjusted) | |||||||||||||||||||||||
(In thousands) | (In thousands) | |||||||||||||||||||||||
Human Health | $ | 100,174 | $ | 101,336 | $ | 81,938 | $ | 20,910 | $ | 24,525 | $ | 16,570 | ||||||||||||
Environmental Health | 25,915 | 23,001 | 27,288 | 16,532 | 14,488 | 12,015 | ||||||||||||||||||
Corporate | 2,382 | 2,528 | 1,695 | 1,549 | 3,395 | 2,007 | ||||||||||||||||||
Continuing operations | $ | 128,471 | $ | 126,865 | $ | 110,921 | $ | 38,991 | $ | 42,408 | $ | 30,592 | ||||||||||||
Additional information relating to the Company’s reporting segments is as follows for the fiscal years ended: | ||||||||||||||||||||||||
Total Assets | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(As adjusted) | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
Human Health | $ | 2,698,640 | $ | 2,714,366 | $ | 2,674,243 | ||||||||||||||||||
Environmental Health | 1,213,801 | 1,153,444 | 1,150,015 | |||||||||||||||||||||
Corporate | 34,271 | 33,952 | 31,181 | |||||||||||||||||||||
Net current and long-term assets of discontinued operations | — | — | 202 | |||||||||||||||||||||
Total assets | $ | 3,946,712 | $ | 3,901,762 | $ | 3,855,641 | ||||||||||||||||||
The following geographic area information for continuing operations includes revenue based on location of external customer for the three fiscal years ended December 29, 2013 and net long-lived assets based on physical location as of December 29, 2013 and December 30, 2012: | ||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
U.S. | $ | 835,637 | $ | 822,951 | $ | 725,849 | ||||||||||||||||||
International: | ||||||||||||||||||||||||
China | 254,838 | 216,425 | 164,005 | |||||||||||||||||||||
United Kingdom | 133,611 | 118,611 | 102,366 | |||||||||||||||||||||
Germany | 99,153 | 105,735 | 113,472 | |||||||||||||||||||||
Japan | 95,676 | 114,300 | 89,977 | |||||||||||||||||||||
France | 81,719 | 84,395 | 85,395 | |||||||||||||||||||||
Italy | 78,120 | 69,599 | 74,925 | |||||||||||||||||||||
Other international | 587,478 | 583,189 | 562,519 | |||||||||||||||||||||
Total international | 1,330,595 | 1,292,254 | 1,192,659 | |||||||||||||||||||||
Total sales | $ | 2,166,232 | $ | 2,115,205 | $ | 1,918,508 | ||||||||||||||||||
Net Long-Lived Assets | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
U.S. | $ | 216,821 | $ | 205,083 | $ | 147,883 | ||||||||||||||||||
International: | ||||||||||||||||||||||||
China | 30,682 | 30,134 | 22,145 | |||||||||||||||||||||
Finland | 13,635 | 11,851 | 12,833 | |||||||||||||||||||||
United Kingdom | 9,882 | 2,960 | 2,508 | |||||||||||||||||||||
Singapore | 6,812 | 6,366 | 5,663 | |||||||||||||||||||||
Netherlands | 4,037 | 3,900 | 4,074 | |||||||||||||||||||||
Italy | 2,735 | 3,303 | 3,288 | |||||||||||||||||||||
Germany | 2,591 | 2,353 | 2,225 | |||||||||||||||||||||
Brazil | 1,967 | 1,515 | 1,637 | |||||||||||||||||||||
Japan | 1,772 | 2,310 | 2,552 | |||||||||||||||||||||
Other international | 7,306 | 7,932 | 12,589 | |||||||||||||||||||||
Total international | 81,419 | 72,624 | 69,514 | |||||||||||||||||||||
Total net long-lived assets | $ | 298,240 | $ | 277,707 | $ | 217,397 | ||||||||||||||||||
Quarterly_Financial_Informatio
Quarterly Financial Information (Unaudited) | 12 Months Ended | |||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | |||||||||||||||||||
Quarterly Financial Information (Unaudited) | ' | |||||||||||||||||||
Quarterly Financial Information (Unaudited) | ||||||||||||||||||||
Selected quarterly financial information is as follows for the fiscal years ended: | ||||||||||||||||||||
First | Second | Third | Fourth | Year | ||||||||||||||||
Quarter | Quarter | Quarter | Quarter(1)(2) | |||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||||||
December 29, 2013 | ||||||||||||||||||||
Revenue | $ | 505,378 | $ | 543,297 | $ | 524,277 | $ | 593,280 | $ | 2,166,232 | ||||||||||
Gross profit | 224,885 | 242,299 | 233,512 | 276,278 | 976,974 | |||||||||||||||
Restructuring and contract termination charges, net | 3,310 | 19,277 | 1,126 | 10,215 | 33,928 | |||||||||||||||
Operating income from continuing operations | 35,901 | 39,664 | 57,196 | 84,681 | 217,442 | |||||||||||||||
Income from continuing operations before income taxes | 23,861 | 26,799 | 44,856 | 57,816 | 153,332 | |||||||||||||||
Income from continuing operations | 32,289 | 26,936 | 40,299 | 68,400 | 167,924 | |||||||||||||||
Net income | 32,216 | 27,925 | 40,198 | 66,873 | 167,212 | |||||||||||||||
Basic earnings per share: | ||||||||||||||||||||
Income from continuing operations | $ | 0.28 | $ | 0.24 | $ | 0.36 | $ | 0.61 | $ | 1.5 | ||||||||||
Net income | 0.28 | 0.25 | 0.36 | 0.6 | 1.49 | |||||||||||||||
Diluted earnings per share: | ||||||||||||||||||||
Income from continuing operations | $ | 0.28 | $ | 0.24 | $ | 0.36 | $ | 0.6 | $ | 1.48 | ||||||||||
Net income | 0.28 | 0.25 | 0.36 | 0.59 | 1.47 | |||||||||||||||
Cash dividends declared per common share | 0.07 | 0.07 | 0.07 | 0.07 | 0.28 | |||||||||||||||
December 30, 2012 | ||||||||||||||||||||
Revenue | $ | 510,890 | $ | 521,790 | $ | 509,604 | $ | 572,921 | $ | 2,115,205 | ||||||||||
Gross profit | 232,014 | 238,794 | 230,740 | 261,658 | 963,206 | |||||||||||||||
Restructuring and contract termination charges, net | 6,159 | 5,203 | 9,672 | 4,103 | 25,137 | |||||||||||||||
Operating income from continuing operations | 36,382 | 49,787 | 43,218 | (30,844 | ) | 98,543 | ||||||||||||||
Income (loss) from continuing operations before income taxes | 23,552 | 38,429 | 31,346 | (42,740 | ) | 50,587 | ||||||||||||||
Income (loss) from continuing operations | 22,076 | 33,568 | 28,989 | (16,192 | ) | 68,441 | ||||||||||||||
Net income (loss) | 22,569 | 33,633 | 29,594 | (15,856 | ) | 69,940 | ||||||||||||||
Basic earnings per share: | ||||||||||||||||||||
Income (loss) from continuing operations | $ | 0.2 | $ | 0.3 | $ | 0.25 | $ | (0.14 | ) | $ | 0.6 | |||||||||
Net income (loss) | 0.2 | 0.3 | 0.26 | (0.14 | ) | 0.61 | ||||||||||||||
Diluted earnings per share: | ||||||||||||||||||||
Income (loss) continuing operations | $ | 0.19 | $ | 0.29 | $ | 0.25 | $ | (0.14 | ) | $ | 0.6 | |||||||||
Net income (loss) | 0.2 | 0.29 | 0.26 | (0.14 | ) | 0.61 | ||||||||||||||
Cash dividends declared per common share | 0.07 | 0.07 | 0.07 | 0.07 | 0.28 | |||||||||||||||
____________________________ | ||||||||||||||||||||
-1 | The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2013 also includes pre-tax impairment charges of $6.7 million as the carrying amounts of certain long-lived assets were not recoverable and exceeded their fair value. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statues of limitations and audit settlements. | |||||||||||||||||||
-2 | The fourth quarter of fiscal year 2012 includes a pre-tax loss of $31.8 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2012 also includes pre-tax impairment charges of $74.2 million as a result of a review of certain trade names within the Company's portfolio as part of a realignment of its marketing strategy. |
Nature_of_Operations_and_Accou1
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Policies) | 12 Months Ended |
Dec. 29, 2013 | |
Accounting Policies [Abstract] | ' |
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | ' |
Recently Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective dates. The Company believes that the impact of recently issued pronouncements will not have a material impact on the Company's consolidated financial position, results of operations, and cash flows or do not apply to the Company's operations. | |
Consolidation [Policy Text Block] | ' |
The consolidated financial statements include the accounts of PerkinElmer, Inc. and its subsidiaries (the “Company”). All intercompany balances and transactions have been eliminated in consolidation. | |
Segment Reporting [Policy Text Block] | ' |
The Company has two operating segments; Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, the Company serves both the diagnostics and research markets. The Company’s Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. | |
The Company realigned its organization at the beginning of fiscal year 2013. The Company's Informatics business, as well as its field service on products previously sold by the Company's former Bio-discovery business, were moved from the Environmental Health segment into the Human Health segment. The results reported for fiscal year 2013 reflect this new alignment of the Company's operating segments. Financial information relating to fiscal years 2012 and 2011 has been retrospectively adjusted to reflect the changes to the operating segments. | |
Fiscal Periods [Policy Text Block] | ' |
The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. Each of the fiscal years ended December 29, 2013, December 30, 2012 and January 1, 2012 included 52 weeks. The fiscal year ending December 28, 2014 will also include 52 weeks. | |
Subsequent Events [Policy Text Block] | ' |
The Company has evaluated subsequent events from December 29, 2013 through the date of the issuance of these consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these consolidated financial statements. | |
Accounting Policies and Estimates [Policy Text Block] | ' |
Accounting Policies and Estimates: The preparation of consolidated financial statements in accordance with United States (“U.S.”) Generally Accepted Accounting Principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. | |
Revenue Recognition [Policy Text Block] | ' |
Revenue Recognition: The Company’s product revenue is recorded when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, product revenue is recognized upon delivery, and installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, revenue is recognized after the acceptance criteria have been met. Certain of the Company’s products require specialized installation. Revenue for these products is deferred until installation is completed. Revenue from services is deferred and recognized over the contractual period, or as services are rendered. | |
In limited circumstances, the Company has arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, such as cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence ("VSOE") if such evidence is available, third-party evidence ("TPE") if VSOE is not available, and management's best estimate of selling price ("BESP") if neither VSOE nor TPE are available. TPE is the price of the Company's or any competitor's largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which the Company would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors. | |
Revenue from software licenses and services was 5% of the Company's total revenue for fiscal year 2013, 3% of the Company's total revenue for fiscal year 2012, and 2% of the Company's total revenue for fiscal year 2011. The Company sells its software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, the Company determines VSOE of fair value to be the price charged when the undelivered element is sold separately. The Company determines VSOE for maintenance sold in connection with a software license based on the amount that will be separately charged for the maintenance renewal period. The Company determines VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved. | |
The Company recognizes revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, the Company defers all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then the Company recognizes the entire fee ratably over the maintenance period. | |
The Company sells products and accessories predominantly through its direct sales force. As a result, the use of distributors is generally limited to geographic regions where the Company has no direct sales force. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. Sales incentives related to distributor revenue are also the same as those for end-user customers. | |
Service revenues represent the Company’s service offerings including service contracts, field service including related time and materials, diagnostic testing, cord blood processing and storage, and training. Service revenues are recognized as the service is performed. Revenues for service and storage contracts are recognized over the contract period. | |
Warranty Costs [Policy Text Block] | ' |
Warranty Costs: The Company provides for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period. | |
Shipping and Handling Costs [Policy Text Block] | ' |
Shipping and Handling Costs: The Company reports shipping and handling revenue in revenue, to the extent they are billed to customers, and the associated costs in cost of product revenue. | |
Inventories [Policy Text Block] | ' |
Inventories: Inventories, which include material, labor and manufacturing overhead, are valued at the lower of cost or market. Inventories are accounted for using the first-in, first-out method of determining inventory costs. Inventory quantities on-hand are regularly reviewed, and where necessary, provisions for excess and obsolete inventory are recorded based primarily on the Company’s estimated forecast of product demand and production requirements. | |
Income Taxes [Policy Text Block] | ' |
Income Taxes: The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases. This method also requires the recognition of future tax benefits such as net operating loss carryforwards, to the extent that realization of such benefits is more likely than not. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established for any deferred tax asset for which realization is not more likely than not. With respect to earnings expected to be indefinitely reinvested offshore, the Company does not accrue tax for the repatriation of such foreign earnings. | |
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. These reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. Potential interest and penalties associated with such uncertain tax positions is recorded as a component of income tax expense. See Note 6, below, for additional details. | |
Property, Plant and Equipment [Policy Text Block] | ' |
Property, Plant and Equipment: The Company depreciates plant and equipment using the straight-line method over its estimated useful lives, which generally fall within the following ranges: buildings- 10 to 40 years; leasehold improvements-estimated useful life or remaining term of lease, whichever is shorter; and machinery and equipment- 3 to 7 years. Certain tooling costs are capitalized and amortized over a 3-year life, while repairs and maintenance costs are expensed. | |
Asset Retirement Obligations [Policy Text Block] | ' |
Asset Retirement Obligations: The Company records obligations associated with its lease obligations, the retirement of tangible long-lived assets and the associated asset-retirement costs in accordance with authoritative guidance on asset retirement obligations. The Company reviews legal obligations associated with the retirement of long-lived assets that result from contractual obligations or the acquisition, construction, development and/or normal use of the assets. If it is determined that a legal obligation exists, regardless of whether the obligation is conditional on a future event, the fair value of the liability for an asset retirement obligation is recognized in the period in which it is incurred, if a reasonable estimate of fair value can be made. The fair value of the liability is added to the carrying amount of the associated asset, and this additional carrying amount is depreciated over the life of the asset. The difference between the gross expected future cash flow and its present value is accreted over the life of the related lease as an operating expense. The amounts recorded in the consolidated financial statements are not material to any year presented. | |
Change in Accounting for Pension and Other Postretirement Benefits [Policy Text Block] | ' |
Pension and Other Postretirement Benefits: The Company sponsors both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. The Company immediately recognizes actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless the Company is required to perform an interim remeasurement. The remaining components of pension expense, primarily service and interest costs and assumed return on plan assets, are recorded on a quarterly basis. The Company’s funding policy provides that payments to the U.S. pension trusts shall at least be equal to the minimum funding requirements of the Employee Retirement Income Security Act of 1974. Non-U.S. plans are accrued for, but generally not fully funded, and benefits are paid from operating funds | |
Translation of Foreign Currencies [Policy Text Block] | ' |
Translation of Foreign Currencies: For foreign operations, asset and liability accounts are translated at current exchange rates; income and expenses are translated using weighted average exchange rates for the reporting period. Resulting translation adjustments, as well as translation gains and losses from certain intercompany transactions considered permanent in nature, are reported in accumulated other comprehensive income, a separate component of stockholders’ equity. Gains and losses arising from transactions and translation of period-end balances denominated in currencies other than the functional currency are included in other expense, net, and were not material. | |
Business Combinations [Policy Text Block] | ' |
Business Combinations: Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense. All changes that do not qualify as measurement period adjustments are included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed. | |
Goodwill and Other Intangible Assets [Policy Text Block] | ' |
Goodwill and Other Intangible Assets: The Company’s intangible assets consist of (i) goodwill, which is not being amortized; (ii) indefinite lived intangibles, which consist of certain trademarks and trade names that are not subject to amortization; and (iii) amortizing intangibles, which consist of patents, trade names and trademarks, licenses, customer relationships, and purchased technologies, which are being amortized over their estimated useful lives. | |
The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. This annual impairment assessment is performed by the Company on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year, should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful life of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization. Recoverability of amortizing intangible assets is assessed only when events have occurred that may give rise to impairment. When a potential impairment has been identified, forecasted undiscounted net cash flows of the operations to which the asset relates are compared to the current carrying value of the long-lived assets present in that operation. If such cash flows are less than such carrying amounts, long-lived assets, including such intangibles, are written down to their respective fair values. See Note 12, below, for additional details. | |
Stock-Based Compensation [Policy Text Block] | ' |
Stock-Based Compensation: The Company accounts for stock-based compensation expense based on estimated grant date fair value, generally using the Black-Scholes option-pricing model. The fair value is recognized, net of estimated forfeitures, as expense in the consolidated financial statements over the requisite service period. The determination of fair value and the timing of expense using option pricing models such as the Black-Scholes model require the input of highly subjective assumptions, including the expected forfeiture rate, life of the option and the expected price volatility of the underlying stock. The Company estimates the expected forfeiture and expected life assumptions based on historical experience. In determining the Company’s expected stock price volatility assumption, the Company reviews both the historical and implied volatility of the Company’s common stock, with implied volatility based on the implied volatility of publicly traded options on the Company’s common stock. The Company has one stock-based compensation plan from which it makes grants, which is described more fully in Note 18, below. | |
Marketable Securities and Investments [Policy Text Block] | ' |
Marketable Securities and Investments: The cost of securities sold is based on the specific identification method. If securities are classified as available for sale, the Company records these investments at their fair values with unrealized gains and losses included in accumulated other comprehensive income. Under the cost method of accounting, equity investments in private companies are carried at cost and are adjusted for other-than-temporary declines in fair value, additional investments or distributions. | |
Cash Flows [Policy Text Block] | ' |
Cash and Cash Equivalents: The Company considers all highly liquid unrestricted instruments with a purchased maturity of three months or less to be cash equivalents. The carrying amount of cash equivalents approximates fair value due to the short maturities of these instruments. | |
Environmental Matters [Policy Text Block] | ' |
Environmental Matters: The Company accrues for costs associated with the remediation of environmental pollution when it is probable that a liability has been incurred and the Company’s proportionate share of the amount can be reasonably estimated. The recorded liabilities have not been discounted. | |
Restructuring Charges [Policy Text Block] | ' |
Restructuring Charges: In recent fiscal years, the Company has undertaken a series of restructuring actions related to the alignment with the Company’s growth strategy, the impact of acquisitions, divestitures and the integration of its business units. In connection with these initiatives, the Company has recorded restructuring charges, as more fully described in Note 4, below. Generally, costs associated with an exit or disposal activity are recognized when the liability is incurred. Costs related to employee separation arrangements requiring future service beyond a specified minimum retention period are recognized over the service period. Costs related to lease terminations are recorded at the fair value of the liability based on the remaining lease rental payments, reduced by estimated sublease rentals that could be reasonably obtained for the property, at the date the Company ceases use. | |
Comprehensive Income [Policy Text Block] | ' |
Comprehensive Income: In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending December 29, 2013, December 30, 2012 and January 1, 2012. See Note 19 for additional details. | |
Comprehensive income is defined as net income or loss and other changes in stockholders’ equity from transactions and other events from sources other than stockholders. Comprehensive income is reflected in the consolidated statements of comprehensive income. | |
New Accounting Pronouncement or Change in Accounting Principle, Description | 'Comprehensive Income:B B B B In February 2013, the FASB issued ASU 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, requiring the presentation of reclassifications out of accumulated other comprehensive income on the face of the financial statements or as a separate disclosure in the notes to the financial statements. The reclassifications out of accumulated other comprehensive income and into net income were not material for the fiscal years ending DecemberB 29, 2013, DecemberB 30, 2012 and JanuaryB 1, 2012. See Note 19 for additional details. |
Derivative Instruments and Hedging [Policy Text Block] | ' |
Derivative Instruments and Hedging: Derivatives are recorded on the consolidated balance sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. | |
For a cash flow hedge, the effective portion of the derivative’s gain or loss is initially reported as a component of other comprehensive income and subsequently amortized into net earnings when the hedged exposure affects net earnings. Cash flow hedges related to anticipated transactions are designated and documented at the inception of each hedge by matching the terms of the contract to the underlying transaction. The Company classifies the cash flows from hedging transactions in the same categories as the cash flows from the respective hedged items. Once established, cash flow hedges are generally recorded in other comprehensive income, unless an anticipated transaction is no longer likely to occur, and subsequently amortized into net earnings when the hedged exposure affects net earnings. Discontinued or dedesignated cash flow hedges are immediately settled with counterparties, and the related accumulated derivative gains or losses are recognized into net earnings on the consolidated financial statements. Settled cash flow hedges related to forecasted transactions that remain probable are recorded as a component of other comprehensive income and are subsequently amortized into net earnings when the hedged exposure affects net earnings. Forward contract effectiveness for cash flow hedges is calculated by comparing the fair value of the contract to the change in value of the anticipated transaction using forward rates on a monthly basis. As of December 29, 2013, the Company had no outstanding cash flow hedges, and as of December 30, 2012, the Company had two outstanding cash flow hedges with Euro denominated notional amounts of €50.0 million. The Company also has entered into foreign currency forward contracts that are not designated as hedging instruments for accounting purposes. These contracts are recorded at fair value, with the changes in fair value recognized into net earnings on the consolidated financial statements. | |
Research and Development Expense, Policy [Policy Text Block] | ' |
Research and Development: Research and development costs are expensed as incurred. The fair value of acquired in-process research and development ("IPR&D") costs are recorded at fair value as an intangible asset at the acquisition date and amortized once the product is ready for sale or expensed if abandoned. |
Business_Combinations_and_Asse1
Business Combinations and Asset Purchases (Tables) | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Business Acquisition [Line Items] | ' | |||||||
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed | ' | |||||||
The total purchase price for the acquisitions in fiscal year 2011 have been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: | ||||||||
Caliper | Other | |||||||
(In thousands) | ||||||||
Fair value of business combination: | ||||||||
Cash payments | $ | 646,317 | $ | 333,581 | ||||
Contingent consideration | — | 20,124 | ||||||
Working capital and other adjustments | — | 32 | ||||||
Less: cash acquired | (43,576 | ) | (26,923 | ) | ||||
Total | $ | 602,741 | $ | 326,814 | ||||
Identifiable assets acquired and liabilities assumed: | ||||||||
Current assets | $ | 55,027 | $ | 16,857 | ||||
Property, plant and equipment | 14,580 | 1,661 | ||||||
Identifiable intangible assets: | ||||||||
Core technology | 52,000 | 35,724 | ||||||
Trade names | 14,200 | 3,374 | ||||||
Licenses | 18,000 | 3,000 | ||||||
Customer relationships | 93,000 | 96,910 | ||||||
IPR&D | — | 3,839 | ||||||
Goodwill | 353,103 | 236,573 | ||||||
Deferred taxes | 52,472 | (45,017 | ) | |||||
Deferred revenue | (6,554 | ) | (10,496 | ) | ||||
Liabilities assumed | (43,087 | ) | (15,611 | ) | ||||
Total | $ | 602,741 | $ | 326,814 | ||||
November 2012 Haoyuan Biotech Co. [Member] | ' | |||||||
Business Acquisition [Line Items] | ' | |||||||
Fair Values of the Business Combinations and Allocations for the Acquisitions Completed | ' | |||||||
The total purchase price has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows: | ||||||||
Haoyuan | ||||||||
(In thousands) | ||||||||
Fair value of business combination: | ||||||||
Cash payments | $ | 38,000 | ||||||
Contingent consideration | 1,900 | |||||||
Working capital and other adjustments | (2,729 | ) | ||||||
Less: cash acquired | (175 | ) | ||||||
Total | $ | 36,996 | ||||||
Identifiable assets acquired and liabilities assumed: | ||||||||
Current assets | $ | 2,389 | ||||||
Property, plant and equipment | 2,906 | |||||||
Identifiable intangible assets: | ||||||||
Core technology | 17,700 | |||||||
Trade names | 400 | |||||||
IPR&D | 300 | |||||||
Goodwill | 19,682 | |||||||
Deferred taxes | (2,656 | ) | ||||||
Liabilities assumed | (3,725 | ) | ||||||
Total | $ | 36,996 | ||||||
November 2011 Caliper Life Sciences [Member] | ' | |||||||
Business Acquisition [Line Items] | ' | |||||||
Business Acquisition, Pro Forma Information | ' | |||||||
The following unaudited pro forma information presents the combined financial results for the Company and Caliper as if the acquisition of Caliper had been completed at the beginning of fiscal year 2011: | ||||||||
January 1, | ||||||||
2012 | ||||||||
(In thousands) | ||||||||
Pro Forma Statement of Operations Information (Unaudited): | ||||||||
Revenue | $ | 2,042,730 | ||||||
Loss from continuing operations | (25,854 | ) | ||||||
Basic loss per share: | ||||||||
Continuing operations | $ | (0.23 | ) | |||||
Diluted loss per share: | ||||||||
Continuing operations | $ | (0.23 | ) |
Discontinued_Operations_Tables
Discontinued Operations (Tables) | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | ' | |||||||||||
Schedule of Gains and Losses on Disposition of Discontinued Operations | ' | |||||||||||
The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations during the three fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Gain (loss) on disposition of Photoflash business | $ | 493 | $ | 2,459 | $ | (134 | ) | |||||
Loss on disposition of Technical Services business | (2,100 | ) | — | — | ||||||||
Net (loss) gain on disposition of other discontinued operations | (203 | ) | (54 | ) | 2,133 | |||||||
Net (loss) gain on disposition of discontinued operations before income taxes | $ | (1,810 | ) | $ | 2,405 | $ | 1,999 | |||||
Restructuring_and_Contract_Ter1
Restructuring and Contract Terminaiton Charges, Net (Tables) | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Q4 2013 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q4 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 3,912 | $ | 7,271 | $ | 11,183 | ||||||
Amounts paid and foreign currency translation | (1,924 | ) | (417 | ) | (2,341 | ) | ||||||
Balance at December 29, 2013 | $ | 1,988 | $ | 6,854 | $ | 8,842 | ||||||
Q3 2013 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q3 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 394 | $ | 138 | $ | 532 | ||||||
Amounts paid and foreign currency translation | (257 | ) | (138 | ) | (395 | ) | ||||||
Balance at December 29, 2013 | $ | 137 | $ | — | $ | 137 | ||||||
Q2 2013 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q2 2013 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 18,746 | $ | 572 | $ | 19,318 | ||||||
Amounts paid and foreign currency translation | (5,996 | ) | (572 | ) | (6,568 | ) | ||||||
Balance at December 29, 2013 | $ | 12,750 | $ | — | $ | 12,750 | ||||||
Q1 2013 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q1 2013 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 2,585 | ||||||||||
Amounts paid and foreign currency translation | (2,377 | ) | ||||||||||
Balance at December 29, 2013 | $ | 208 | ||||||||||
Q4 2012 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q4 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 2,936 | ||||||||||
Amounts paid and foreign currency translation | (254 | ) | ||||||||||
Balance at December 30, 2012 | 2,682 | |||||||||||
Amounts paid and foreign currency translation | (2,089 | ) | ||||||||||
Balance at December 29, 2013 | $ | 593 | ||||||||||
Q3 2012 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q3 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 7,446 | ||||||||||
Change in estimate | 326 | |||||||||||
Amounts paid and foreign currency translation | (219 | ) | ||||||||||
Balance at December 30, 2012 | 7,553 | |||||||||||
Change in estimate | (524 | ) | ||||||||||
Amounts paid and foreign currency translation | (3,271 | ) | ||||||||||
Balance at December 29, 2013 | $ | 3,758 | ||||||||||
Q2 2012 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q2 2012 Plan activity: | ||||||||||||
Severance | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 7,422 | ||||||||||
Amounts paid and foreign currency translation | (2,836 | ) | ||||||||||
Balance at December 30, 2012 | 4,586 | |||||||||||
Provision | 2,115 | |||||||||||
Change in estimate | (294 | ) | ||||||||||
Amounts paid and foreign currency translation | (5,072 | ) | ||||||||||
Balance at December 29, 2013 | $ | 1,335 | ||||||||||
Q1 2012 Restructuring Plan [Member] | ' | |||||||||||
Restructuring Cost and Reserve [Line Items] | ' | |||||||||||
Schedule of Restructuring Plan Activity | ' | |||||||||||
The following table summarizes the Q1 2012 Plan activity: | ||||||||||||
Severance | Closure of | Total | ||||||||||
Excess Facility | ||||||||||||
Space | ||||||||||||
(In thousands) | ||||||||||||
Provision | $ | 6,315 | $ | 79 | $ | 6,394 | ||||||
Amounts paid and foreign currency translation | (5,034 | ) | (79 | ) | (5,113 | ) | ||||||
Balance at December 30, 2012 | 1,281 | — | 1,281 | |||||||||
Change in estimate | (537 | ) | — | (537 | ) | |||||||
Amounts paid and foreign currency translation | (619 | ) | — | (619 | ) | |||||||
Balance at December 29, 2013 | $ | 125 | $ | — | $ | 125 | ||||||
Interest_and_Other_Expense_Inc1
Interest and Other Expense (Income), Net (Tables) | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Other Income and Expenses [Abstract] | ' | |||||||||||
Interest and Other Expense (Income), Net | ' | |||||||||||
Interest and other expense, net, consisted of the following for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Interest income | $ | (650 | ) | $ | (747 | ) | $ | (1,884 | ) | |||
Interest expense | 49,924 | 45,787 | 24,783 | |||||||||
Other expense, net | 14,836 | 2,916 | 3,875 | |||||||||
Total interest and other expense, net | $ | 64,110 | $ | 47,956 | $ | 26,774 | ||||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Summary of Income Tax Contingencies [Table Text Block] | ' | |||||||||||
The tabular reconciliation of the total amounts of unrecognized tax benefits is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Unrecognized tax benefits, beginning of period | $ | 58,110 | $ | 51,740 | $ | 39,226 | ||||||
Gross increases—tax positions in prior period | 325 | 10,653 | 2,753 | |||||||||
Gross decreases—tax positions in prior period | (10,539 | ) | (4,665 | ) | (4,729 | ) | ||||||
Gross increases—current-period tax positions | 2,222 | 3,343 | 2,451 | |||||||||
Gross increases—related to acquisitions | — | — | 14,412 | |||||||||
Settlements | (3,643 | ) | (2,822 | ) | (430 | ) | ||||||
Lapse of statute of limitations | (6,495 | ) | (595 | ) | (2,224 | ) | ||||||
Foreign currency translation adjustments | (570 | ) | 456 | 281 | ||||||||
Unrecognized tax benefits, end of period | $ | 39,410 | $ | 58,110 | $ | 51,740 | ||||||
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | ' | |||||||||||
The components of (loss) income from continuing operations before income taxes were as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
U.S. | $ | (82,253 | ) | $ | (118,546 | ) | $ | (145,298 | ) | |||
Non-U.S. | 235,585 | 169,133 | 209,652 | |||||||||
Total | $ | 153,332 | $ | 50,587 | $ | 64,354 | ||||||
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | ' | |||||||||||
The components of the provision for (benefit from) income taxes for continuing operations were as follows: | ||||||||||||
Current Expense (Benefit) | Deferred Expense | Total | ||||||||||
(Benefit) | ||||||||||||
(In thousands) | ||||||||||||
Fiscal year ended December 29, 2013 | ||||||||||||
Federal | $ | (1,292 | ) | $ | (29,961 | ) | $ | (31,253 | ) | |||
State | 1,582 | (2,147 | ) | (565 | ) | |||||||
Non-U.S. | 15,025 | 2,201 | 17,226 | |||||||||
Total | $ | 15,315 | $ | (29,907 | ) | $ | (14,592 | ) | ||||
Fiscal year ended December 30, 2012 | ||||||||||||
Federal | $ | (5,234 | ) | $ | (34,920 | ) | $ | (40,154 | ) | |||
State | 2,617 | (2,794 | ) | (177 | ) | |||||||
Non-U.S. | 50,314 | (27,837 | ) | 22,477 | ||||||||
Total | $ | 47,697 | $ | (65,551 | ) | $ | (17,854 | ) | ||||
Fiscal year ended January 1, 2012 | ||||||||||||
Federal | $ | 18,309 | $ | 8,615 | $ | 26,924 | ||||||
State | 3,397 | (4,583 | ) | (1,186 | ) | |||||||
Non-U.S. | 41,765 | (4,321 | ) | 37,444 | ||||||||
Total | $ | 63,471 | $ | (289 | ) | $ | 63,182 | |||||
Schedule of Income Tax Expense (Benefit), Continuing Operations and Discontinued Operations [Table Text Block] | ' | |||||||||||
The total provision for income taxes included in the consolidated financial statements is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Continuing operations | $ | (14,592 | ) | $ | (17,854 | ) | $ | 63,182 | ||||
Discontinued operations | (1,098 | ) | 906 | (4,484 | ) | |||||||
Total | $ | (15,690 | ) | $ | (16,948 | ) | $ | 58,698 | ||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | ' | |||||||||||
A reconciliation of income tax expense at the U.S. federal statutory income tax rate to the recorded tax provision (benefit) is as follows for the fiscal years ended: | ||||||||||||
December 29, | December 30, | January 1, | ||||||||||
2013 | 2012 | 2012 | ||||||||||
(In thousands) | ||||||||||||
Tax at statutory rate | $ | 53,663 | $ | 17,708 | $ | 22,526 | ||||||
Non-U.S. rate differential, net | (36,377 | ) | (26,652 | ) | (37,797 | ) | ||||||
U.S. taxation of multinational operations | 3,658 | 1,727 | 1,487 | |||||||||
State income taxes, net | (2,145 | ) | 3,265 | (5,536 | ) | |||||||
Prior year tax matters | (23,534 | ) | 3,389 | (9,079 | ) | |||||||
Estimated taxes on repatriation | — | — | 79,662 | |||||||||
Federal tax credits | (5,452 | ) | (1,657 | ) | (1,509 | ) | ||||||
Change in valuation allowance | (4,675 | ) | (14,446 | ) | 11,364 | |||||||
Other, net | 270 | (1,188 | ) | 2,064 | ||||||||
Total | $ | (14,592 | ) | $ | (17,854 | ) | $ | 63,182 | ||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | |||||||||||
The tax effects of temporary differences and attributes that gave rise to deferred income tax assets and liabilities as of December 29, 2013 and December 30, 2012 were as follows: | ||||||||||||
December 29, | December 30, | |||||||||||
2013 | 2012 | |||||||||||
(In thousands) | ||||||||||||
Deferred tax assets: | ||||||||||||
Inventory | $ | 9,850 | $ | 9,893 | ||||||||
Reserves and accruals | 30,269 | 19,845 | ||||||||||
Accrued compensation | 15,920 | 15,803 | ||||||||||
Net operating loss and credit carryforwards | 132,710 | 165,274 | ||||||||||
Accrued pension | 23,353 | 34,016 | ||||||||||
Restructuring reserve | 6,853 | 7,951 | ||||||||||
Deferred revenue | 42,687 | 42,054 | ||||||||||
All other, net | 1,666 | 1,432 | ||||||||||
Total deferred tax assets | 263,308 | 296,268 | ||||||||||
Deferred tax liabilities: | ||||||||||||
Postretirement health benefits | (3,894 | ) | (3,472 | ) | ||||||||
Depreciation and amortization | (163,269 | ) | (191,075 | ) | ||||||||
Repatriation accrual | — | (31,447 | ) | |||||||||
Total deferred tax liabilities | (167,163 | ) | (225,994 | ) | ||||||||
Valuation allowance | (63,139 | ) | (67,814 | ) | ||||||||
Net deferred tax assets | $ | 33,006 | $ | 2,460 | ||||||||
Schedule of Deferred Income Taxes, Domestic and Foreign [Table Text Block] | ' | |||||||||||
The components of net deferred tax assets (liabilities) as of December 29, 2013 and December 30, 2012 were as follows: | ||||||||||||
December 29, | December 30, | |||||||||||
2013 | 2012 | |||||||||||
(In thousands) | ||||||||||||
U.S. | $ | 22,565 | $ | (10,919 | ) | |||||||
Non-U.S. | 10,441 | 13,379 | ||||||||||
Total | $ | 33,006 | $ | 2,460 | ||||||||
Earnings_Per_Share_Tables
Earnings Per Share (Tables) | 12 Months Ended | ||||||||
Dec. 29, 2013 | |||||||||
Earnings Per Share [Abstract] | ' | ||||||||
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations | ' | ||||||||
The following table reconciles the number of shares utilized in the earnings per share calculations for the fiscal years ended: | |||||||||
December 29, | December 30, | January 1, | |||||||
2013 | 2012 | 2012 | |||||||
(In thousands) | |||||||||
Number of common shares—basic | 112,254 | 113,728 | 112,976 | ||||||
Effect of dilutive securities: | |||||||||
Stock options | 982 | 847 | 739 | ||||||
Restricted stock awards | 267 | 285 | 149 | ||||||
Number of common shares—diluted | 113,503 | 114,860 | 113,864 | ||||||
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 485 | 1,288 | 2,281 | ||||||
Inventories_Net_Tables
Inventories, Net (Tables) | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Inventory Disclosure [Abstract] | ' | |||||||
Schedule of Net Inventories | ' | |||||||
Inventories as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Raw materials | $ | 92,891 | $ | 74,924 | ||||
Work in progress | 15,505 | 12,768 | ||||||
Finished goods | 152,640 | 159,996 | ||||||
Total inventories, net | $ | 261,036 | $ | 247,688 | ||||
Property_Plant_and_Equipment_N1
Property, Plant and Equipment, Net (Tables) | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Property, Plant and Equipment, Net [Abstract] | ' | |||||||
Property, Plant and Equipment [Table Text Block] | ' | |||||||
Property, plant and equipment, at cost, as of December 29, 2013 and December 30, 2012, consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Land | $ | 1,779 | $ | 8,050 | ||||
Building and leasehold improvements | 174,449 | 180,821 | ||||||
Machinery and equipment | 327,956 | 324,608 | ||||||
Total property, plant and equipment | 504,184 | 513,479 | ||||||
Accumulated depreciation | (318,811 | ) | (302,963 | ) | ||||
Total property, plant and equipment, net | $ | 185,373 | $ | 210,516 | ||||
Marketable_Securities_and_Inve1
Marketable Securities and Investments (Tables) | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Marketable Securities [Abstract] | ' | |||||||||||||||
Schedule of Investments, Noncurrent [Table Text Block] | ' | |||||||||||||||
Investments as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||||||||||
December 29, | December 30, | |||||||||||||||
2013 | 2012 | |||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,319 | $ | 1,149 | ||||||||||||
Available-for-sale Securities [Table Text Block] | ' | |||||||||||||||
Marketable securities classified as available for sale as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||||||||||
Market | Gross Unrealized Holding | |||||||||||||||
Value | Cost | Gains | (Losses) | |||||||||||||
(In thousands) | ||||||||||||||||
December 29, 2013 | ||||||||||||||||
Equity securities | $ | 740 | $ | 871 | $ | — | $ | (131 | ) | |||||||
Fixed-income securities | 308 | 308 | — | — | ||||||||||||
Other | 271 | 334 | — | (63 | ) | |||||||||||
$ | 1,319 | $ | 1,513 | $ | — | $ | (194 | ) | ||||||||
December 30, 2012 | ||||||||||||||||
Equity securities | $ | 657 | $ | 804 | $ | — | $ | (147 | ) | |||||||
Fixed-income securities | 294 | 294 | — | — | ||||||||||||
Other | 198 | 261 | — | (63 | ) | |||||||||||
$ | 1,149 | $ | 1,359 | $ | — | $ | (210 | ) | ||||||||
Goodwill_and_Intangible_Assets1
Goodwill and Intangible Assets, Net (Tables) | 12 Months Ended | |||||||||||
Dec. 29, 2013 | ||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||
Changes in the Carrying Amount of Goodwill | ' | |||||||||||
The changes in the carrying amount of goodwill for fiscal years 2013 and 2012 are as follows (the January 1, 2012 and December 30, 2012 balances have been retrospectively adjusted to reflect the realignment of the Company, see Note 23): | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(In thousands) | ||||||||||||
Adjusted balance at January 1, 2012 | $ | 1,606,913 | $ | 487,322 | $ | 2,094,235 | ||||||
Foreign currency translation | 5,892 | 2,979 | 8,871 | |||||||||
Acquisitions, earnouts and other | 19,682 | — | 19,682 | |||||||||
Adjusted balance at December 30, 2012 | 1,632,487 | 490,301 | 2,122,788 | |||||||||
Foreign currency translation | 12,867 | 2,300 | 15,167 | |||||||||
Acquisitions, earnouts and other | 2,978 | 2,187 | 5,165 | |||||||||
Balance at December 29, 2013 | $ | 1,648,332 | $ | 494,788 | $ | 2,143,120 | ||||||
Identifiable Intangible Asset Balances | ' | |||||||||||
Identifiable intangible asset balances at December 29, 2013 by category and by business segment were as follows: | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(In thousands) | ||||||||||||
Patents | $ | 36,791 | $ | 2,800 | $ | 39,591 | ||||||
Less: Accumulated amortization | (22,205 | ) | (2,002 | ) | (24,207 | ) | ||||||
Net patents | 14,586 | 798 | 15,384 | |||||||||
Trade names and trademarks | 35,972 | 86 | 36,058 | |||||||||
Less: Accumulated amortization | (16,371 | ) | (86 | ) | (16,457 | ) | ||||||
Net trade names and trademarks | 19,601 | — | 19,601 | |||||||||
Licenses | 71,580 | 7,600 | 79,180 | |||||||||
Less: Accumulated amortization | (45,835 | ) | (7,095 | ) | (52,930 | ) | ||||||
Net licenses | 25,745 | 505 | 26,250 | |||||||||
Core technology | 187,387 | 114,683 | 302,070 | |||||||||
Less: Accumulated amortization | (88,811 | ) | (80,515 | ) | (169,326 | ) | ||||||
Net core technology | 98,576 | 34,168 | 132,744 | |||||||||
Customer relationships | 305,038 | 16,357 | 321,395 | |||||||||
Less: Accumulated amortization | (127,397 | ) | (5,436 | ) | (132,833 | ) | ||||||
Net customer relationships | 177,641 | 10,921 | 188,562 | |||||||||
IPR&D | 4,257 | 5,226 | 9,483 | |||||||||
Less: Accumulated amortization | (695 | ) | (1,483 | ) | (2,178 | ) | ||||||
Net IPR&D | 3,562 | 3,743 | 7,305 | |||||||||
Net amortizable intangible assets | 339,711 | 50,135 | 389,846 | |||||||||
Non-amortizable intangible assets: | ||||||||||||
Trade names and trademarks | — | 70,584 | 70,584 | |||||||||
Total | $ | 339,711 | $ | 120,719 | $ | 460,430 | ||||||
Identifiable intangible asset balances at December 30, 2012 by category and business segment were as follows: | ||||||||||||
Human | Environmental | Consolidated | ||||||||||
Health | Health | |||||||||||
(As adjusted) | ||||||||||||
(In thousands) | ||||||||||||
Patents | $ | 91,948 | $ | 16,021 | $ | 107,969 | ||||||
Less: Accumulated amortization | (74,831 | ) | (15,123 | ) | (89,954 | ) | ||||||
Net patents | 17,117 | 898 | 18,015 | |||||||||
Trade names and trademarks | 37,511 | 183 | 37,694 | |||||||||
Less: Accumulated amortization | (13,707 | ) | (179 | ) | (13,886 | ) | ||||||
Net trade names and trademarks | 23,804 | 4 | 23,808 | |||||||||
Licenses | 72,674 | 7,933 | 80,607 | |||||||||
Less: Accumulated amortization | (41,493 | ) | (5,875 | ) | (47,368 | ) | ||||||
Net licenses | 31,181 | 2,058 | 33,239 | |||||||||
Core technology | 268,902 | 138,643 | 407,545 | |||||||||
Less: Accumulated amortization | (146,662 | ) | (101,848 | ) | (248,510 | ) | ||||||
Net core technology | 122,240 | 36,795 | 159,035 | |||||||||
Customer relationships | 321,732 | 5,905 | 327,637 | |||||||||
Less: Accumulated amortization | (105,764 | ) | (2,620 | ) | (108,384 | ) | ||||||
Net customer relationships | 215,968 | 3,285 | 219,253 | |||||||||
IPR&D | 4,163 | 3,300 | 7,463 | |||||||||
Less: Accumulated amortization | (376 | ) | (1,120 | ) | (1,496 | ) | ||||||
Net IPR&D | 3,787 | 2,180 | 5,967 | |||||||||
Net amortizable intangible assets | 414,097 | 45,220 | 459,317 | |||||||||
Non-amortizable intangible assets: | ||||||||||||
Trade names and trademarks | — | 70,584 | 70,584 | |||||||||
Total | $ | 414,097 | $ | 115,804 | $ | 529,901 | ||||||
Debt_Tables
Debt (Tables) | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Debt Disclosure [Abstract] | ' | |||||||||||||||
Schedule of Maturities of Long-term Debt [Table Text Block] | ' | |||||||||||||||
The following table summarizes the maturities of the Company’s indebtedness as of December 29, 2013: | ||||||||||||||||
Sr. Unsecured | 5.0% Sr. Notes | Financing Lease Obligations | Total | |||||||||||||
Revolving | Maturing 2021 | |||||||||||||||
Credit Facility | ||||||||||||||||
Maturing 2016(1) | ||||||||||||||||
(In thousands) | ||||||||||||||||
2014 | $ | — | $ | — | $ | 2,624 | $ | 2,624 | ||||||||
2015 | — | — | 2,632 | 2,632 | ||||||||||||
2016 | 397,000 | — | 2,641 | 399,641 | ||||||||||||
2017 | — | — | 2,649 | 2,649 | ||||||||||||
2018 | — | — | 2,802 | 2,802 | ||||||||||||
2019 and thereafter | — | 500,000 | 26,948 | 526,948 | ||||||||||||
Total before unamortized discount | 397,000 | 500,000 | 40,296 | 937,296 | ||||||||||||
Unamortized discount | — | (2,568 | ) | — | (2,568 | ) | ||||||||||
Total | $ | 397,000 | $ | 497,432 | $ | 40,296 | $ | 934,728 | ||||||||
___________________________ | ||||||||||||||||
-1 | On January 8, 2014, the Company refinanced its debt held under the senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility, with an initial maturity of January 8, 2019. |
Accrued_Expenses_and_Other_Cur1
Accrued Expenses and Other Current Liabilities (Tables) | 12 Months Ended | |||||||
Dec. 29, 2013 | ||||||||
Accounts Payable and Accrued Liabilities, Current [Abstract] | ' | |||||||
Schedule of Accrued Liabilities [Table Text Block] | ' | |||||||
Accrued expenses and other current liabilities as of December 29, 2013 and December 30, 2012 consisted of the following: | ||||||||
December 29, | December 30, | |||||||
2013 | 2012 | |||||||
(In thousands) | ||||||||
Payroll and incentives | $ | 53,049 | $ | 55,342 | ||||
Employee benefits | 41,019 | 42,485 | ||||||
Deferred revenue | 164,723 | 154,247 | ||||||
Federal, non-U.S. and state income taxes | 11,783 | 16,091 | ||||||
Other accrued operating expenses | 133,490 | 119,861 | ||||||
Total accrued expenses and other current liabilities | $ | 404,064 | $ | 388,026 | ||||
Employee_Benefit_Plans_Tables
Employee Benefit Plans (Tables) | 12 Months Ended | |||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||
Pension Plans, Defined Benefit | ' | |||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ' | |||||||||||||||||
Components of Net Periodic Benefit Cost (Credit) | ' | |||||||||||||||||
Net periodic pension (credit) cost for U.S. and non-U.S. plans included the following components for fiscal years ended: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Service cost | $ | 3,664 | $ | 3,852 | $ | 3,880 | ||||||||||||
Interest cost | 21,334 | 23,164 | 25,169 | |||||||||||||||
Expected return on plan assets | (25,106 | ) | (20,768 | ) | (22,534 | ) | ||||||||||||
Actuarial (gain) loss | (16,464 | ) | 28,355 | 64,005 | ||||||||||||||
Amortization of prior service cost | (267 | ) | (242 | ) | (221 | ) | ||||||||||||
Net periodic pension (credit) cost | $ | (16,839 | ) | $ | 34,361 | $ | 70,299 | |||||||||||
Schedule of Net Funded Status | ' | |||||||||||||||||
The following table sets forth the changes in the funded status of the principal U.S. pension plan and the principal non-U.S. pension plans and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2013 and December 30, 2012. | ||||||||||||||||||
December 29, 2013 | December 30, 2012 | |||||||||||||||||
Non-U.S. | U.S. | Non-U.S. | U.S. | |||||||||||||||
(In thousands) | ||||||||||||||||||
Actuarial present value of benefit obligations: | ||||||||||||||||||
Accumulated benefit obligations | $ | 277,125 | $ | 279,299 | $ | 271,153 | $ | 301,770 | ||||||||||
Change in benefit obligations: | ||||||||||||||||||
Projected benefit obligations at beginning of year | $ | 278,707 | $ | 301,770 | $ | 231,325 | $ | 297,001 | ||||||||||
Service cost | 2,589 | 1,075 | 2,502 | 1,350 | ||||||||||||||
Interest cost | 9,834 | 11,500 | 11,235 | 11,929 | ||||||||||||||
Benefits paid and plan expenses | (11,218 | ) | (17,817 | ) | (10,625 | ) | (17,568 | ) | ||||||||||
Participants’ contributions | 391 | — | 432 | — | ||||||||||||||
Plan settlement | (918 | ) | — | — | — | |||||||||||||
Actuarial loss (gain) | 1,678 | (17,229 | ) | 38,541 | 9,058 | |||||||||||||
Effect of exchange rate changes | 7,153 | — | 5,297 | — | ||||||||||||||
Projected benefit obligations at end of year | $ | 288,216 | $ | 279,299 | $ | 278,707 | $ | 301,770 | ||||||||||
Change in plan assets: | ||||||||||||||||||
Fair value of plan assets at beginning of year | $ | 114,515 | $ | 221,755 | $ | 97,836 | $ | 195,022 | ||||||||||
Actual return on plan assets | 17,201 | 8,818 | 12,710 | 27,301 | ||||||||||||||
Benefits paid and plan expenses | (11,218 | ) | (17,817 | ) | (10,625 | ) | (17,568 | ) | ||||||||||
Employer’s contributions | 20,200 | 37,000 | 10,882 | 17,000 | ||||||||||||||
Participants’ contributions | 391 | — | 432 | — | ||||||||||||||
Plan settlement | (918 | ) | — | — | — | |||||||||||||
Effect of exchange rate changes | 3,533 | — | 3,280 | — | ||||||||||||||
Fair value of plan assets at end of year | 143,704 | 249,756 | 114,515 | 221,755 | ||||||||||||||
Net liabilities recognized in the consolidated balance sheets | $ | (144,512 | ) | $ | (29,543 | ) | $ | (164,192 | ) | $ | (80,015 | ) | ||||||
Net amounts recognized in the consolidated balance sheets consist of: | ||||||||||||||||||
Noncurrent assets | $ | 6,879 | $ | — | $ | — | $ | — | ||||||||||
Current liabilities | (7,360 | ) | — | (7,398 | ) | — | ||||||||||||
Noncurrent liabilities | (144,031 | ) | (29,543 | ) | (156,794 | ) | (80,015 | ) | ||||||||||
Net liabilities recognized in the consolidated balance sheets | $ | (144,512 | ) | $ | (29,543 | ) | $ | (164,192 | ) | $ | (80,015 | ) | ||||||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||||||||||||||||
Prior service cost | $ | (1,745 | ) | $ | — | $ | (2,048 | ) | $ | — | ||||||||
Net amounts recognized in accumulated other comprehensive income | $ | (1,745 | ) | $ | — | $ | (2,048 | ) | $ | — | ||||||||
Actuarial assumptions as of the year-end measurement date: | ||||||||||||||||||
Discount rate | 3.77 | % | 4.77 | % | 3.62 | % | 3.92 | % | ||||||||||
Rate of compensation increase | 3.23 | % | None | 2.88 | % | None | ||||||||||||
Actuarial assumptions used to determine net periodic pension cost during the year were as follows: | ||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | ||||||||||||||||
Non-U.S. | U.S. | Non-U.S. | U.S. | Non-U.S. | U.S. | |||||||||||||
Discount rate | 3.62 | % | 3.92 | % | 4.91 | % | 4.1 | % | 5.14 | % | 5.3 | % | ||||||
Rate of compensation increase | 2.88 | % | None | 3.22 | % | 3.5 | % | 3.42 | % | 3.5 | % | |||||||
Expected rate of return on assets | 5.5 | % | 7.5 | % | 5.4 | % | 7.75 | % | 6.7 | % | 8.1 | % | ||||||
Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets [Table Text Block] | ' | |||||||||||||||||
The following table provides a breakdown of the non-U.S. benefit obligations and fair value of assets for pension plans that have benefit obligations in excess of plan assets: | ||||||||||||||||||
December 29, | December 30, | |||||||||||||||||
2013 | 2012 | |||||||||||||||||
(In thousands) | ||||||||||||||||||
Pension Plans with Projected Benefit Obligations in Excess of Plan Assets | ||||||||||||||||||
Projected benefit obligations | $ | 151,391 | $ | 278,707 | ||||||||||||||
Fair value of plan assets | — | 114,515 | ||||||||||||||||
Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets | ||||||||||||||||||
Accumulated benefit obligations | $ | 148,235 | $ | 271,153 | ||||||||||||||
Fair value of plan assets | — | 114,515 | ||||||||||||||||
Schedule of Allocation of Plan Assets | ' | |||||||||||||||||
Assets of the defined benefit pension plans are primarily equity and debt securities. Asset allocations as of December 29, 2013 and December 30, 2012, and target asset allocations for fiscal year 2014 are as follows: | ||||||||||||||||||
Target Allocation | Percentage of Plan Assets at | |||||||||||||||||
December 28, 2014 | December 29, 2013 | December 30, 2012 | ||||||||||||||||
Asset Category | Non-U.S. | U.S. | Non-U.S. | U.S. | Non-U.S. | U.S. | ||||||||||||
Equity securities | 45-55% | 40-50% | 51 | % | 43 | % | 71 | % | 55 | % | ||||||||
Debt securities | 45-55% | 50-60% | 48 | % | 57 | % | 29 | % | 39 | % | ||||||||
Other | 0-5% | 0-5% | 1 | % | 0 | % | 0 | % | 6 | % | ||||||||
Total | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | 100 | % | ||||||
Schedule of Changes in Fair Value of Plan Assets | ' | |||||||||||||||||
The fair values of the Company’s pension plan assets as of December 29, 2013 and December 30, 2012 by asset category, classified in the three levels of inputs described in Note 21 to the consolidated financial statements are as follows: | ||||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 29, 2013 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 4,458 | $ | 4,458 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 34,127 | 34,127 | — | — | ||||||||||||||
International large-cap value | 27,595 | 27,595 | — | — | ||||||||||||||
Emerging markets growth | 12,517 | 12,517 | — | — | ||||||||||||||
Equity index funds | 73,796 | — | 73,796 | — | ||||||||||||||
Domestic real estate funds | 2,471 | 2,471 | — | — | ||||||||||||||
Commodity funds | 8,179 | 8,179 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Non-U.S. Treasury Securities | 18,344 | — | 18,344 | — | ||||||||||||||
Corporate and U.S. debt instruments | 132,828 | 45,215 | 87,613 | — | ||||||||||||||
Corporate bonds | 22,619 | — | 22,619 | — | ||||||||||||||
High yield bond funds | 6,170 | 6,170 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 22,689 | — | — | 22,689 | ||||||||||||||
Venture capital funds | 8 | — | — | 8 | ||||||||||||||
Non-U.S. government index linked bonds | 27,659 | — | 27,659 | — | ||||||||||||||
Total assets measured at fair value | $ | 393,460 | $ | 140,732 | $ | 230,031 | $ | 22,697 | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 30, 2012 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 13,940 | $ | 13,940 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 37,674 | 37,674 | — | — | ||||||||||||||
International large-cap value | 37,239 | 37,239 | — | — | ||||||||||||||
U.S. small-cap | 3,567 | 3,567 | — | — | ||||||||||||||
Emerging markets growth | 12,390 | 12,390 | — | — | ||||||||||||||
Equity index funds | 80,999 | — | 80,999 | — | ||||||||||||||
Domestic real estate funds | 2,235 | 2,235 | — | — | ||||||||||||||
Commodity funds | 8,940 | 8,940 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 565 | — | 565 | — | ||||||||||||||
Corporate and U.S. debt instruments | 73,362 | 18,985 | 54,377 | — | ||||||||||||||
Corporate bonds | 22,497 | — | 22,497 | — | ||||||||||||||
High yield bond funds | 11,624 | 11,624 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 20,262 | — | — | 20,262 | ||||||||||||||
Venture capital funds | 7 | — | — | 7 | ||||||||||||||
Private funds | 162 | — | — | 162 | ||||||||||||||
Non-U.S. government index linked bonds | 10,807 | — | 10,807 | — | ||||||||||||||
Total assets measured at fair value | $ | 336,270 | $ | 146,594 | $ | 169,245 | $ | 20,431 | ||||||||||
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | ' | |||||||||||||||||
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2013, 2012, and 2011 is as follows: | ||||||||||||||||||
Fair Value Measurements Using | ||||||||||||||||||
Significant Unobservable Inputs | ||||||||||||||||||
(Level 3): | ||||||||||||||||||
Common | Venture | Multi-strategy | Total | |||||||||||||||
Collective | Capital | Hedge | ||||||||||||||||
Trusts/Private Funds | Funds | Funds | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Balance at January 2, 2011 | $ | — | $ | 14 | $ | 20,073 | $ | 20,087 | ||||||||||
Realized losses | — | — | (84 | ) | (84 | ) | ||||||||||||
Unrealized losses | — | (7 | ) | (704 | ) | (711 | ) | |||||||||||
Balance at January 1, 2012 | — | 7 | 19,285 | 19,292 | ||||||||||||||
Realized gains | 1,162 | — | — | 1,162 | ||||||||||||||
Unrealized gains | 19 | — | 977 | 996 | ||||||||||||||
Purchases | 9,448 | — | — | 9,448 | ||||||||||||||
Issuances, Sales and Settlements | (10,467 | ) | — | — | (10,467 | ) | ||||||||||||
Balance at December 30, 2012 | 162 | 7 | 20,262 | 20,431 | ||||||||||||||
Realized gains | 7 | — | — | 7 | ||||||||||||||
Unrealized (losses) gains | (19 | ) | 1 | 2,427 | 2,409 | |||||||||||||
Issuances, Sales and Settlements | (150 | ) | — | — | (150 | ) | ||||||||||||
Balance at December 29, 2013 | $ | — | $ | 8 | $ | 22,689 | $ | 22,697 | ||||||||||
Schedule of Expected Benefit Payments | ' | |||||||||||||||||
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: | ||||||||||||||||||
Non-U.S. | U.S. | |||||||||||||||||
(In thousands) | ||||||||||||||||||
2014 | $ | 11,878 | $ | 17,836 | ||||||||||||||
2015 | 12,931 | 17,848 | ||||||||||||||||
2016 | 13,312 | 17,916 | ||||||||||||||||
2017 | 13,627 | 17,990 | ||||||||||||||||
2018 | 14,156 | 18,219 | ||||||||||||||||
2019-2023 | 77,736 | 91,400 | ||||||||||||||||
Other Postretirement Benefit Plans, Defined Benefit [Member] | ' | |||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] | ' | |||||||||||||||||
Components of Net Periodic Benefit Cost (Credit) | ' | |||||||||||||||||
Net periodic postretirement medical benefit credit included the following components for the fiscal years ended: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Service cost | $ | 106 | $ | 106 | $ | 85 | ||||||||||||
Interest cost | 135 | 144 | 163 | |||||||||||||||
Expected return on plan assets | (965 | ) | (877 | ) | (884 | ) | ||||||||||||
Actuarial (gain) loss | (182 | ) | (929 | ) | 705 | |||||||||||||
Amortization of prior service cost | — | — | (253 | ) | ||||||||||||||
Net periodic postretirement medical benefit credit | $ | (906 | ) | $ | (1,556 | ) | $ | (184 | ) | |||||||||
Schedule of Net Funded Status | ' | |||||||||||||||||
The following table sets forth the changes in the postretirement medical plan’s funded status and the amounts recognized in the Company’s consolidated balance sheets as of December 29, 2013 and December 30, 2012. | ||||||||||||||||||
December 29, | December 30, | |||||||||||||||||
2013 | 2012 | |||||||||||||||||
(In thousands) | ||||||||||||||||||
Actuarial present value of benefit obligations: | ||||||||||||||||||
Retirees | $ | 1,331 | $ | 1,475 | ||||||||||||||
Active employees eligible to retire | 470 | 431 | ||||||||||||||||
Other active employees | 2,009 | 1,913 | ||||||||||||||||
Accumulated benefit obligations at beginning of year | 3,810 | 3,819 | ||||||||||||||||
Service cost | 106 | 106 | ||||||||||||||||
Interest cost | 135 | 144 | ||||||||||||||||
Benefits paid | (189 | ) | (205 | ) | ||||||||||||||
Actuarial (gain) loss | (520 | ) | (54 | ) | ||||||||||||||
Change in accumulated benefit obligations during the year | (468 | ) | (9 | ) | ||||||||||||||
Retirees | 1,159 | 1,331 | ||||||||||||||||
Active employees eligible to retire | 388 | 470 | ||||||||||||||||
Other active employees | 1,795 | 2,009 | ||||||||||||||||
Accumulated benefit obligations at end of year | 3,342 | 3,810 | ||||||||||||||||
Change in plan assets: | ||||||||||||||||||
Fair value of plan assets at beginning of year | 12,958 | 11,411 | ||||||||||||||||
Actual return on plan assets | 438 | 1,547 | ||||||||||||||||
Fair value of plan assets at end of year | 13,396 | 12,958 | ||||||||||||||||
Net assets recognized in the consolidated balance sheets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net amounts recognized in the consolidated balance sheets consist of: | ||||||||||||||||||
Noncurrent assets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net assets recognized in the consolidated balance sheets | $ | 10,054 | $ | 9,148 | ||||||||||||||
Net amounts recognized in accumulated other comprehensive income consist of: | ||||||||||||||||||
Prior service cost | $ | — | $ | — | ||||||||||||||
Net amounts recognized in accumulated other comprehensive income | $ | — | $ | — | ||||||||||||||
Actuarial assumptions as of the year-end measurement date: | ||||||||||||||||||
Discount rate | 4.77 | % | 3.86 | % | ||||||||||||||
Actuarial assumptions used to determine net cost during the year are as follows: | ||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||
Discount rate | 3.86 | % | 4 | % | 5.3 | % | ||||||||||||
Expected rate of return on assets | 7.5 | % | 7.75 | % | 8.1 | % | ||||||||||||
Schedule of Changes in Fair Value of Plan Assets | ' | |||||||||||||||||
The fair values of the Company’s plan assets at December 29, 2013 and December 30, 2012 by asset category, classified in the three levels of inputs described in Note 21, are as follows: | ||||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 29, 2013 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 167 | $ | 167 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S. large-cap | 1,831 | 1,831 | — | — | ||||||||||||||
International large-cap value | 1,480 | 1,480 | — | — | ||||||||||||||
Emerging markets growth | 672 | 672 | — | — | ||||||||||||||
Domestic real estate funds | 133 | 133 | — | — | ||||||||||||||
Commodity funds | 439 | 439 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 7,126 | 2,426 | 4,700 | — | ||||||||||||||
High yield bond funds | 331 | 331 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 1,217 | — | — | 1,217 | ||||||||||||||
Total assets measured at fair value | $ | 13,396 | $ | 7,479 | $ | 4,700 | $ | 1,217 | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable | |||||||||||||||
December 30, 2012 | (Level 1) | (Level 2) | Inputs | |||||||||||||||
(Level 3) | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
Cash | $ | 798 | $ | 798 | $ | — | $ | — | ||||||||||
Equity Securities: | ||||||||||||||||||
U.S large-cap | 2,202 | 2,202 | — | — | ||||||||||||||
International large-cap value | 2,177 | 2,177 | — | — | ||||||||||||||
U.S. small-cap | 209 | 209 | — | — | ||||||||||||||
Emerging markets growth | 724 | 724 | — | — | ||||||||||||||
Domestic real estate funds | 131 | 131 | — | — | ||||||||||||||
Commodity funds | 523 | 523 | — | — | ||||||||||||||
Fixed income securities: | ||||||||||||||||||
Corporate debt instruments | 33 | — | 33 | — | ||||||||||||||
Corporate and U.S. debt instruments | 4,288 | 1,110 | 3,178 | — | ||||||||||||||
High yield bond funds | 679 | 679 | — | — | ||||||||||||||
Other types of investments: | ||||||||||||||||||
Multi-strategy hedge funds | 1,184 | — | — | 1,184 | ||||||||||||||
Private funds | 9 | — | — | 9 | ||||||||||||||
Venture capital funds | 1 | — | — | 1 | ||||||||||||||
Total assets measured at fair value | $ | 12,958 | $ | 8,553 | $ | 3,211 | $ | 1,194 | ||||||||||
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets | ' | |||||||||||||||||
A reconciliation of the beginning and ending Level 3 assets for fiscal years 2013, 2012, and 2011 is as follows: | ||||||||||||||||||
Fair Value Measurements Using | ||||||||||||||||||
Significant Unobservable Inputs | ||||||||||||||||||
(Level 3): | ||||||||||||||||||
Common | Venture | Multi-strategy | Total | |||||||||||||||
Collective | Capital | Hedge | ||||||||||||||||
Trusts/Private Funds | Funds | Funds | ||||||||||||||||
(In thousands) | ||||||||||||||||||
Balance at January 2, 2011 | $ | — | $ | 1 | $ | 1,086 | $ | 1,087 | ||||||||||
Realized gains | — | — | 84 | 84 | ||||||||||||||
Unrealized losses | — | — | (41 | ) | (41 | ) | ||||||||||||
Purchases | — | — | — | — | ||||||||||||||
Issuances, Sales and Settlements | — | — | — | — | ||||||||||||||
Balance at January 1, 2012 | — | 1 | 1,129 | 1,130 | ||||||||||||||
Realized gains | 68 | — | — | 68 | ||||||||||||||
Unrealized gains | 1 | — | 55 | 56 | ||||||||||||||
Purchases | 552 | — | — | 552 | ||||||||||||||
Issuances, Sales and Settlements | (612 | ) | — | — | (612 | ) | ||||||||||||
Balance at December 30, 2012 | 9 | 1 | 1,184 | 1,194 | ||||||||||||||
Realized gains | — | — | — | — | ||||||||||||||
Unrealized (losses) gains | (1 | ) | (1 | ) | 33 | 31 | ||||||||||||
Purchases | — | — | — | — | ||||||||||||||
Issuances, Sales and Settlements | (8 | ) | — | — | (8 | ) | ||||||||||||
Balance at December 29, 2013 | $ | — | $ | — | $ | 1,217 | $ | 1,217 | ||||||||||
Schedule of Expected Benefit Payments | ' | |||||||||||||||||
The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows: | ||||||||||||||||||
Postretirement Medical Plan | ||||||||||||||||||
(In thousands) | ||||||||||||||||||
2014 | $ | 202 | ||||||||||||||||
2015 | 205 | |||||||||||||||||
2016 | 210 | |||||||||||||||||
2017 | 217 | |||||||||||||||||
2018 | 224 | |||||||||||||||||
2019-2023 | 1,227 | |||||||||||||||||
Warranty_Reserves_Tables
Warranty Reserves (Tables) | 12 Months Ended | |||
Dec. 29, 2013 | ||||
Product Warranties Disclosures [Abstract] | ' | |||
Warranty Reserve Activity | ' | |||
A summary of warranty reserve activity for the fiscal years ended December 29, 2013, December 30, 2012 and January 1, 2012 is as follows: | ||||
(In thousands) | ||||
Balance at January 2, 2011 | $ | 8,250 | ||
Provision charged to income | 15,001 | |||
Payments | (15,154 | ) | ||
Adjustments to previously provided warranties, net | 926 | |||
Foreign currency translation and acquisitions | 1,389 | |||
Balance at January 1, 2012 | 10,412 | |||
Provision charged to income | 17,750 | |||
Payments | (18,022 | ) | ||
Adjustments to previously provided warranties, net | 801 | |||
Foreign currency translation and acquisitions | 62 | |||
Balance at December 30, 2012 | 11,003 | |||
Provision charged to income | 17,291 | |||
Payments | (17,116 | ) | ||
Adjustments to previously provided warranties, net | (693 | ) | ||
Foreign currency translation and acquisitions | 49 | |||
Balance at December 29, 2013 | $ | 10,534 | ||
Stock_Plans_Tables
Stock Plans (Tables) | 12 Months Ended | ||||||||||||||||||||
Dec. 29, 2013 | |||||||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||||||||||
Summary of Total Compensation Recognized Related to Outstanding Equity Awards | ' | ||||||||||||||||||||
The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s consolidated statements of operations for fiscal years 2013, 2012, and 2011: | |||||||||||||||||||||
December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | |||||||||||||||||||
(In thousands) | |||||||||||||||||||||
Cost of product and service revenue | $ | 1,304 | $ | 1,276 | $ | 1,139 | |||||||||||||||
Research and development expenses | 853 | 769 | 583 | ||||||||||||||||||
Selling, general and administrative expenses | 11,896 | 18,986 | 13,760 | ||||||||||||||||||
Total stock-based compensation expense | $ | 14,053 | $ | 21,031 | $ | 15,482 | |||||||||||||||
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model | ' | ||||||||||||||||||||
The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows for the fiscal years ended: | |||||||||||||||||||||
December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | |||||||||||||||||||
Risk-free interest rate | 0.9 | % | 0.6 | % | 1.9 | % | |||||||||||||||
Expected dividend yield | 0.8 | % | 1.2 | % | 1.1 | % | |||||||||||||||
Expected lives | 5 years | 4 years | 4 years | ||||||||||||||||||
Expected stock volatility | 38.5 | % | 38.7 | % | 38.1 | % | |||||||||||||||
Summary of Stock Option Activity | ' | ||||||||||||||||||||
The following table summarizes stock option activity for the three fiscal years ended December 29, 2013: | |||||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | |||||||||||||||||||
Number | Weighted- | Number | Weighted- | Number | Weighted- | ||||||||||||||||
of | Average | of | Average | of | Average | ||||||||||||||||
Shares | Price | Shares | Price | Shares | Price | ||||||||||||||||
(Shares in thousands) | |||||||||||||||||||||
Outstanding at beginning of year | 4,266 | $ | 21.64 | 5,346 | $ | 20.57 | 6,983 | $ | 21.86 | ||||||||||||
Granted | 518 | 33.62 | 756 | 26.28 | 847 | 24.2 | |||||||||||||||
Exercised | (947 | ) | 21.45 | (1,611 | ) | 20.16 | (1,138 | ) | 20.86 | ||||||||||||
Canceled | (8 | ) | 22.88 | (210 | ) | 22.34 | (1,237 | ) | 30.29 | ||||||||||||
Forfeited | (335 | ) | 23.04 | (15 | ) | 21.98 | (109 | ) | 18.27 | ||||||||||||
Outstanding at end of year | 3,494 | $ | 23.34 | 4,266 | $ | 21.64 | 5,346 | $ | 20.57 | ||||||||||||
Exercisable at end of year | 2,392 | $ | 20.66 | 2,677 | $ | 20 | 3,549 | $ | 20.74 | ||||||||||||
Summary of Restricted Stock Award Activity | ' | ||||||||||||||||||||
The following table summarizes restricted stock award activity for the three fiscal years ended December 29, 2013: | |||||||||||||||||||||
December 29, 2013 | December 30, 2012 | January 1, 2012 | |||||||||||||||||||
Number | Weighted- | Number | Weighted- | Number | Weighted- | ||||||||||||||||
of | Average | of | Average | of | Average | ||||||||||||||||
Shares | Grant- | Shares | Grant- | Shares | Grant- | ||||||||||||||||
Date Fair | Date Fair | Date Fair | |||||||||||||||||||
Value | Value | Value | |||||||||||||||||||
(Shares in thousands) | |||||||||||||||||||||
Nonvested at beginning of year | 781 | $ | 24.71 | 672 | $ | 23.62 | 578 | $ | 22 | ||||||||||||
Granted | 289 | 33.87 | 358 | 25.86 | 460 | 26.31 | |||||||||||||||
Vested | (346 | ) | 22.98 | (184 | ) | 23.19 | (272 | ) | 23.96 | ||||||||||||
Forfeited | (75 | ) | 28.76 | (65 | ) | 24.03 | (94 | ) | 24.58 | ||||||||||||
Nonvested at end of year | 649 | $ | 29.24 | 781 | $ | 24.71 | 672 | $ | 23.62 | ||||||||||||
Stockholders_Equity_Tables
Stockholders' Equity (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||||||||
Components of Accumulated Other Comprehensive Loss | ' | |||||||||||||||||||
The components of accumulated other comprehensive income consisted of the following: | ||||||||||||||||||||
Foreign | Unrecognized | Unrealized | Unrealized and Realized (Losses) Gains on Derivatives, net of tax | Accumulated | ||||||||||||||||
Currency | Prior Service | (Losses) | Other | |||||||||||||||||
Translation | Costs, net of | Gains on | Comprehensive | |||||||||||||||||
Adjustment, | tax | Securities, | Income | |||||||||||||||||
net of tax | net of tax | |||||||||||||||||||
(In thousands) | ||||||||||||||||||||
Balance, January 2, 2011 | $ | 54,350 | $ | 2,062 | $ | (100 | ) | $ | (5,284 | ) | $ | 51,028 | ||||||||
Current year change | 1,814 | 107 | (59 | ) | 1,196 | 3,058 | ||||||||||||||
Balance, January 1, 2012 | 56,164 | 2,169 | (159 | ) | (4,088 | ) | 54,086 | |||||||||||||
Current year change | 11,363 | (82 | ) | 30 | 1,196 | 12,507 | ||||||||||||||
Balance, December 30, 2012 | 67,527 | 2,087 | (129 | ) | (2,892 | ) | 66,593 | |||||||||||||
Current year change | 8,756 | (658 | ) | 8 | 2,892 | 10,998 | ||||||||||||||
Balance, December 29, 2013 | $ | 76,283 | $ | 1,429 | $ | (121 | ) | $ | — | $ | 77,591 | |||||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 12 Months Ended | |||||||||||||||
Dec. 29, 2013 | ||||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||||
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis | ' | |||||||||||||||
The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of December 29, 2013 and December 30, 2012 classified in one of the three classifications described above: | ||||||||||||||||
Fair Value Measurements at December 29, 2013 Using: | ||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable Inputs | |||||||||||||
December 29, | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
2013 | ||||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,319 | $ | 1,319 | $ | — | $ | — | ||||||||
Foreign exchange derivative assets | 293 | — | 293 | — | ||||||||||||
Foreign exchange derivative liabilities | (396 | ) | — | (396 | ) | — | ||||||||||
Contingent consideration | (4,926 | ) | — | — | (4,926 | ) | ||||||||||
Fair Value Measurements at December 30, 2012 Using: | ||||||||||||||||
Total Carrying | Quoted Prices in | Significant Other | Significant | |||||||||||||
Value at | Active Markets | Observable Inputs | Unobservable Inputs | |||||||||||||
December 30, | (Level 1) | (Level 2) | (Level 3) | |||||||||||||
2012 | ||||||||||||||||
(In thousands) | ||||||||||||||||
Marketable securities | $ | 1,149 | $ | 1,149 | $ | — | $ | — | ||||||||
Foreign exchange derivative assets | 274 | — | 274 | — | ||||||||||||
Foreign exchange derivative liabilities, net | (294 | ) | — | (294 | ) | — | ||||||||||
Contingent consideration | (3,017 | ) | — | — | (3,017 | ) | ||||||||||
Reconciliation of Beginning and Ending Level 3 Net Liabilities | ' | |||||||||||||||
A reconciliation of the beginning and ending Level 3 net liabilities is as follows: | ||||||||||||||||
(In thousands) | ||||||||||||||||
Balance at January 2, 2011 | $ | (1,731 | ) | |||||||||||||
Additions | (20,131 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 1,908 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | (344 | ) | ||||||||||||||
Balance at January 1, 2012 | (20,298 | ) | ||||||||||||||
Additions | (1,900 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 17,433 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | 1,748 | |||||||||||||||
Balance at December 30, 2012 | (3,017 | ) | ||||||||||||||
Additions | (1,100 | ) | ||||||||||||||
Amounts paid and foreign currency translation | 135 | |||||||||||||||
Change in fair value (included within selling, general and administrative expenses) | (944 | ) | ||||||||||||||
Balance at December 29, 2013 | $ | (4,926 | ) |
Industry_Segment_and_Geographi1
Industry Segment and Geographic Area Information (Tables) | 12 Months Ended | |||||||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||||||
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations | ' | |||||||||||||||||||||||
Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below for the fiscal years ended: | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(As adjusted) | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
Human Health | ||||||||||||||||||||||||
Product revenue | $ | 957,022 | $ | 926,733 | $ | 761,665 | ||||||||||||||||||
Service revenue | 252,734 | 247,909 | 216,227 | |||||||||||||||||||||
Total revenue | 1,209,756 | 1,174,642 | 977,892 | |||||||||||||||||||||
Operating income from continuing operations(1) | 146,100 | 59,196 | 89,725 | |||||||||||||||||||||
Environmental Health | ||||||||||||||||||||||||
Product revenue | 541,048 | 547,941 | 557,845 | |||||||||||||||||||||
Service revenue | 415,428 | 392,622 | 382,771 | |||||||||||||||||||||
Total revenue | 956,476 | 940,563 | 940,616 | |||||||||||||||||||||
Operating income from continuing operations(1) | 97,052 | 111,844 | 108,922 | |||||||||||||||||||||
Corporate | ||||||||||||||||||||||||
Operating loss from continuing operations(2) | (25,710 | ) | (72,497 | ) | (107,519 | ) | ||||||||||||||||||
Continuing Operations | ||||||||||||||||||||||||
Product revenue | $ | 1,498,070 | $ | 1,474,674 | $ | 1,319,510 | ||||||||||||||||||
Service revenue | 668,162 | 640,531 | 598,998 | |||||||||||||||||||||
Total revenue | 2,166,232 | 2,115,205 | 1,918,508 | |||||||||||||||||||||
Operating income from continuing operations | 217,442 | 98,543 | 91,128 | |||||||||||||||||||||
Interest and other expense, net (see Note 5) | 64,110 | 47,956 | 26,774 | |||||||||||||||||||||
Income from continuing operations before income taxes | $ | 153,332 | $ | 50,587 | $ | 64,354 | ||||||||||||||||||
____________________________ | ||||||||||||||||||||||||
(1) | Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company recognized a $6.7 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012. The Company recognized a $3.0 million pre-tax impairment charge in the Human Health segment in fiscal year 2011. | |||||||||||||||||||||||
(2) | Activity related to the mark-to-market adjustment on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted pre-tax income of $17.6 million in fiscal year 2013, a pre-tax loss of $31.8 million in fiscal year 2012, and a pre-tax loss of $67.9 million in fiscal year 2011. | |||||||||||||||||||||||
Schedule of Depreciation, Amortization and Capital Expenditures | ' | |||||||||||||||||||||||
Additional information relating to the Company’s reporting segments is as follows for the three fiscal years ended December 29, 2013: | ||||||||||||||||||||||||
Depreciation and Amortization | Capital Expenditures | |||||||||||||||||||||||
Expense | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | December 29, | December 30, | January 1, | |||||||||||||||||||
2013 | 2012 | 2012 | 2013 | 2012 | 2012 | |||||||||||||||||||
(As adjusted) | (As adjusted) | |||||||||||||||||||||||
(In thousands) | (In thousands) | |||||||||||||||||||||||
Human Health | $ | 100,174 | $ | 101,336 | $ | 81,938 | $ | 20,910 | $ | 24,525 | $ | 16,570 | ||||||||||||
Environmental Health | 25,915 | 23,001 | 27,288 | 16,532 | 14,488 | 12,015 | ||||||||||||||||||
Corporate | 2,382 | 2,528 | 1,695 | 1,549 | 3,395 | 2,007 | ||||||||||||||||||
Continuing operations | $ | 128,471 | $ | 126,865 | $ | 110,921 | $ | 38,991 | $ | 42,408 | $ | 30,592 | ||||||||||||
Schedule of Total Assets by Segment | ' | |||||||||||||||||||||||
Additional information relating to the Company’s reporting segments is as follows for the fiscal years ended: | ||||||||||||||||||||||||
Total Assets | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(As adjusted) | ||||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
Human Health | $ | 2,698,640 | $ | 2,714,366 | $ | 2,674,243 | ||||||||||||||||||
Environmental Health | 1,213,801 | 1,153,444 | 1,150,015 | |||||||||||||||||||||
Corporate | 34,271 | 33,952 | 31,181 | |||||||||||||||||||||
Net current and long-term assets of discontinued operations | — | — | 202 | |||||||||||||||||||||
Total assets | $ | 3,946,712 | $ | 3,901,762 | $ | 3,855,641 | ||||||||||||||||||
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | ' | |||||||||||||||||||||||
The following geographic area information for continuing operations includes revenue based on location of external customer for the three fiscal years ended December 29, 2013 and net long-lived assets based on physical location as of December 29, 2013 and December 30, 2012: | ||||||||||||||||||||||||
Revenue | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
U.S. | $ | 835,637 | $ | 822,951 | $ | 725,849 | ||||||||||||||||||
International: | ||||||||||||||||||||||||
China | 254,838 | 216,425 | 164,005 | |||||||||||||||||||||
United Kingdom | 133,611 | 118,611 | 102,366 | |||||||||||||||||||||
Germany | 99,153 | 105,735 | 113,472 | |||||||||||||||||||||
Japan | 95,676 | 114,300 | 89,977 | |||||||||||||||||||||
France | 81,719 | 84,395 | 85,395 | |||||||||||||||||||||
Italy | 78,120 | 69,599 | 74,925 | |||||||||||||||||||||
Other international | 587,478 | 583,189 | 562,519 | |||||||||||||||||||||
Total international | 1,330,595 | 1,292,254 | 1,192,659 | |||||||||||||||||||||
Total sales | $ | 2,166,232 | $ | 2,115,205 | $ | 1,918,508 | ||||||||||||||||||
Net Long-Lived Assets | ||||||||||||||||||||||||
December 29, | December 30, | January 1, | ||||||||||||||||||||||
2013 | 2012 | 2012 | ||||||||||||||||||||||
(In thousands) | ||||||||||||||||||||||||
U.S. | $ | 216,821 | $ | 205,083 | $ | 147,883 | ||||||||||||||||||
International: | ||||||||||||||||||||||||
China | 30,682 | 30,134 | 22,145 | |||||||||||||||||||||
Finland | 13,635 | 11,851 | 12,833 | |||||||||||||||||||||
United Kingdom | 9,882 | 2,960 | 2,508 | |||||||||||||||||||||
Singapore | 6,812 | 6,366 | 5,663 | |||||||||||||||||||||
Netherlands | 4,037 | 3,900 | 4,074 | |||||||||||||||||||||
Italy | 2,735 | 3,303 | 3,288 | |||||||||||||||||||||
Germany | 2,591 | 2,353 | 2,225 | |||||||||||||||||||||
Brazil | 1,967 | 1,515 | 1,637 | |||||||||||||||||||||
Japan | 1,772 | 2,310 | 2,552 | |||||||||||||||||||||
Other international | 7,306 | 7,932 | 12,589 | |||||||||||||||||||||
Total international | 81,419 | 72,624 | 69,514 | |||||||||||||||||||||
Total net long-lived assets | $ | 298,240 | $ | 277,707 | $ | 217,397 | ||||||||||||||||||
Quarterly_Financial_Informatio1
Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 29, 2013 | ||||||||||||||||||||
Quarterly Financial Information Disclosure [Abstract] | ' | |||||||||||||||||||
Schedule of Quarterly Financial Information | ' | |||||||||||||||||||
Selected quarterly financial information is as follows for the fiscal years ended: | ||||||||||||||||||||
First | Second | Third | Fourth | Year | ||||||||||||||||
Quarter | Quarter | Quarter | Quarter(1)(2) | |||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||||||
December 29, 2013 | ||||||||||||||||||||
Revenue | $ | 505,378 | $ | 543,297 | $ | 524,277 | $ | 593,280 | $ | 2,166,232 | ||||||||||
Gross profit | 224,885 | 242,299 | 233,512 | 276,278 | 976,974 | |||||||||||||||
Restructuring and contract termination charges, net | 3,310 | 19,277 | 1,126 | 10,215 | 33,928 | |||||||||||||||
Operating income from continuing operations | 35,901 | 39,664 | 57,196 | 84,681 | 217,442 | |||||||||||||||
Income from continuing operations before income taxes | 23,861 | 26,799 | 44,856 | 57,816 | 153,332 | |||||||||||||||
Income from continuing operations | 32,289 | 26,936 | 40,299 | 68,400 | 167,924 | |||||||||||||||
Net income | 32,216 | 27,925 | 40,198 | 66,873 | 167,212 | |||||||||||||||
Basic earnings per share: | ||||||||||||||||||||
Income from continuing operations | $ | 0.28 | $ | 0.24 | $ | 0.36 | $ | 0.61 | $ | 1.5 | ||||||||||
Net income | 0.28 | 0.25 | 0.36 | 0.6 | 1.49 | |||||||||||||||
Diluted earnings per share: | ||||||||||||||||||||
Income from continuing operations | $ | 0.28 | $ | 0.24 | $ | 0.36 | $ | 0.6 | $ | 1.48 | ||||||||||
Net income | 0.28 | 0.25 | 0.36 | 0.59 | 1.47 | |||||||||||||||
Cash dividends declared per common share | 0.07 | 0.07 | 0.07 | 0.07 | 0.28 | |||||||||||||||
December 30, 2012 | ||||||||||||||||||||
Revenue | $ | 510,890 | $ | 521,790 | $ | 509,604 | $ | 572,921 | $ | 2,115,205 | ||||||||||
Gross profit | 232,014 | 238,794 | 230,740 | 261,658 | 963,206 | |||||||||||||||
Restructuring and contract termination charges, net | 6,159 | 5,203 | 9,672 | 4,103 | 25,137 | |||||||||||||||
Operating income from continuing operations | 36,382 | 49,787 | 43,218 | (30,844 | ) | 98,543 | ||||||||||||||
Income (loss) from continuing operations before income taxes | 23,552 | 38,429 | 31,346 | (42,740 | ) | 50,587 | ||||||||||||||
Income (loss) from continuing operations | 22,076 | 33,568 | 28,989 | (16,192 | ) | 68,441 | ||||||||||||||
Net income (loss) | 22,569 | 33,633 | 29,594 | (15,856 | ) | 69,940 | ||||||||||||||
Basic earnings per share: | ||||||||||||||||||||
Income (loss) from continuing operations | $ | 0.2 | $ | 0.3 | $ | 0.25 | $ | (0.14 | ) | $ | 0.6 | |||||||||
Net income (loss) | 0.2 | 0.3 | 0.26 | (0.14 | ) | 0.61 | ||||||||||||||
Diluted earnings per share: | ||||||||||||||||||||
Income (loss) continuing operations | $ | 0.19 | $ | 0.29 | $ | 0.25 | $ | (0.14 | ) | $ | 0.6 | |||||||||
Net income (loss) | 0.2 | 0.29 | 0.26 | (0.14 | ) | 0.61 | ||||||||||||||
Cash dividends declared per common share | 0.07 | 0.07 | 0.07 | 0.07 | 0.28 | |||||||||||||||
____________________________ | ||||||||||||||||||||
-1 | The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2013 also includes pre-tax impairment charges of $6.7 million as the carrying amounts of certain long-lived assets were not recoverable and exceeded their fair value. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statues of limitations and audit settlements. | |||||||||||||||||||
-2 | The fourth quarter of fiscal year 2012 includes a pre-tax loss of $31.8 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2012 also includes pre-tax impairment charges of $74.2 million as a result of a review of certain trade names within the Company's portfolio as part of a realignment of its marketing strategy. |
Nature_of_Operations_and_Accou2
Nature of Operations and Accounting Policies Nature of Operations and Accounting Policies (Narrative) (Details) (Details) (EUR €) | 12 Months Ended | |||
In Millions, unless otherwise specified | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Operating Cycle | '52 | '52 | ' | ' |
License and services revenue as a percentage of total revenue | ' | 5.00% | 3.00% | 2.00% |
Minimum [Member] | Building [Member] | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life, Maximum | ' | '10 years 0 months | ' | ' |
Minimum [Member] | Machinery and Equipment [Member] | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life, Maximum | ' | '3 years 0 months | ' | ' |
Maximum [Member] | Building [Member] | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life, Maximum | ' | '40 years 0 months | ' | ' |
Maximum [Member] | Machinery and Equipment [Member] | ' | ' | ' | ' |
Property, Plant and Equipment, Useful Life, Maximum | ' | '7 years 0 months | ' | ' |
Cash Flow Hedging [Member] | ' | ' | ' | ' |
Derivative, Number of Instruments Held | ' | 0 | 2 | ' |
Derivative, Notional Amount | ' | ' | 50 | ' |
Business_Combinations_and_Asse2
Business Combinations and Asset Purchases (Narrative) (Details) (USD $) | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Dec. 29, 2013 | Jan. 01, 2012 | Nov. 30, 2011 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2011 | Nov. 30, 2011 | |
Fiscal Year 2013 Acquisitions [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Minimum [Member] | Maximum [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | |||||
Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | Core Technology [Member] | Core Technology [Member] | Trade Names [Member] | Trade Names [Member] | Licenses [Member] | Customer Relationships [Member] | |||||||||
November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | |||||||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | ' | ' | ' | ' | ' | ($3,000,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Acquisition, Transaction Costs | ' | ' | ' | ' | ' | ' | 18,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate Revenue from Immaterial Acquisitions | ' | ' | ' | ' | ' | ' | ' | 32,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Acquisition, Cost of Acquired Entity, Cash Paid | ' | ' | ' | ' | 11,400,000 | ' | ' | 333,581,000 | ' | ' | 38,000,000 | 646,317,000 | ' | ' | ' | ' | ' | ' |
Working capital and other adjustments | ' | ' | ' | ' | ' | ' | ' | -32,000 | ' | ' | 2,729,000 | 0 | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 4,926,000 | 3,017,000 | 20,298,000 | 1,731,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Contingent Consideration Arrangements, Description | 'Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Contingent consideration | ' | ' | ' | ' | -1,100,000 | ' | ' | -20,124,000 | ' | ' | -1,900,000 | 0 | ' | ' | ' | ' | ' | ' |
Business Acquisition, Goodwill, Expected Tax Deductible Amount | ' | ' | ' | ' | ' | ' | ' | 4,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average amortization period (in years) | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | '11 years | ' | ' | '8 years | '5 years | '8 years | '7 years | '6 years | '7 years |
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments | ' | ' | ' | ' | ' | ' | ' | 333,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | ' | ' | ' | ' | ' | 29,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred revenue acquisition liability | ' | ' | ' | ' | ' | ' | ' | -10,496,000 | ' | ' | ' | -6,554,000 | ' | ' | ' | ' | ' | ' |
Total transaction costs | 100,000 | 1,200,000 | 10,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $31,300,000 | ' | ' | ' | $2,200,000 | ' | ' | $50,800,000 | ' | ' | $30,000,000 | ' | ' | ' | ' | ' | ' | ' |
Business_Combinations_and_Asse3
Business Combinations and Asset Purchases (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2012 | Nov. 30, 2011 | Nov. 30, 2011 | Nov. 30, 2011 | Nov. 30, 2012 | Nov. 30, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
In Thousands, unless otherwise specified | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Core Technology [Member] | Trade Names [Member] | Licenses [Member] | Customer Relationships [Member] | In Process Research and Development [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Environmental Health [Member] | |||
Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | Fiscal year 2011 acquisitions (excluding Caliper) [Member] | November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | Core Technology [Member] | Core Technology [Member] | Trade Names [Member] | Trade Names [Member] | Licenses [Member] | Customer Relationships [Member] | In Process Research and Development [Member] | In Process Research and Development [Member] | |||||||||||
November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | November 2012 Haoyuan Biotech Co. [Member] | November 2011 Caliper Life Sciences [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Acquisition, Cost of Acquired Entity, Cash Paid | ' | ' | ' | $333,581 | ' | ' | ' | ' | ' | ' | ' | ' | $38,000 | $646,317 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Less: cash acquired | ' | ' | ' | 26,923 | ' | ' | ' | ' | ' | ' | ' | ' | 175 | 43,576 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total | ' | ' | ' | 326,814 | ' | ' | ' | ' | ' | ' | ' | ' | 36,996 | 602,741 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Current assets | ' | ' | ' | 16,857 | ' | ' | ' | ' | ' | ' | ' | ' | 2,389 | 55,027 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Property, plant and equipment | ' | ' | ' | 1,661 | ' | ' | ' | ' | ' | ' | ' | ' | 2,906 | 14,580 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | ' | ' | ' | ' | 35,724 | 3,374 | 3,000 | 96,910 | 3,839 | ' | ' | ' | ' | ' | 17,700 | 52,000 | 400 | 14,200 | 18,000 | 93,000 | 300 | 0 | ' | ' | ' |
Goodwill | 2,143,120 | 2,122,788 | 2,094,235 | 236,573 | ' | ' | ' | ' | ' | 1,648,332 | 1,632,487 | 1,606,913 | 19,682 | 353,103 | ' | ' | ' | ' | ' | ' | ' | ' | 494,788 | 490,301 | 487,322 |
Deferred taxes | ' | ' | ' | -45,017 | ' | ' | ' | ' | ' | ' | ' | ' | -2,656 | 52,472 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred revenue | ' | ' | ' | 10,496 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,554 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Contingent consideration | ' | ' | ' | 20,124 | ' | ' | ' | ' | ' | ' | ' | ' | 1,900 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Liabilities assumed | ' | ' | ' | 15,611 | ' | ' | ' | ' | ' | ' | ' | ' | 3,725 | 43,087 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total | ' | ' | ' | 326,814 | ' | ' | ' | ' | ' | ' | ' | ' | 36,996 | 602,741 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Working capital and other adjustments | ' | ' | ' | $32 | ' | ' | ' | ' | ' | ' | ' | ' | ($2,729) | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business_Combinations_and_Asse4
Business Combinations and Asset Purchases Business Combinations and Asset Purchase (Pro Forma Statement of Operations Information) (Details) (November 2011 Caliper Life Sciences [Member], USD $) | 12 Months Ended |
In Thousands, except Per Share data, unless otherwise specified | Jan. 01, 2012 |
November 2011 Caliper Life Sciences [Member] | ' |
Business Acquisition [Line Items] | ' |
Business Acquisition, Pro Forma Revenue | $2,042,730 |
Business Acquisition, Pro Forma Net Income (Loss) | ($25,854) |
Business Acquisition, Pro Forma Earnings Per Share, Basic | ($0.23) |
Business Acquisition, Pro Forma Earnings Per Share, Diluted | ($0.23) |
Discontinued_Operations_Narrat
Discontinued Operations Narrative (Details) (USD $) | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Jan. 01, 2012 | Jun. 30, 2010 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Aug. 31, 1999 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 01, 2012 | |
Illumination And Detection Solutions [Member] | Photoflash Business [Member] | Photoflash Business [Member] | Photoflash Business [Member] | Photoflash Business [Member] | Technical Services Business [Member] | Technical Services Business [Member] | Technical Services Business [Member] | Technical Services Business [Member] | Other Discontinued Operations [Member] | Other Discontinued Operations [Member] | Other Discontinued Operations [Member] | Semiconductor Business [Member] | |||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceed from business divestiture | ' | ' | ' | ' | ' | $13,500,000 | ' | ' | ' | $250,000,000 | ' | ' | ' | ' | ' | ' | ' |
Gain (loss) on disposition of discontinued operations before income taxes | -1,810,000 | 2,405,000 | 1,999,000 | ' | -1,800,000 | ' | 493,000 | 2,459,000 | -134,000 | ' | -2,100,000 | 0 | 0 | -203,000 | -54,000 | 2,133,000 | 4,000,000 |
(Benefit from) provision for income taxes on discontinued operations and dispositions | -1,098,000 | 906,000 | -4,484,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Tax provision related to repatriation of unremitted foreign earnings | ' | ' | $6,700,000 | $65,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discontinued_Operations_Schedu
Discontinued Operations Schedule Of Gains And Losses On Disposition Of Discontinued Operations (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' |
Gain (loss) on disposition of discontinued operations before income taxes | ($1,810) | $2,405 | $1,999 |
Photoflash Business [Member] | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' |
Gain (loss) on disposition of discontinued operations before income taxes | 493 | 2,459 | -134 |
Technical Services Business [Member] | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' |
Gain (loss) on disposition of discontinued operations before income taxes | -2,100 | 0 | 0 |
Other Discontinued Operations [Member] | ' | ' | ' |
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ' | ' | ' |
Gain (loss) on disposition of discontinued operations before income taxes | ($203) | ($54) | $2,133 |
Restructuring_and_Contract_Ter2
Restructuring and Contract Termination Charges, Net (Narrative) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | $26,374,000 | ' | ' | ' | $21,364,000 | ' | ' | ' | $26,374,000 | $21,364,000 | ' |
Provision | 10,215,000 | 1,126,000 | 19,277,000 | 3,310,000 | 4,103,000 | 9,672,000 | 5,203,000 | 6,159,000 | 33,928,000 | 25,137,000 | 13,452,000 |
Q4 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of employees reduced | 74 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 8,842,000 | ' | ' | ' | ' | ' | ' | ' | 8,842,000 | ' | ' |
Provision | 11,183,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | -2,341,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q4 2013 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q4 2013 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 8,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q4 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 1,988,000 | ' | ' | ' | ' | ' | ' | ' | 1,988,000 | ' | ' |
Provision | 3,912,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | -1,924,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q4 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 6,854,000 | ' | ' | ' | ' | ' | ' | ' | 6,854,000 | ' | ' |
Provision | 7,271,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | -417,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q3 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of employees reduced | ' | 30 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 137,000 | ' | ' | ' | ' | ' | ' | ' | 137,000 | ' | ' |
Provision | ' | 532,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -395,000 | ' | ' |
Q3 2013 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Q3 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 137,000 | ' | ' | ' | ' | ' | ' | ' | 137,000 | ' | ' |
Provision | ' | 394,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -257,000 | ' | ' |
Q3 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Provision | ' | 138,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -138,000 | ' | ' |
Q2 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of employees reduced | ' | ' | ' | ' | ' | ' | ' | ' | 265 | ' | ' |
Remaining payments | 12,750,000 | ' | ' | ' | ' | ' | ' | ' | 12,750,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 19,318,000 | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -6,568,000 | ' | ' |
Q2 2013 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 8,800,000 | ' | ' |
Q2 2013 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 600,000 | ' | 9,900,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Q2 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 12,750,000 | ' | ' | ' | ' | ' | ' | ' | 12,750,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 18,746,000 | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -5,996,000 | ' | ' |
Q2 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 572,000 | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -572,000 | ' | ' |
Q1 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of employees reduced | ' | ' | ' | 62 | ' | ' | ' | ' | ' | ' | ' |
Q1 2013 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' |
Q1 2013 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | 2,300,000 | ' | ' | ' | ' | ' | ' | ' |
Q1 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 208,000 | ' | ' | ' | ' | ' | ' | ' | 208,000 | ' | ' |
Provision | ' | ' | ' | 2,585,000 | ' | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -2,377,000 | ' | ' |
Q4 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of employees reduced | ' | ' | ' | ' | 54 | ' | ' | ' | ' | ' | ' |
Q4 2012 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | 2,400,000 | ' | ' | ' | ' | ' | ' |
Q4 2012 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | 600,000 | ' | ' | ' | ' | ' | ' |
Q4 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 593,000 | ' | ' | ' | 2,682,000 | ' | ' | ' | 593,000 | 2,682,000 | ' |
Provision | ' | ' | ' | ' | 2,936,000 | ' | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -2,089,000 | -254,000 | ' |
Q3 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -524,000 | 326,000 | ' |
Number of employees reduced | ' | ' | ' | ' | ' | ' | ' | ' | ' | 66 | ' |
Q3 2012 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,891,000 | ' |
Q3 2012 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,900,000 | ' |
Q3 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 3,758,000 | ' | ' | ' | 7,553,000 | ' | ' | ' | 3,758,000 | 7,553,000 | ' |
Provision | ' | ' | ' | ' | ' | 7,446,000 | ' | ' | ' | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -3,271,000 | -219,000 | ' |
Q2 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300,000 | ' | ' |
Number of employees reduced | ' | ' | ' | ' | ' | ' | ' | ' | ' | 203 | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 2,115,000 | ' | ' |
Restructuring and Related Cost, Remaining Cost | 100,000 | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' |
Q2 2012 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' |
Q2 2012 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,200,000 | ' |
Q2 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -294,000 | ' | ' |
Remaining payments | 1,335,000 | ' | ' | ' | 4,586,000 | ' | ' | ' | 1,335,000 | 4,586,000 | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,422,000 | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -5,072,000 | -2,836,000 | ' |
Q1 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -537,000 | ' | ' |
Number of employees reduced | ' | ' | ' | ' | ' | ' | ' | ' | ' | 112 | ' |
Remaining payments | 125,000 | ' | ' | ' | 1,281,000 | ' | ' | ' | 125,000 | 1,281,000 | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,394,000 | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -619,000 | -5,113,000 | ' |
Q1 2012 Restructuring Plan [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -100,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' |
Q1 2012 Restructuring Plan [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -400,000 | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,400,000 | ' |
Q1 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -537,000 | ' | ' |
Remaining payments | 125,000 | ' | ' | ' | 1,281,000 | ' | ' | ' | 125,000 | 1,281,000 | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,315,000 | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -619,000 | -5,034,000 | ' |
Q1 2012 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Remaining payments | 0 | ' | ' | ' | 0 | ' | ' | ' | 0 | 0 | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 79,000 | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | 0 | -79,000 | ' |
Previous restructuring and integration plans [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining payments | 7,500,000 | ' | ' | ' | ' | ' | ' | ' | 7,500,000 | ' | ' |
Restructuring reserve Settled with Cash and Translation Adjustment | ' | ' | ' | ' | ' | ' | ' | ' | -2,400,000 | ' | ' |
Previous restructuring and integration plans [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -1,100,000 | ' | ' |
Contract Termination [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | 700,000 | 1,500,000 | 2,000,000 |
Remaining payments | 300,000 | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' |
Restructuring Reserve, Settled with Cash | ' | ' | ' | ' | ' | ' | ' | ' | ($1,000,000) | ($2,900,000) | ($400,000) |
Restructuring_and_Contract_Ter3
Restructuring and Contract Termination Charges, Net (Schedule of Restructuring Plan Activity) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | $10,215 | $1,126 | $19,277 | $3,310 | $4,103 | $9,672 | $5,203 | $6,159 | $33,928 | $25,137 | $13,452 |
Ending balance | 26,374 | ' | ' | ' | 21,364 | ' | ' | ' | 26,374 | 21,364 | ' |
Q4 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 11,183 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | -2,341 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending balance | 8,842 | ' | ' | ' | ' | ' | ' | ' | 8,842 | ' | ' |
Q4 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 3,912 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | -1,924 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending balance | 1,988 | ' | ' | ' | ' | ' | ' | ' | 1,988 | ' | ' |
Q4 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 7,271 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | -417 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Ending balance | 6,854 | ' | ' | ' | ' | ' | ' | ' | 6,854 | ' | ' |
Q3 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | 532 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -395 | ' | ' |
Ending balance | 137 | ' | ' | ' | ' | ' | ' | ' | 137 | ' | ' |
Q3 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | 394 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -257 | ' | ' |
Ending balance | 137 | ' | ' | ' | ' | ' | ' | ' | 137 | ' | ' |
Q3 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | 138 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -138 | ' | ' |
Ending balance | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Q2 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 19,318 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -6,568 | ' | ' |
Ending balance | 12,750 | ' | ' | ' | ' | ' | ' | ' | 12,750 | ' | ' |
Q2 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 18,746 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -5,996 | ' | ' |
Ending balance | 12,750 | ' | ' | ' | ' | ' | ' | ' | 12,750 | ' | ' |
Q2 2013 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 572 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -572 | ' | ' |
Ending balance | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Q1 2013 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | 2,585 | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -2,377 | ' | ' |
Ending balance | 208 | ' | ' | ' | ' | ' | ' | ' | 208 | ' | ' |
Q4 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | 2,936 | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -2,089 | -254 | ' |
Ending balance | 593 | ' | ' | ' | 2,682 | ' | ' | ' | 593 | 2,682 | ' |
Q3 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -524 | 326 | ' |
Q3 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | 7,446 | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -3,271 | -219 | ' |
Ending balance | 3,758 | ' | ' | ' | 7,553 | ' | ' | ' | 3,758 | 7,553 | ' |
Q2 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 2,115 | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300 | ' | ' |
Q2 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,422 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -294 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -5,072 | -2,836 | ' |
Ending balance | 1,335 | ' | ' | ' | 4,586 | ' | ' | ' | 1,335 | 4,586 | ' |
Q1 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,394 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -537 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -619 | -5,113 | ' |
Ending balance | 125 | ' | ' | ' | 1,281 | ' | ' | ' | 125 | 1,281 | ' |
Q1 2012 Restructuring Plan [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,315 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -537 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -619 | -5,034 | ' |
Ending balance | 125 | ' | ' | ' | 1,281 | ' | ' | ' | 125 | 1,281 | ' |
Q1 2012 Restructuring Plan [Member] | Closure Of Excess Facility Space [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 79 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | 0 | -79 | ' |
Ending balance | 0 | ' | ' | ' | 0 | ' | ' | ' | 0 | 0 | ' |
Previous restructuring and integration plans [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amounts paid and foreign currency translation | ' | ' | ' | ' | ' | ' | ' | ' | -2,400 | ' | ' |
Ending balance | 7,500 | ' | ' | ' | ' | ' | ' | ' | 7,500 | ' | ' |
Previous restructuring and integration plans [Member] | Severance [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -1,100 | ' | ' |
Contract Termination [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | 700 | 1,500 | 2,000 |
Ending balance | 300 | ' | ' | ' | ' | ' | ' | ' | 300 | ' | ' |
Environmental Health [Member] | Q4 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 3,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Environmental Health [Member] | Q2 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | 8,800 | ' | ' |
Environmental Health [Member] | Q1 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | 200 | ' | ' | ' | ' | ' | ' | ' |
Environmental Health [Member] | Q4 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | 2,400 | ' | ' | ' | ' | ' | ' |
Environmental Health [Member] | Q3 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,891 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300 | ' | ' |
Environmental Health [Member] | Q2 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200 | ' |
Environmental Health [Member] | Q1 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -100 | ' | ' |
Human Health [Member] | Q4 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 8,200 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Human Health [Member] | Q3 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | 500 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Human Health [Member] | Q2 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | 600 | ' | 9,900 | ' | ' | ' | ' | ' | ' | ' | ' |
Human Health [Member] | Q1 2013 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | 2,300 | ' | ' | ' | ' | ' | ' | ' |
Human Health [Member] | Q4 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | 600 | ' | ' | ' | ' | ' | ' |
Human Health [Member] | Q3 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,900 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | -300 | ' | ' |
Human Health [Member] | Q2 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,200 | ' |
Human Health [Member] | Q1 2012 Restructuring Plan [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Provision | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,400 | ' |
Change in estimates | ' | ' | ' | ' | ' | ' | ' | ' | ($400) | ' | ' |
Interest_and_Other_Expense_Inc2
Interest and Other Expense (Income), Net (Details) (USD $) | 12 Months Ended | 3 Months Ended | 3 Months Ended | 12 Months Ended | |||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | 30-May-08 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
2015 Notes [Member] | 2015 Notes [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | ||||
Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | ||||||
Unsecured senior notes, interest rate percent | ' | ' | ' | ' | 6.00% | ' | ' | ' | ' |
Early Repayment of Senior Debt | $150,000,000 | $0 | $0 | $150,000,000 | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | -4,800,000 | ' | ' | ' | ' | -2,800,000 | -2,000,000 | -2,000,000 | -2,000,000 |
Write off of Deferred Debt Issuance Cost | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Payments of Debt Extinguishment Costs | -11,119,000 | 0 | 0 | ' | ' | ' | ' | ' | ' |
Interest income | -650,000 | -747,000 | -1,884,000 | ' | ' | ' | ' | ' | ' |
Interest expense | 49,924,000 | 45,787,000 | 24,783,000 | ' | ' | ' | ' | ' | ' |
Other expense, net | 14,836,000 | 2,916,000 | 3,875,000 | ' | ' | ' | ' | ' | ' |
Total interest and other expense (income), net | $64,110,000 | $47,956,000 | $26,774,000 | ' | ' | ' | ' | ' | ' |
Income_Taxes_Details
Income Taxes (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||
Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Dec. 29, 2013 | Jan. 01, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Nov. 30, 2011 | |
November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | General Business [Member] | Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | ||||||
November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | ||||||||||
Income Tax Contingency [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Loss Carryforwards | ' | ' | ' | ' | ' | ' | ' | ' | $113,400,000 | $88,800,000 | $223,400,000 |
Valuation Allowance, Amount | 63,139,000 | 63,139,000 | 67,814,000 | ' | ' | ' | ' | 10,400,000 | ' | ' | ' |
Document Period End Date | ' | 29-Dec-13 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized tax benefits, beginning of period | ' | 58,110,000 | 51,740,000 | 39,226,000 | ' | ' | ' | ' | ' | ' | ' |
Gross increases - tax positions in prior period | ' | 325,000 | 10,653,000 | 2,753,000 | ' | ' | ' | ' | ' | ' | ' |
Gross decreases - tax positions in prior period | ' | -10,539,000 | -4,665,000 | -4,729,000 | ' | ' | ' | ' | ' | ' | ' |
Gross increases - current-period tax positions | ' | 2,222,000 | 3,343,000 | 2,451,000 | ' | ' | ' | ' | ' | ' | ' |
Gross increases - related to acquisitions | ' | 0 | 0 | 14,412,000 | ' | ' | ' | ' | ' | ' | ' |
Settlements | ' | -3,643,000 | -2,822,000 | -430,000 | ' | ' | ' | ' | ' | ' | ' |
Lapse of statute of limitations | ' | -6,495,000 | -595,000 | -2,224,000 | ' | ' | ' | ' | ' | ' | ' |
Foreign currency translation adjustments | ' | -570,000 | 456,000 | 281,000 | ' | ' | ' | ' | ' | ' | ' |
Unrecognized tax benefits, end of period | 39,410,000 | 39,410,000 | 58,110,000 | 51,740,000 | 39,226,000 | ' | ' | ' | ' | ' | ' |
Interest on income taxes accrued | 4,000,000 | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest on income taxes expense | ' | -3,900,000 | 1,100,000 | 500,000 | ' | ' | ' | ' | ' | ' | ' |
Income tax penalties expense | ' | -3,700,000 | -2,200,000 | 0 | ' | ' | ' | ' | ' | ' | ' |
Income tax penalties accrued | 400,000 | 400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate | 33,400,000 | 33,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized Tax Benefits Expected To Be Resolved With In A Year | 4,000,000 | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Foreign earnings planned to be repatriated | ' | ' | ' | 350,000,000 | 250,000,000 | ' | ' | ' | ' | ' | ' |
Increase (decrease) to tax provision in discontinued operations | ' | ' | ' | 6,700,000 | 65,800,000 | ' | 79,700,000 | ' | ' | ' | ' |
Repatriated Foreign Earnings | ' | ' | ' | ' | ' | 350,000,000 | ' | ' | ' | ' | ' |
Foreign earnings invested outside U.S. | ' | 607,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Open Tax Years by Major Tax Jurisdiction, Begin Date | ' | '2006 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Tax Adjustments, Settlements, and Unusual Provisions | ($9,200,000) | ($24,000,000) | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Income_Taxes_Income_Before_Inc
Income Taxes Income Before Income taxes (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | ||
Income Tax Contingency [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||
U.S. | ' | ' | ' | ' | ' | ' | ' | ' | ($82,253) | ($118,546) | ($145,298) | ||
Non-U.S. | ' | ' | ' | ' | ' | ' | ' | ' | 235,585 | 169,133 | 209,652 | ||
Income from continuing operations before income taxes | $57,816 | [1] | $44,856 | $26,799 | $23,861 | ($42,740) | [2] | $31,346 | $38,429 | $23,552 | $153,332 | $50,587 | $64,354 |
[1] | The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2013 also includes pre-tax impairment charges of $6.7 million as the carrying amounts of certain long-lived assets were not recoverable and exceeded their fair value. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statues of limitations and audit settlements. | ||||||||||||
[2] | The fourth quarter of fiscal year 2012 includes a pre-tax loss of $31.8 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2012 also includes pre-tax impairment charges of $74.2 million as a result of a review of certain trade names within the Company's portfolio as part of a realignment of its marketing strategy. |
Income_Taxes_Components_of_the
Income Taxes Components of the Provision (Benefits from) Income Tax (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Income Tax Contingency [Line Items] | ' | ' | ' |
Federal current | ($1,292) | ($5,234) | $18,309 |
Federal deferred expense (benefit) | -29,961 | -34,920 | 8,615 |
Federal total | -31,253 | -40,154 | 26,924 |
State current | 1,582 | 2,617 | 3,397 |
State deferred expense (benefit) | -2,147 | -2,794 | -4,583 |
State total | -565 | -177 | -1,186 |
Non-U.S. current | 15,025 | 50,314 | 41,765 |
Non-U.S.deferred expense benefit | 2,201 | -27,837 | -4,321 |
Non-U.S. total | 17,226 | 22,477 | 37,444 |
Total current | 15,315 | 47,697 | 63,471 |
Total deferred expense (benefit) | -29,907 | -65,551 | -289 |
Total | -14,592 | -17,854 | 63,182 |
Discontinued operations | -1,098 | 906 | -4,484 |
Total provision for income taxes | ($15,690) | ($16,948) | $58,698 |
Income_Taxes_Reconciliation_of
Income Taxes Reconciliation of Income Tax Expense (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Income Tax Contingency [Line Items] | ' | ' | ' |
Tax at statutory rate | $53,663 | $17,708 | $22,526 |
Non-U.S. rate differential, net | -36,377 | -26,652 | -37,797 |
U.S. taxation of multinational operations | 3,658 | 1,727 | 1,487 |
State income taxes, net | -2,145 | 3,265 | -5,536 |
Prior year tax matters | -23,534 | 3,389 | -9,079 |
Estimated Taxes on Repatriation | 0 | 0 | 79,662 |
Federal tax credits | -5,452 | -1,657 | -1,509 |
Change in valuation allowance | -4,675 | -14,446 | 11,364 |
Other, net | 270 | -1,188 | 2,064 |
Total | ($14,592) | ($17,854) | $63,182 |
Income_Taxes_Components_of_Def
Income Taxes Components of Deferred Tax Assets and Liabilities (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
Income Tax Contingency [Line Items] | ' | ' |
Long-term deferred tax liabilities | $45,300,000 | $32,400,000 |
Current deferred tax assets | 78,300,000 | 34,900,000 |
Inventory | 9,850,000 | 9,893,000 |
Reserves and accruals | 30,269,000 | 19,845,000 |
Accrued compensation | 15,920,000 | 15,803,000 |
Net operating loss and credit carryforwards | 132,710,000 | 165,274,000 |
Accrued pension | 23,353,000 | 34,016,000 |
Restructuring reserve | 6,853,000 | 7,951,000 |
Deferred revenue | 42,687,000 | 42,054,000 |
All other, net | 1,666,000 | 1,432,000 |
Total deferred tax assets | 263,308,000 | 296,268,000 |
Postretirement health benefits | -3,894,000 | -3,472,000 |
Depreciation and amortization | -163,269,000 | -191,075,000 |
Repatriation accrual | 0 | -31,447,000 |
Total deferred tax liabilities | -167,163,000 | -225,994,000 |
Valuation allowance | -63,139,000 | -67,814,000 |
Net deferred tax liabilities | 33,006,000 | 2,460,000 |
Domestic Country [Member] | ' | ' |
Income Tax Contingency [Line Items] | ' | ' |
Net deferred tax liabilities | 22,565,000 | -10,919,000 |
Foreign Country [Member] | ' | ' |
Income Tax Contingency [Line Items] | ' | ' |
Net deferred tax liabilities | $10,441,000 | $13,379,000 |
Income_Taxes_Summary_of_Loss_a
Income Taxes Summary of Loss and Tax Credit Carryforwards (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | Jan. 01, 2012 | Dec. 29, 2013 | Nov. 30, 2011 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 |
State and Local Jurisdiction [Member] | Foreign Country [Member] | Internal Revenue Service (IRS) [Member] | General Business [Member] | General Business [Member] | November 2011 Caliper Life Sciences [Member] | November 2011 Caliper Life Sciences [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | |||
Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | Foreign Country [Member] | November 2011 Caliper Life Sciences [Member] | Foreign Country [Member] | November 2011 Caliper Life Sciences [Member] | ||||||||
Internal Revenue Service (IRS) [Member] | Internal Revenue Service (IRS) [Member] | ||||||||||||
Income Tax Contingency [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Operating Loss Carryforwards | ' | ' | $275,000,000 | $177,200,000 | $113,400,000 | ' | ' | $88,800,000 | $223,400,000 | ' | ' | ' | ' |
Foreign tax credit carryforwards | ' | ' | 11,900,000 | 5,000,000 | ' | 29,600,000 | ' | ' | ' | ' | ' | ' | ' |
Valuation Allowance, Amount | $63,139,000 | $67,814,000 | ' | ' | ' | ' | $10,400,000 | ' | ' | ' | ' | ' | ' |
Tax Credit Carryforward, Expiration Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Jan-14 | ' | 1-Jan-32 | ' |
Operating Loss Carryforwards, Expiration Dates | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Jan-14 | ' | 1-Jan-30 |
Earnings_Per_Share_Schedule_of
Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Earnings Per Share [Abstract] | ' | ' | ' |
Number of common shares-basic | 112,254 | 113,728 | 112,976 |
Effect of dilutive securities, Stock options | 982 | 847 | 739 |
Effect of dilutive securities, Restricted stock | 267 | 285 | 149 |
Number of common shares-diluted | 113,503 | 114,860 | 113,864 |
Number of potentially dilutive securities excluded from calculation due to antidilutive impact | 485 | 1,288 | 2,281 |
Accounts_Receivable_Net_Detail
Accounts Receivable, Net (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Millions, unless otherwise specified | ||
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract] | ' | ' |
Reserves for doubtful accounts | $30.20 | $23.40 |
Inventories_Net_Details
Inventories, Net (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Thousands, unless otherwise specified | ||
Inventory Disclosure [Abstract] | ' | ' |
Raw materials | $92,891 | $74,924 |
Work in progress | 15,505 | 12,768 |
Finished goods | 152,640 | 159,996 |
Total inventories, net | $261,036 | $247,688 |
Property_Plant_and_Equipment_N2
Property, Plant and Equipment, Net (Details) (USD $) | 12 Months Ended | ||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | $504,184,000 | $513,479,000 | ' |
Accumulated depreciation | -318,811,000 | -302,963,000 | ' |
Total property, plant and equipment, net | 185,373,000 | 210,516,000 | ' |
Depreciation expense | 38,100,000 | 35,600,000 | 30,900,000 |
Land [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 1,779,000 | 8,050,000 | ' |
Building and leasehold Improvements [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | 174,449,000 | 180,821,000 | ' |
Machinery and Equipment [Member] | ' | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' | ' |
Property, plant and equipment, gross | $327,956,000 | $324,608,000 | ' |
Marketable_Securities_and_Inve2
Marketable Securities and Investments (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Unrealized (losses) gains on securities, net of tax | $8 | $30 | ($59) |
Marketable securities | 1,319 | 1,149 | ' |
Marketable securities and investments | 1,319 | 1,149 | ' |
Equity Securities [Member] | ' | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Cost | 871 | 804 | ' |
Gross unrealized holding gains | 0 | 0 | ' |
Gross unrealized holding losses | -131 | -147 | ' |
Market value | 740 | 657 | ' |
Fixed Income Securities [Member] | ' | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Cost | 308 | 294 | ' |
Gross unrealized holding gains | 0 | 0 | ' |
Gross unrealized holding losses | 0 | 0 | ' |
Market value | 308 | 294 | ' |
Available-for-sale Securities, Other [Member] | ' | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Cost | 334 | 261 | ' |
Gross unrealized holding gains | 0 | 0 | ' |
Gross unrealized holding losses | -63 | -63 | ' |
Market value | 271 | 198 | ' |
Available-for-sale Securities [Member] | ' | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' | ' |
Cost | 1,513 | 1,359 | ' |
Gross unrealized holding gains | 0 | 0 | ' |
Gross unrealized holding losses | -194 | -210 | ' |
Market value | $1,319 | $1,149 | ' |
Goodwill_and_Intangible_Assets2
Goodwill and Intangible Assets, Net (Narrative) (Details) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | |
Minimum [Member] | Maximum [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Licenses [Member] | Licenses [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Human Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Environmental Health [Member] | Other Asset Acquisitions [Member] | Other Asset Acquisitions [Member] | ||||
Minimum [Member] | Maximum [Member] | Weighted Average [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Customer Lists [Member] | Customer Lists [Member] | Licenses [Member] | Licenses [Member] | Licenses [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Licenses [Member] | Licenses [Member] | |||||||||||||||||
Goodwill and Intangible Assets Net [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reallocation of Goodwill Resulting from Realignment Within Operating Segments | ' | ' | $215,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount | 30.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term terminal growth rates for reporting units | ' | ' | ' | 4.50% | 6.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discount rates for reporting units | ' | ' | ' | 10.50% | 12.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Change in any one of the input assumptions for the various reporting units | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining Fair Value After Impairment for Finite and Indefinite Lived Intangible Assets | ' | ' | ' | ' | ' | 6,100,000 | 6,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | '8 years | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | 74,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 73,400,000 | ' | ' | 6,700,000 | ' | ' | ' | ' | ' | 700,000 | ' | ' | ' | ' | ' |
Total amortization expense related to finite-lived intangible assets | 90,400,000 | 91,200,000 | 80,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Future Amortization Expense, Year One | 83,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Future Amortization Expense, Year Two | 69,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Future Amortization Expense, Year Three | 60,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Future Amortization Expense, Year Four | 50,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Future Amortization Expense, Year Five | 39,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Finite-Lived Intangible Assets, Net | 389,846,000 | 459,317,000 | ' | ' | ' | 23,808,000 | 23,808,000 | 19,601,000 | ' | ' | ' | 26,250,000 | 33,239,000 | 339,711,000 | 414,097,000 | 23,804,000 | 19,601,000 | ' | ' | ' | 25,745,000 | 31,181,000 | 50,135,000 | 45,220,000 | 4,000 | 0 | 505,000 | 2,058,000 | 7,000,000 | 6,800,000 |
Prepaid Royalties | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,300,000 | 25,000,000 |
Prepaid Royalties To Be Paid Within One Year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' |
Asset impairment | $6,731,000 | $74,153,000 | $3,006,000 | ' | ' | ' | $2,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $6,700,000 | ' | $3,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill_and_Intangible_Assets3
Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 |
Changes in the carrying amount of goodwill | ' | ' |
Beginning balance | $2,122,788 | $2,094,235 |
Foreign currency translation | 15,167 | 8,871 |
Acquisitions, earn outs and other | 5,165 | 19,682 |
Ending balance | 2,143,120 | 2,122,788 |
Human Health [Member] | ' | ' |
Changes in the carrying amount of goodwill | ' | ' |
Beginning balance | 1,632,487 | 1,606,913 |
Foreign currency translation | 12,867 | 5,892 |
Acquisitions, earn outs and other | 2,978 | 19,682 |
Ending balance | 1,648,332 | 1,632,487 |
Environmental Health [Member] | ' | ' |
Changes in the carrying amount of goodwill | ' | ' |
Beginning balance | 490,301 | 487,322 |
Foreign currency translation | 2,300 | 2,979 |
Acquisitions, earn outs and other | 2,187 | 0 |
Ending balance | $494,788 | $490,301 |
Goodwill_and_Intangible_Assets4
Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Thousands, unless otherwise specified | ||
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Net amortizable intangible assets | $389,846 | $459,317 |
Totals | 460,430 | 529,901 |
Patents [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 39,591 | 107,969 |
Less: Accumulated amortization | -24,207 | -89,954 |
Net amortizable intangible assets | 15,384 | 18,015 |
Trade Names And Trademarks [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 36,058 | 37,694 |
Less: Accumulated amortization | -16,457 | -13,886 |
Net amortizable intangible assets | 19,601 | 23,808 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Licenses [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 79,180 | 80,607 |
Less: Accumulated amortization | -52,930 | -47,368 |
Net amortizable intangible assets | 26,250 | 33,239 |
Core Technology [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 302,070 | 407,545 |
Less: Accumulated amortization | -169,326 | -248,510 |
Net amortizable intangible assets | 132,744 | 159,035 |
Customer Relationships [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 321,395 | 327,637 |
Less: Accumulated amortization | -132,833 | -108,384 |
Net amortizable intangible assets | 188,562 | 219,253 |
In Process Research and Development [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 9,483 | 7,463 |
Less: Accumulated amortization | -2,178 | -1,496 |
Net amortizable intangible assets | 7,305 | 5,967 |
Human Health [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Net amortizable intangible assets | 339,711 | 414,097 |
Totals | 339,711 | 414,097 |
Human Health [Member] | Patents [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 36,791 | 91,948 |
Less: Accumulated amortization | -22,205 | -74,831 |
Net amortizable intangible assets | 14,586 | 17,117 |
Human Health [Member] | Trade Names And Trademarks [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 35,972 | 37,511 |
Less: Accumulated amortization | -16,371 | -13,707 |
Net amortizable intangible assets | 19,601 | 23,804 |
Non-amortizing intangible assets | 0 | 0 |
Human Health [Member] | Licenses [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 71,580 | 72,674 |
Less: Accumulated amortization | -45,835 | -41,493 |
Net amortizable intangible assets | 25,745 | 31,181 |
Human Health [Member] | Core Technology [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 187,387 | 268,902 |
Less: Accumulated amortization | -88,811 | -146,662 |
Net amortizable intangible assets | 98,576 | 122,240 |
Human Health [Member] | Customer Relationships [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 305,038 | 321,732 |
Less: Accumulated amortization | -127,397 | -105,764 |
Net amortizable intangible assets | 177,641 | 215,968 |
Human Health [Member] | In Process Research and Development [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 4,257 | 4,163 |
Less: Accumulated amortization | -695 | -376 |
Net amortizable intangible assets | 3,562 | 3,787 |
Environmental Health [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Net amortizable intangible assets | 50,135 | 45,220 |
Totals | 120,719 | 115,804 |
Environmental Health [Member] | Patents [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 2,800 | 16,021 |
Less: Accumulated amortization | -2,002 | -15,123 |
Net amortizable intangible assets | 798 | 898 |
Environmental Health [Member] | Trade Names And Trademarks [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 86 | 183 |
Less: Accumulated amortization | -86 | -179 |
Net amortizable intangible assets | 0 | 4 |
Non-amortizing intangible assets | 70,584 | 70,584 |
Environmental Health [Member] | Licenses [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 7,600 | 7,933 |
Less: Accumulated amortization | -7,095 | -5,875 |
Net amortizable intangible assets | 505 | 2,058 |
Environmental Health [Member] | Core Technology [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 114,683 | 138,643 |
Less: Accumulated amortization | -80,515 | -101,848 |
Net amortizable intangible assets | 34,168 | 36,795 |
Environmental Health [Member] | Customer Relationships [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 16,357 | 5,905 |
Less: Accumulated amortization | -5,436 | -2,620 |
Net amortizable intangible assets | 10,921 | 3,285 |
Environmental Health [Member] | In Process Research and Development [Member] | ' | ' |
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items] | ' | ' |
Gross amortizable intangible assets | 5,226 | 3,300 |
Less: Accumulated amortization | -1,483 | -1,120 |
Net amortizable intangible assets | $3,743 | $2,180 |
Debt_Details
Debt (Details) (USD $) | 12 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 29, 2013 | 30-May-08 | Dec. 29, 2013 | Oct. 25, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing January 8, 2019 [Member] | 2015 Notes [Member] | 2015 Notes [Member] | 2021 Notes [Member] | 2021 Notes [Member] | 2021 Notes [Member] | 2021 Notes [Member] | Financing Lease Obligations [Member] | Financing Lease Obligations [Member] | Financing Lease Obligations [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | ||||
Base Rate Option Three [Member] | Eurocurrency Rate [Member] | Base Rate Option Two [Member] | Treasury Rate [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | |||||||||||||||
Additional Financing Lease Obligations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $11,500,000 | ' | ' | ' | ' | ' | ' |
Long-term Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | 497,400,000 | 497,200,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured revolving credit facility, amount | ' | ' | ' | 700,000,000 | ' | ' | ' | ' | 700,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured revolving credit facility, expiry date | ' | ' | ' | 16-Dec-16 | ' | ' | ' | ' | 8-Jan-19 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Remaining Borrowing Capacity | ' | ' | ' | 291,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Letters of credit issued and outstanding | ' | ' | ' | 12,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest rate terms under amended senior unsecured revolving credit facility | ' | ' | ' | 'The interest rates under the former senior unsecured revolving credit facility were based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate was the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by Bank of America, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. | ' | ' | ' | ' | 'The interest rates under the new senior unsecured revolving credit facility will be based on the Eurocurrency rate at the time of borrowing plus a margin, or the base rate from time to time. The base rate will be the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by JPMorgan Chase Bank, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average interest rates under amended senior unsecured revolving credit facility | ' | ' | ' | 'The Eurocurrency margin as of DecemberB 29, 2013 was 130 basis points. The weighted average Eurocurrency interest rate as of DecemberB 29, 2013 was 0.17%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.47%, which was the interest applicable to borrowings outstanding under the Eurocurrency rate as of DecemberB 29, 2013. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Description of variable rate basis | ' | ' | ' | ' | ' | ' | 'Eurocurrency | 'Federal Funds | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Basis spread on variable rate | ' | ' | ' | ' | ' | 1.00% | 1.30% | 0.50% | ' | ' | ' | ' | ' | ' | 0.45% | ' | ' | ' | ' | ' | ' | ' |
Weighted average Eurocurrency interest rate | ' | ' | ' | ' | ' | ' | 0.17% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average effective Eurocurrency rate, including the margin | ' | ' | ' | ' | ' | ' | 1.47% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate borrowings under the amended facility | ' | ' | ' | 397,000,000 | 258,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured senior notes, interest rate percent | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6.00% | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Early Repayment of Senior Debt | 150,000,000 | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured senior notes, face value | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | 500,000,000 | 500,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments of Debt Extinguishment Costs | 11,119,000 | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | -4,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,800,000 | -2,000,000 | -2,000,000 | -2,000,000 |
Write off of Deferred Debt Issuance Cost | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gross proceeds from the issuance of debt instrument | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | 496,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Senior unsecured notes issuance as percentage of principal amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 99.37% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discount on senior unsecured notes | -2,568,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | -3,100,000 | -2,568,000 | -2,800,000 | ' | 0 | ' | ' | ' | ' | ' | ' |
Debt instrument maturity date | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30-May-15 | ' | 25-Nov-21 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of redemption of senior notes on or after August 15, 2021 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 101.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maturities of Long-term Debt [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
2014 | 2,624,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 2,624,000 | ' | ' | ' | ' | ' | ' |
2015 | 2,632,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 2,632,000 | ' | ' | ' | ' | ' | ' |
2016 | 399,641,000 | ' | ' | 397,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 2,641,000 | ' | ' | ' | ' | ' | ' |
2017 | 2,649,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 2,649,000 | ' | ' | ' | ' | ' | ' |
2018 | 2,802,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | 2,802,000 | ' | ' | ' | ' | ' | ' |
Thereafter | 526,948,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 500,000,000 | ' | ' | 26,948,000 | ' | ' | ' | ' | ' | ' |
Long-term Debt Before Unamortized Discount | 937,296,000 | ' | ' | 397,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | 500,000,000 | ' | ' | 40,296,000 | ' | ' | ' | ' | ' | ' |
Total | 934,728,000 | ' | ' | 397,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | 497,432,000 | ' | ' | 40,296,000 | ' | ' | ' | ' | ' | ' |
Other Long-term Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 40,300,000 | 34,600,000 | 29,300,000 | ' | ' | ' | ' |
Other Long-term Debt, Current | 2,624,000 | 1,772,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,600,000 | 1,700,000 | ' | ' | ' | ' | ' |
Other Long-term Debt, Noncurrent | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $37,700,000 | $32,900,000 | ' | ' | ' | ' | ' |
Accrued_Expenses_and_Other_Cur2
Accrued Expenses and Other Current Liabilities (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Thousands, unless otherwise specified | ||
Accounts Payable and Accrued Liabilities, Current [Abstract] | ' | ' |
Payroll and incentives | $53,049 | $55,342 |
Employee benefits | 41,019 | 42,485 |
Deferred revenue | 164,723 | 154,247 |
Federal, non-U.S. and state income taxes | 11,783 | 16,091 |
Other accrued operating expenses | 133,490 | 119,861 |
Total accrued expenses and other current liabilities | $404,064 | $388,026 |
Employee_Benefit_Plans_Schedul
Employee Benefit Plans (Schedule of Net Benefit Costs, Pension Plans) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Net periodic benefit cost | ($16,839) | $34,361 | $70,299 |
Pension Plans, Defined Benefit | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Service cost | 3,664 | 3,852 | 3,880 |
Interest cost | 21,334 | 23,164 | 25,169 |
Expected return on plan assets | -25,106 | -20,768 | -22,534 |
Actuarial loss (gain) | -16,464 | 28,355 | 64,005 |
Amortization of prior service cost | ($267) | ($242) | ($221) |
Employee_Benefit_Plans_Schedul1
Employee Benefit Plans (Schedule of Net Funded Status, Pension Plans) (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation | $151,391 | $278,707 | ' | ' |
Actuarial assumptions as of the year-end measurement date: | ' | ' | ' | ' |
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets | 0 | 114,515 | ' | ' |
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Projected Benefit Obligation | 148,235 | 271,153 | ' | ' |
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets | 0 | 114,515 | ' | ' |
Foreign Pension Plans, Defined Benefit [Member] | ' | ' | ' | ' |
Actuarial present value of benefit obligations: [Abstract] | ' | ' | ' | ' |
Accumulated benefit obligations | 277,125 | 271,153 | ' | ' |
Change in benefit obligations: | ' | ' | ' | ' |
Projected benefit obligations at beginning of year | 278,707 | 231,325 | ' | ' |
Service cost | 2,589 | 2,502 | ' | ' |
Interest cost | 9,834 | 11,235 | ' | ' |
Benefits paid and plan expenses | -11,218 | -10,625 | ' | ' |
Participant's contributions | 391 | 432 | ' | ' |
Defined Benefit Plan, Settlements, Benefit Obligation | -918 | 0 | ' | ' |
Actuarial loss (gain) | 1,678 | 38,541 | ' | ' |
Effect of exchange rate changes | 7,153 | 5,297 | ' | ' |
Projected benefit obligations at end of year | 288,216 | 278,707 | 231,325 | ' |
Change in plan assets: | ' | ' | ' | ' |
Fair value of plan assets at beginning of year | 114,515 | 97,836 | ' | ' |
Actual return on plan assets | 17,201 | 12,710 | ' | ' |
Benefits paid and plan expenses | -11,218 | -10,625 | ' | ' |
Employer's contributions | 20,200 | 10,882 | ' | ' |
Defined Benefit Plan, Settlements, Plan Assets | -918 | 0 | ' | ' |
Participant's contributions | 391 | 432 | ' | ' |
Effect of exchange rate changes | 3,533 | 3,280 | ' | ' |
Fair value of plan assets at end of year | 143,704 | 114,515 | 97,836 | ' |
Net amounts recognized in the consolidated balance sheets consist of: | ' | ' | ' | ' |
Net amounts recognized in the consolidated balance sheets | -144,512 | -164,192 | ' | ' |
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 6,879 | 0 | ' | ' |
Current liabilities | -7,360 | -7,398 | ' | ' |
Noncurrent liabilities | -144,031 | -156,794 | ' | ' |
Net amounts recognized in accumulated other comprehensive income consist of: | ' | ' | ' | ' |
Prior service cost | -1,745 | -2,048 | ' | ' |
Net amounts recognized in accumulated other comprehensive income | -1,745 | -2,048 | ' | ' |
Actuarial assumptions as of the year-end measurement date: | ' | ' | ' | ' |
Discount rate | 3.77% | 3.62% | 4.91% | 5.14% |
Rate of compensation increase | 3.23% | 2.88% | 3.22% | 3.42% |
Expected rate of return on assets | 5.50% | 5.40% | 6.70% | ' |
United States Pension Plans of US Entity, Defined Benefit [Member] | ' | ' | ' | ' |
Actuarial present value of benefit obligations: [Abstract] | ' | ' | ' | ' |
Accumulated benefit obligations | 279,299 | 301,770 | ' | ' |
Change in benefit obligations: | ' | ' | ' | ' |
Projected benefit obligations at beginning of year | 301,770 | 297,001 | ' | ' |
Service cost | 1,075 | 1,350 | ' | ' |
Interest cost | 11,500 | 11,929 | ' | ' |
Benefits paid and plan expenses | -17,817 | -17,568 | ' | ' |
Participant's contributions | 0 | 0 | ' | ' |
Defined Benefit Plan, Settlements, Benefit Obligation | 0 | 0 | ' | ' |
Actuarial loss (gain) | -17,229 | 9,058 | ' | ' |
Effect of exchange rate changes | 0 | 0 | ' | ' |
Projected benefit obligations at end of year | 279,299 | 301,770 | 297,001 | ' |
Change in plan assets: | ' | ' | ' | ' |
Fair value of plan assets at beginning of year | 221,755 | 195,022 | ' | ' |
Actual return on plan assets | 8,818 | 27,301 | ' | ' |
Benefits paid and plan expenses | -17,817 | -17,568 | ' | ' |
Employer's contributions | 37,000 | 17,000 | ' | ' |
Defined Benefit Plan, Settlements, Plan Assets | 0 | 0 | ' | ' |
Participant's contributions | 0 | 0 | ' | ' |
Effect of exchange rate changes | 0 | 0 | ' | ' |
Fair value of plan assets at end of year | 249,756 | 221,755 | 195,022 | ' |
Net amounts recognized in the consolidated balance sheets consist of: | ' | ' | ' | ' |
Net amounts recognized in the consolidated balance sheets | -29,543 | -80,015 | ' | ' |
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 0 | 0 | ' | ' |
Current liabilities | 0 | 0 | ' | ' |
Noncurrent liabilities | -29,543 | -80,015 | ' | ' |
Net amounts recognized in accumulated other comprehensive income consist of: | ' | ' | ' | ' |
Prior service cost | 0 | 0 | ' | ' |
Net amounts recognized in accumulated other comprehensive income | $0 | $0 | ' | ' |
Actuarial assumptions as of the year-end measurement date: | ' | ' | ' | ' |
Discount rate | 4.77% | 3.92% | 4.10% | 5.30% |
Rate of compensation increase | 0.00% | 0.00% | 3.50% | 3.50% |
Expected rate of return on assets | 7.50% | 7.75% | 8.10% | ' |
Employee_Benefit_Plans_Schedul2
Employee Benefit Plans (Schedule of Allocation of Plan Assets, Pension Plans) (Details) | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | |
Foreign Pension Plans, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Other Securities [Member] | Other Securities [Member] | Other Securities [Member] | Other Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Equity Securities [Member] | Equity Securities [Member] | Equity Securities [Member] | Equity Securities [Member] | |
Equity Securities [Member] | Equity Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Equity Securities [Member] | Equity Securities [Member] | Debt Securities [Member] | Debt Securities [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Trading Assets, Excluding Debt and Equity Securities [Member] | Foreign Pension Plans, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||||
Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | Foreign Pension Plans, Defined Benefit [Member] | United States Pension Plans of US Entity, Defined Benefit [Member] | |||||||||||||||||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Defined Benefit, Target Asset Allocation Percentage | ' | ' | ' | ' | 45.00% | 40.00% | 45.00% | 50.00% | 0.00% | 0.00% | 55.00% | 50.00% | 55.00% | 60.00% | 5.00% | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Defined Benefit Plan, Equity Securities | 100.00% | 100.00% | 100.00% | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.00% | 0.00% | 0.00% | 6.00% | 48.00% | 29.00% | 57.00% | 39.00% | 51.00% | 71.00% | 43.00% | 55.00% |
Defined Benefit Plan, Target Allocation Percentage | '1 | ' | '1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee_Benefit_Plans_Schedul3
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Pension Plans) (Details) (Pension Plans, Defined Benefit, USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 |
In Thousands, unless otherwise specified | ||||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | $393,460 | $336,270 | ' | ' |
Cash [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 4,458 | 13,940 | ' | ' |
Equity Securities, U.S. Large-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 34,127 | 37,674 | ' | ' |
Equity Securities, International large-cap value[Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 27,595 | 37,239 | ' | ' |
Equity Securities, U.S. Small-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 3,567 | ' | ' |
Equity Securities, Emerging Markets Growth [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 12,517 | 12,390 | ' | ' |
Equity Securities, Equity Index Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 73,796 | 80,999 | ' | ' |
Equity Securities, Domestic Real Estate Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 2,471 | 2,235 | ' | ' |
Equity Securities, Commodity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 8,179 | 8,940 | ' | ' |
Foreign Government Debt Securities [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 18,344 | ' | ' | ' |
Fixed Income Funds, Corporate Debt Instruments - Preferred [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 565 | ' | ' |
Fixed Income Funds, Corporate Debt Instruments [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 132,828 | 73,362 | ' | ' |
Fixed Income Funds, Corporate Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 22,619 | 22,497 | ' | ' |
Fixed Income Funds, High Yield Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 6,170 | 11,624 | ' | ' |
Other Types of Investments, Multi-strategy hedge funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 22,689 | 20,262 | ' | ' |
Other Types of Investments, Venture Capital Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 8 | 7 | ' | ' |
Private Equity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 162 | ' | ' |
Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 27,659 | 10,807 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 140,732 | 146,594 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Cash [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 4,458 | 13,940 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Large-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 34,127 | 37,674 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, International large-cap value[Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 27,595 | 37,239 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, U.S. Small-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 3,567 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Emerging Markets Growth [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 12,517 | 12,390 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Equity Index Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 2,471 | 2,235 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Equity Securities, Commodity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 8,179 | 8,940 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt Securities [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | ' | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments - Preferred [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 45,215 | 18,985 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 6,170 | 11,624 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Private Equity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 230,031 | 169,245 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Cash [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Large-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, International large-cap value[Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, U.S. Small-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Emerging Markets Growth [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Equity Index Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 73,796 | 80,999 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Equity Securities, Commodity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt Securities [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 18,344 | ' | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments - Preferred [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 565 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 87,613 | 54,377 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 22,619 | 22,497 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Private Equity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 27,659 | 10,807 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 22,697 | 20,431 | 19,292 | 20,087 |
Fair Value, Inputs, Level 3 [Member] | Cash [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Large-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, International large-cap value[Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, U.S. Small-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Emerging Markets Growth [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Equity Index Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Domestic Real Estate Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Equity Securities, Commodity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt Securities [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | ' | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments - Preferred [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Debt Instruments [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, Corporate Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Fixed Income Funds, High Yield Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Multi-strategy hedge funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 22,689 | 20,262 | 19,285 | 20,073 |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Venture Capital Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 8 | 7 | 7 | 14 |
Fair Value, Inputs, Level 3 [Member] | Private Equity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 162 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | Other Types of Investments, Non U.S. Government Index Linked Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | $0 | $0 | ' | ' |
Employee_Benefit_Plans_Schedul4
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Pension Plans) (Details) (Pension Plans, Defined Benefit, USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at end of year | $393,460 | $336,270 | ' |
Venture Capital Funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at end of year | 8 | 7 | ' |
Multi-strategy hedge funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at end of year | 22,689 | 20,262 | ' |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at beginning of year | 20,431 | 19,292 | 20,087 |
Realized gains (losses) | 7 | 1,162 | -84 |
Unrealized gains (losses) | 2,409 | 996 | -711 |
Fair value of plan assets at end of year | 22,697 | 20,431 | 19,292 |
Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at beginning of year | 162 | 0 | 0 |
Realized gains (losses) | 7 | 1,162 | 0 |
Unrealized gains (losses) | -19 | 19 | 0 |
Fair value of plan assets at end of year | 0 | 162 | 0 |
Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at beginning of year | 7 | 7 | 14 |
Realized gains (losses) | 0 | 0 | 0 |
Unrealized gains (losses) | 1 | 0 | -7 |
Fair value of plan assets at end of year | 8 | 7 | 7 |
Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at beginning of year | 20,262 | 19,285 | 20,073 |
Realized gains (losses) | 0 | 0 | -84 |
Unrealized gains (losses) | 2,427 | 977 | -704 |
Fair value of plan assets at end of year | 22,689 | 20,262 | 19,285 |
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | ' | 9,448 | ' |
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | ' | 9,448 | ' |
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | ' | 0 | ' |
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | ' | 0 | ' |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | -150 | -10,467 | ' |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Common Collective Trusts [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | 150 | 10,467 | ' |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Venture Capital Funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 0 | ' |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | Multi-strategy hedge funds [Member] | ' | ' | ' |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Purchases, issuances, and settlements | $0 | $0 | ' |
Employee_Benefit_Plans_Schedul5
Employee Benefit Plans (Schedule of Expected Benefit Payments, Pension Plans) (Details) (USD $) | 12 Months Ended | ||
Dec. 28, 2014 | Dec. 29, 2013 | Dec. 30, 2012 | |
United States Pension Plans of US Entity, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
2014 | ' | $17,836,000 | ' |
2015 | ' | 17,848,000 | ' |
2016 | ' | 17,916,000 | ' |
2017 | ' | 17,990,000 | ' |
2018 | ' | 18,219,000 | ' |
2019-2024 | ' | 91,400,000 | ' |
Defined Benefit Plan, Contributions by Employer | ' | 37,000,000 | 17,000,000 |
Foreign Pension Plans, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Expected contributions in next fiscal year | 11,100,000 | ' | ' |
2014 | ' | 11,878,000 | ' |
2015 | ' | 12,931,000 | ' |
2016 | ' | 13,312,000 | ' |
2017 | ' | 13,627,000 | ' |
2018 | ' | 14,156,000 | ' |
2019-2024 | ' | 77,736,000 | ' |
Defined Benefit Plan, Contributions by Employer | ' | 20,200,000 | 10,882,000 |
United Kingdom Pension Plans, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Contributions by Employer | ' | $10,000,000 | ' |
Employee_Benefit_Plans_Schedul6
Employee Benefit Plans (Schedule of Net Benefit Costs, Other Postretirement Benefits) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Net periodic benefit cost | ($16,839) | $34,361 | $70,299 |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Service cost | 106 | 106 | 85 |
Interest cost | 135 | 144 | 163 |
Expected return on plan assets | -965 | -877 | -884 |
Defined Benefit Plan, Amortization of Gains (Losses) | -182 | -929 | 705 |
Actuarial loss (gain) | -520 | -54 | ' |
Amortization of prior service cost | 0 | 0 | -253 |
Net periodic benefit cost | ($906) | ($1,556) | ($184) |
Employee_Benefit_Plans_Schedul7
Employee Benefit Plans (Schedule of Net Funded Status, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plans, Defined Benefit [Member], USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate | 3.86% | 4.00% | 5.30% |
Change in benefit obligations: | ' | ' | ' |
Projected benefit obligations at beginning of year | $3,810 | $3,819 | ' |
Service cost | 106 | 106 | 85 |
Interest cost | 135 | 144 | 163 |
Benefits Paid | -189 | -205 | ' |
Actuarial loss (gain) | -520 | -54 | ' |
Change in accumulated benefit obligations during the year | -468 | -9 | ' |
Projected benefit obligations at end of year | 3,342 | 3,810 | 3,819 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of plan assets at beginning of year | 12,958 | 11,411 | ' |
Actual return on plan assets | 438 | 1,547 | ' |
Benefits Paid | -189 | -205 | ' |
Fair value of plan assets at end of year | 13,396 | 12,958 | 11,411 |
Net amounts recognized in the consolidated balance sheets | 10,054 | 9,148 | ' |
Defined Benefit Plan, Assets for Plan Benefits, Noncurrent | 10,054 | 9,148 | ' |
Prior service cost | 0 | 0 | ' |
Net amounts recognized in accumulated other comprehensive income | 0 | 0 | ' |
Discount rate | 4.77% | 3.86% | ' |
Expected rate of return on assets | 7.50% | 7.75% | 8.10% |
Retirees [Member] | ' | ' | ' |
Change in benefit obligations: | ' | ' | ' |
Projected benefit obligations at end of year | 1,159 | 1,331 | 1,475 |
Active Employees Eligible to Retire [Member] | ' | ' | ' |
Change in benefit obligations: | ' | ' | ' |
Projected benefit obligations at end of year | 388 | 470 | 431 |
Other Active Employees [Member] | ' | ' | ' |
Change in benefit obligations: | ' | ' | ' |
Projected benefit obligations at end of year | $1,795 | $2,009 | $1,913 |
Employee_Benefit_Plans_Schedul8
Employee Benefit Plans (Schedule of Changes in Fair Value of Plan Assets, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plans, Defined Benefit [Member], USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 |
In Thousands, unless otherwise specified | ||||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | $13,396 | $12,958 | $11,411 | ' |
Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 7,479 | 8,553 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 4,700 | 3,211 | ' | ' |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,217 | 1,194 | 1,130 | 1,087 |
Cash [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 167 | 798 | ' | ' |
Cash [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 167 | 798 | ' | ' |
Cash [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Cash [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, U.S. Large-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,831 | 2,202 | ' | ' |
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,831 | 2,202 | ' | ' |
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, U.S. Large-cap [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, International large-cap value[Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,480 | 2,177 | ' | ' |
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,480 | 2,177 | ' | ' |
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, International large-cap value[Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, U.S. Small-cap [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 209 | ' | ' |
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 209 | ' | ' |
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Equity Securities, U.S. Small-cap [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Equity Securities, Equity Index Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 672 | 724 | ' | ' |
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 672 | 724 | ' | ' |
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, Equity Index Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, Domestic Real Estate Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 133 | 131 | ' | ' |
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 133 | 131 | ' | ' |
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, Domestic Real Estate Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, Commodity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 439 | 523 | ' | ' |
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 439 | 523 | ' | ' |
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Equity Securities, Commodity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fixed Income Funds, Corporate Debt Instruments [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 7,126 | 33 | ' | ' |
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 2,426 | 0 | ' | ' |
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 4,700 | 33 | ' | ' |
Fixed Income Funds, Corporate Debt Instruments [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fixed Income Funds, Corporate Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 4,288 | ' | ' |
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 1,110 | ' | ' |
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 3,178 | ' | ' |
Fixed Income Funds, Corporate Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Fixed Income Funds, High Yield Bonds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 331 | 679 | ' | ' |
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 331 | 679 | ' | ' |
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Fixed Income Funds, High Yield Bonds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Other Types of Investments, Multi-strategy hedge funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,217 | 1,184 | ' | ' |
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 0 | 0 | ' | ' |
Other Types of Investments, Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | 1,217 | 1,184 | 1,129 | 1,086 |
Private Equity Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 9 | ' | ' |
Private Equity Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Private Equity Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Private Equity Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 9 | ' | ' |
Other Types of Investments, Venture Capital Funds [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 1 | ' | ' |
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | ' | 0 | ' | ' |
Other Types of Investments, Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' |
Fair value of plan assets | $0 | $1 | $1 | $1 |
Employee_Benefit_Plans_Schedul9
Employee Benefit Plans (Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets, Other Postretirement Benefit Plans) (Details) (Other Postretirement Benefit Plans, Defined Benefit [Member], USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at beginning of year | $12,958 | $11,411 | ' |
Realized gains (losses) | 182 | 929 | -705 |
Fair value of plan assets at end of year | 13,396 | 12,958 | 11,411 |
Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at beginning of year | 1,194 | 1,130 | 1,087 |
Realized gains (losses) | 0 | 68 | 84 |
Unrealized gains (losses) | 31 | 56 | -41 |
Fair value of plan assets at end of year | 1,217 | 1,194 | 1,130 |
Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at beginning of year | 9 | 0 | 0 |
Realized gains (losses) | 0 | 68 | 0 |
Unrealized gains (losses) | -1 | 1 | 0 |
Fair value of plan assets at end of year | 0 | 9 | 0 |
Venture Capital Funds [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at end of year | ' | 1 | ' |
Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at beginning of year | 1 | 1 | 1 |
Realized gains (losses) | 0 | 0 | 0 |
Unrealized gains (losses) | -1 | 0 | 0 |
Fair value of plan assets at end of year | 0 | 1 | 1 |
Multi-strategy hedge funds [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at end of year | 1,217 | 1,184 | ' |
Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets at beginning of year | 1,184 | 1,129 | 1,086 |
Realized gains (losses) | 0 | 0 | 84 |
Unrealized gains (losses) | 33 | 55 | -41 |
Fair value of plan assets at end of year | 1,217 | 1,184 | 1,129 |
Defined Benefit Plan, Purchases [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 552 | 0 |
Defined Benefit Plan, Purchases [Member] | Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 552 | 0 |
Defined Benefit Plan, Purchases [Member] | Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 0 | 0 |
Defined Benefit Plan, Purchases [Member] | Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 0 | 0 |
Defined Benefit Plans, Sales and Settlements [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | -8 | -612 | 0 |
Defined Benefit Plans, Sales and Settlements [Member] | Common Collective Trusts [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | -8 | -612 | 0 |
Defined Benefit Plans, Sales and Settlements [Member] | Venture Capital Funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | 0 | 0 | 0 |
Defined Benefit Plans, Sales and Settlements [Member] | Multi-strategy hedge funds [Member] | Fair Value, Inputs, Level 3 [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Purchases, issuances, and settlements | $0 | $0 | $0 |
Recovered_Sheet1
Employee Benefit Plans (Schedule of Expected Benefit Payments, Other Postretirement Benefits) (Details) (USD $) | Dec. 29, 2013 |
In Thousands, unless otherwise specified | |
United States Pension Plan of US Entity, Defined Benefit [Member] | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
2014 | $17,836 |
2015 | 17,848 |
2016 | 17,916 |
2017 | 17,990 |
2018 | 18,219 |
2019-2024 | 91,400 |
Other Postretirement Benefit Plans, Defined Benefit [Member] | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
2014 | 202 |
2015 | 205 |
2016 | 210 |
2017 | 217 |
2018 | 224 |
2019-2024 | 1,227 |
Foreign Pension Plan, Defined Benefit [Member] | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
2014 | 11,878 |
2015 | 12,931 |
2016 | 13,312 |
2017 | 13,627 |
2018 | 14,156 |
2019-2024 | $77,736 |
Employee_Benefit_Plans_Savings
Employee Benefit Plans (Savings Plan) (Details) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation | 100.00% | ' | ' |
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match | 5.00% | ' | ' |
Defined Benefit, 401(k) Savings Plan Expense | $12.80 | $12.30 | $10.60 |
November 2011 Caliper Life Sciences [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Defined Benefit Plan, 401(k) Savings Plan, Employer Contribution Match of Employees Eligible Compensation | 100.00% | 50.00% | ' |
Defined Benefit Plan, 401(k) Savings Plan, Maximum Employee Match Percent for Employer Match | 5.00% | 5.00% | ' |
Employee_Benefit_Plans_Supplem
Employee Benefit Plans (Supplemental Executive Retirement Plan) (Details) (Supplemental Employee Retirement Plans, Defined Benefit [Member], USD $) | 12 Months Ended | ||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Supplemental Employee Retirement Plans, Defined Benefit [Member] | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Projected benefit obligation | $21,100,000 | $23,200,000 | ' |
Fair value of plan assets | 300,000 | 200,000 | ' |
Pension expense | ($400,000) | $2,500,000 | $4,900,000 |
Employee_Benefit_Plans_Nonqual
Employee Benefit Plans (Nonqualified Deferred Compensation Plans) (Details) (Management [Member], USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Millions, unless otherwise specified | ||
Management [Member] | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' |
Deferred Compensation Arrangement with Individual, Recorded Liability | $1 | $0.90 |
Contingencies_Details
Contingencies (Details) (USD $) | 12 Months Ended |
In Millions, unless otherwise specified | Dec. 29, 2013 |
years | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Accrual for Environmental Loss Contingencies, Component Amount | $5.70 |
Management's estimate of total cost of ultimate disposition of known environmental matters | $13.50 |
Number of years over which estimated environmental cost will be paid | 10 |
Warranty_Reserves_Details
Warranty Reserves (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
years | |||
Warranty reserve activity | ' | ' | ' |
Period of warranty protection beyond date of sale (in years) | 1 | ' | ' |
Balance beginning of period | $11,003 | $10,412 | $8,250 |
Provision charged to income | 17,291 | 17,750 | 15,001 |
Payments | -17,116 | -18,022 | -15,154 |
Adjustments to previously provided warranties, net | -693 | 801 | 926 |
Foreign currency and acquisitions | 49 | 62 | 1,389 |
Balance end of period | $10,534 | $11,003 | $10,412 |
Stock_Plans_Narrative_Details
Stock Plans (Narrative) (Details) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | |
plan | Performance Units [Member] | Performance Units [Member] | Performance Units [Member] | Stock Awards [Member] | Stock Awards [Member] | Stock Awards [Member] | Stock Awards [Member] | Stock Awards [Member] | Restricted Stock Awards [Member] | Restricted Stock Awards [Member] | Restricted Stock Awards [Member] | Restricted Stock Awards [Member] | Employee Stock Purchase Plan [Member] | Employee Stock Purchase Plan [Member] | Employee Stock Purchase Plan [Member] | Stock Options [Member] | Stock Options [Member] | Stock Options [Member] | Two Thousand Nine Incentive Plan [Member] | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Former Stock-based Compensation Plans | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares authorized under plan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000,000 | ' | ' | ' | ' | ' | 10,700,000 |
Total income tax benefit recognized for stock-based compensation | $4,400,000 | $6,800,000 | $5,100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock-based compensation costs capitalized as part of inventory | 400,000 | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Options related excess tax benefit, classified as a financing cash activity | 0 | 1,767,000 | 9,321,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate intrinsic value for stock options outstanding | 51,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average remaining contractual term of options (in years) | '3 years 6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate intrinsic value for stock options exercisable | 41,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average remaining contractual term of options exercisable (in years) | '2 years 8 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of shares vested and expected to vest in the future | 3,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Aggregate intrinsic value of vested and expected to vest stock options | 51,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average remaining contractual term for options vested and expected to vest | '3 years 6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted-average grant-date fair value of options | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $10.82 | $7.36 | $7.03 | ' |
Total intrinsic value of options exercised | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13,800,000 | 13,100,000 | 6,900,000 | ' |
Cash received from option exercises | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,300,000 | 32,500,000 | 23,700,000 | ' |
Weighted-average grant-date fair value of stock granted (per share) | ' | ' | ' | $34.06 | $26.18 | $26.71 | ' | ' | $30.65 | $27.87 | $28.22 | $33.87 | $25.86 | $26.31 | ' | $30.51 | $24.51 | $21.33 | ' | ' | ' | ' |
Fair value of restricted stock awards vested | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000,000 | 4,300,000 | 6,500,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Total pre-tax stock-based compensation expense | 14,053,000 | 21,031,000 | 15,482,000 | 1,400,000 | 7,100,000 | 3,700,000 | ' | ' | 700,000 | 700,000 | 800,000 | 7,500,000 | 8,200,000 | 6,500,000 | ' | ' | ' | ' | 4,400,000 | 5,100,000 | 4,500,000 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 95.00% | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' |
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,000,000 | ' | ' | ' | ' | ' | ' | 5,600,000 | ' | ' | ' |
Shares/units granted | ' | ' | ' | 98,056 | 122,675 | 89,828 | 955 | 3,580 | 3,263 | ' | 3,544 | 289,000 | 358,000 | 460,000 | ' | 89,521 | 53,961 | 102,970 | ' | ' | ' | ' |
Awards/units outstanding | ' | ' | ' | 282,044 | ' | ' | ' | ' | ' | ' | ' | 649,000 | 781,000 | 672,000 | 578,000 | ' | ' | ' | ' | ' | ' | ' |
Deferred compensation liability | 4,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock award program for non-employees Directors, fair market value | ' | ' | ' | ' | ' | ' | ' | ' | $100,000 | $100,000 | $100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted-average period for recognition of unrecognized compensation cost, years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '1 year 2 months | ' | ' | ' | ' | ' | ' | '1 year 8 months | ' | ' | ' |
Shares available for grant under employee stock purchase plan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,100,000 | ' | ' | ' | ' | ' | ' |
Option vesting period (in years) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years 0 months | ' | ' | ' | ' | ' | ' | '3 years 0 months | ' | ' | ' |
Stock Options Expiration Period After Date of Grant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years 0 months | ' | ' | ' |
Stock_Plans_Summary_of_Total_C
Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Total stock-based compensation expense | $14,053 | $21,031 | $15,482 |
Cost of sales [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Total stock-based compensation expense | 1,304 | 1,276 | 1,139 |
Research and development expenses [Member ] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Total stock-based compensation expense | 853 | 769 | 583 |
Selling, general and administrative and other expenses [Member] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Total stock-based compensation expense | $11,896 | $18,986 | $13,760 |
Stock_Plans_WeightedAverage_As
Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details) | 12 Months Ended | ||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ' | ' |
Risk-free interest rate | 0.90% | 0.60% | 1.90% |
Expected dividend yield | 0.80% | 1.20% | 1.10% |
Expected lives, years | '5 years | '4 years | '4 years |
Expected stock volatility | 38.50% | 38.70% | 38.10% |
Stock_Plans_Summary_of_Stock_O
Stock Plans (Summary of Stock Option Activity) (Details) (USD $) | 12 Months Ended | ||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Stock option activity | ' | ' | ' |
Shares outstanding at beginning of the year | 4,266,000 | 5,346,000 | 6,983,000 |
Shares granted | 518,000 | 756,000 | 847,000 |
Shares exercised | -947,000 | -1,611,000 | -1,138,000 |
Shares canceled | -8,000 | -210,000 | -1,237,000 |
Shares forfeited | -335,000 | -15,000 | -109,000 |
Shares outstanding at end of year | 3,494,000 | 4,266,000 | 5,346,000 |
Shares exercisable at end of year | 2,392,000 | 2,677,000 | 3,549,000 |
Number of shares vested and expected to vest in the future | 3,400,000 | ' | ' |
Weighted-average price, outstanding at beginning of year (per share) | $21.64 | $20.57 | $21.86 |
Weighted-average price, granted (per share) | $33.62 | $26.28 | $24.20 |
Weighted-average price, exercised (per share) | $21.45 | $20.16 | $20.86 |
Weighted-average price, canceled (per share) | $22.88 | $22.34 | $30.29 |
Weighted-average price, forfeited (per share) | $23.04 | $21.98 | $18.27 |
Weighted-average price, outstanding at end of year (per share) | $23.34 | $21.64 | $20.57 |
Weighted-average price, exercisable at end of year (per share) | $20.66 | $20 | $20.74 |
Stock_Plans_Summary_of_Restric
Stock Plans (Summary of Restricted Stock Award Activity) (Details) (USD $) | 12 Months Ended | ||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | |
Restricted Stock Units (RSUs) [Member] | ' | ' | ' |
Restricted stock award activity | ' | ' | ' |
Performance factor percentage minimum | 0.00% | ' | ' |
Performance factor percentage maximum | 200.00% | ' | ' |
Restricted Stock Awards [Member] | ' | ' | ' |
Restricted stock award activity | ' | ' | ' |
Nonvested at beginning of year | 781,000 | 672,000 | 578,000 |
Shares, granted | 289,000 | 358,000 | 460,000 |
Shares, vested | -346,000 | -184,000 | -272,000 |
Shares, forfeited | -75,000 | -65,000 | -94,000 |
Nonvested at end of year | 649,000 | 781,000 | 672,000 |
Weighted-average grant-date fair value, nonvested at beginning of year (per share) | $24.71 | $23.62 | $22 |
Weighted-average grant-date fair value of stock granted (per share) | $33.87 | $25.86 | $26.31 |
Weighted-average grant-date fair value, vested (per share) | $22.98 | $23.19 | $23.96 |
Weighted-average grant-date fair value, forfeited (per share) | $28.76 | $24.03 | $24.58 |
Weighted-average grant-date fair value, nonvested at end of year (per share) | $29.24 | $24.71 | $23.62 |
Stockholders_Equity_Narrative_
Stockholders' Equity (Narrative) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |||||||||||
Mar. 30, 2014 | Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Oct. 24, 2012 | |
Schedule of Stockholders' Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | ' | ' | ' | ' | ' | ' | ' | ' | ' | ($4,800,000) | ' | ' | ' |
Stock repurchase program, number of shares authorized to be repurchased | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,000,000 |
Cash dividends (per share) | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.28 | $0.28 | ' | ' |
Aggregate cost of repurchased common stock to satisfy statutory tax withholding obligation requirements | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,400,000 | 2,100,000 | 2,200,000 | ' |
Number of common stock repurchased in open market | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,600,000 | 0 | 4,000,000 | ' |
Stock repurchase program, number of shares remained available for repurchase | ' | 2,400,000 | ' | ' | ' | ' | ' | ' | ' | 2,400,000 | ' | ' | ' |
Repurchases of common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | 123,000,000 | ' | 107,800,000 | ' |
Repurchased shares of common stock to satisfy statutory tax withholding obligation requirements | ' | ' | ' | ' | ' | ' | ' | ' | ' | 127,544 | 82,186 | 84,243 | ' |
Dividends accrued | ' | 7,900,000 | ' | ' | ' | ' | ' | ' | ' | 7,900,000 | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,900,000 | 800,000 | 800,000 | ' |
Other Comprehensive Income (Loss), Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service (Cost) Credit, Net of Tax | ' | ' | ' | ' | ' | ' | ' | ' | ' | -658,000 | -82,000 | 107,000 | ' |
Interest Rate Contract [Member] | Interest Expense [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Schedule of Stockholders' Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | ' | ($2,800,000) | ' | ' | ' | ' | ' | ' | ' | ($2,000,000) | ($2,000,000) | ($2,000,000) | ' |
Stockholders_Equity_Components
Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) (USD $) | 12 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 |
Cumulative Translation Adjustment Summary [Roll Forward] | ' | ' | ' | ' |
Foreign currency translation adjustment, net of tax, beginning of year | $67,527 | $56,164 | $54,350 | ' |
Current year change | 8,756 | 11,363 | 1,814 | ' |
Foreign currency translation adjustment, net of tax, end of year | 76,283 | 67,527 | 56,164 | ' |
Unrecognized prior service costs, net of tax | 1,429 | 2,087 | 2,169 | 2,062 |
Unrecognized prior service costs, net of tax, current year change | -658 | -82 | 107 | ' |
Unrealized (losses) gains on securities, net of tax | -121 | -129 | -159 | -100 |
Unrealized (losses) gains on securities, net of tax, current year change | 8 | 30 | -59 | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax | 2,892 | 1,196 | 1,196 | ' |
Unrealized and realized (losses) gains on derivatives, net of income tax | 0 | -2,892 | -4,088 | -5,284 |
Other comprehensive income (loss) | 10,998 | 12,507 | 3,058 | ' |
Accumulated other comprehensive income (loss) | $77,591 | $66,593 | $54,086 | $51,028 |
Derivatives_And_Hedging_Activi1
Derivatives And Hedging Activities (Details) | 1 Months Ended | 12 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||
31-May-08 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | European And Asian Currencies [Member] | European And Asian Currencies [Member] | European And Asian Currencies [Member] | Fair Value Hedging [Member] | Fair Value Hedging [Member] | Fair Value Hedging [Member] | Cash Flow Hedging [Member] | Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Interest Rate Contract [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Measurements, Recurring [Member] | |
USD ($) | USD ($) | USD ($) | EUR (€) | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Interest Expense [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Inputs, Level 2 [Member] | ||||||||||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | ||||||||||||||
Derivative [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Company's business conducted outside United States | ' | 60.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum maturity period for foreign exchange contracts, in months | ' | ' | ' | ' | ' | '12 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Duration of foreign currency derivative contract, days | ' | ' | ' | ' | ' | '30 days | '30 days | '30 days | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Derivative, Number of Instruments Held | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 2 | ' | ' | ' | ' | ' | ' |
Derivative, Notional Amount | ' | ' | ' | ' | ' | ' | ' | ' | $138,400,000 | $64,300,000 | $268,900,000 | ' | € 50,000,000 | ' | ' | ' | ' | ' | ' |
Foreign Currency Contract, Asset, Fair Value Disclosure | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 293,000 | -274,000 |
Settlement of forward interest rate contracts with notional amounts | 150,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated derivative losses in other comprehensive (loss) income, net of taxes | 8,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated derivative losses in other comprehensive (loss) income, tax | 5,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accumulated derivative losses related to effective cash flow hedges in accumulated other comprehensive loss, net of taxes | ' | 0 | -2,892,000 | -4,088,000 | -5,284,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, before Tax | ' | -4,800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,800,000 | -2,000,000 | -2,000,000 | -2,000,000 | ' | ' |
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair_Value_Measurements_Narrat
Fair Value Measurements (Narrative) (Details) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | ||||||||||||||||
Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 29, 2013 | 30-May-08 | Dec. 29, 2013 | Dec. 30, 2012 | Oct. 25, 2011 | Dec. 29, 2013 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | Dec. 30, 2012 | |
Line of Credit, Maturing December 16, 2016 [Member] | Line of Credit, Maturing December 16, 2016 [Member] | 2015 Notes [Member] | 2015 Notes [Member] | 2021 Notes [Member] | 2021 Notes [Member] | 2021 Notes [Member] | Financing Lease Obligations [Member] | Financing Lease Obligations [Member] | Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | Maximum [Member] | Maximum [Member] | Minimum [Member] | Minimum [Member] | |||||
Trade Names And Trademarks [Member] | Trade Names And Trademarks [Member] | ||||||||||||||||||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $71,900,000 | ' | ' | ' | ' |
Carrying Value of Impaired Finite-lived Intangible Assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,800,000 | ' | ' | ' | ' |
Fair Value of Impaired Finite-lived Intangible Assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500,000 | ' | ' | ' | ' |
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 74,200,000 | ' | ' | ' | ' | ' |
Fair Value Inputs, Royalty Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.00% | ' | 0.50% | ' |
Fair Value Inputs, Discount Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12.00% | ' | 11.00% | ' |
Remaining Useful Life After Impairment for Finite and Indefinite Lived Intangible Assets | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '8 years | ' | '1 year |
Carrying Value of Impaired Indefinite-lived Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 76,400,000 | ' | ' | ' | ' |
Fair Value of Impaired Indefinite-lived Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,500,000 | ' | ' | ' | ' |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 31,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 4,926,000 | 3,017,000 | 20,298,000 | 1,731,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Asset impairment | 6,731,000 | 74,153,000 | 3,006,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,300,000 | ' | ' | ' | ' |
Unsecured revolving credit facility, amount | ' | ' | ' | ' | 700,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured senior notes, face value | ' | ' | ' | ' | ' | ' | ' | 150,000,000 | 500,000,000 | ' | 500,000,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Revolving credit facility outstanding balance | ' | ' | ' | ' | 397,000,000 | 258,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unsecured senior notes, carrying value | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | 497,400,000 | 497,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term Debt | ' | ' | ' | ' | ' | ' | 150,000,000 | ' | 497,400,000 | 497,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Discount on senior unsecured notes | -2,568,000 | ' | ' | ' | 0 | ' | ' | ' | -2,568,000 | -2,800,000 | -3,100,000 | 0 | ' | ' | ' | ' | ' | ' | ' |
Unsecured senior notes, fair value | ' | ' | ' | ' | ' | ' | $165,400,000 | ' | $513,000,000 | $558,300,000 | ' | $40,300,000 | $34,600,000 | ' | ' | ' | ' | ' | ' |
Business Combination, Contingent Consideration Arrangements, Description | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business Combination, Contingent Consideration Arrangements, Weighted Average Period | '2 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair_Value_Measurements_Assets
Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $) | Dec. 29, 2013 | Dec. 30, 2012 |
In Thousands, unless otherwise specified | ||
Carrying Value [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Marketable securities | ($1,319) | ($1,149) |
Foreign Currency Contract, Asset, Fair Value Disclosure | 293 | 274 |
Foreign exchange derivative liabilities, net | -396 | -294 |
Contingent consideration | -4,926 | -3,017 |
Fair Value, Inputs, Level 1 [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Marketable securities | -1,319 | -1,149 |
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 |
Foreign exchange derivative liabilities, net | 0 | 0 |
Contingent consideration | 0 | 0 |
Significant Other Observable Inputs (Level 2) [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Marketable securities | 0 | 0 |
Foreign Currency Contract, Asset, Fair Value Disclosure | 293 | -274 |
Foreign exchange derivative liabilities, net | -396 | -294 |
Contingent consideration | 0 | 0 |
Significant Unobservable Inputs (Level 3) [Member] | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Marketable securities | 0 | 0 |
Foreign Currency Contract, Asset, Fair Value Disclosure | 0 | 0 |
Foreign exchange derivative liabilities, net | 0 | 0 |
Contingent consideration | ($4,926) | ($3,017) |
Fair_Value_Measurements_Reconc
Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ' | ' | ' |
Balance beginning of period | ($3,017) | ($20,298) | ($1,731) |
Additions | -1,100 | -1,900 | -20,131 |
Payments | 135 | 17,433 | 1,908 |
Change in fair value (included within selling, general and administrative expenses) | -944 | 1,748 | -344 |
Balance end of period | ($4,926) | ($3,017) | ($20,298) |
Leases_Details
Leases (Details) (USD $) | 12 Months Ended | |||
In Millions, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Aug. 22, 2013 |
Sale Leaseback Transaction [Line Items] | ' | ' | ' | ' |
Sale Leaseback Transaction, Description of Accounting for Leaseback | 'The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years. | ' | ' | ' |
Sale Leaseback Transaction, Date | '8/22/2013 | ' | ' | ' |
Sale Leaseback Transaction, Gross Proceeds | $47.60 | ' | ' | ' |
Sale Leaseback Transaction, Lease Terms | 'P15Y0M | ' | ' | ' |
Sale Leaseback Transaction, Deferred Gain, Gross | ' | ' | ' | 26.5 |
Sale Leaseback Transaction, Cumulative Gain Recognized | 0.6 | ' | ' | ' |
Sale Leaseback Transaction, Deferred Gain, Net | 25.9 | ' | ' | ' |
Rental expense charged to continiuing operations | 52.7 | 60.3 | 49.1 | ' |
Minimum rental commitments in fiscal 2012 | 56.5 | ' | ' | ' |
Minimum rental commitments in fiscal 2013 | 39.1 | ' | ' | ' |
Minimum rental commitments in fiscal 2014 | 27.2 | ' | ' | ' |
Minimum rental commitments in fiscal 2015 | 22.5 | ' | ' | ' |
Minimum rental commitments in fiscal 2016 | 19.5 | ' | ' | ' |
Minimum rental commitments in fiscal 2017 and thereafter | $91.50 | ' | ' | ' |
Schedule_of_Sales_and_Operatin
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations (Details) (USD $) | 3 Months Ended | 12 Months Ended | ||||||||||||||
Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | ||||||
segments | ||||||||||||||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | $6,731,000 | $74,153,000 | $3,006,000 | |||||
Number of operating segments | ' | ' | ' | ' | ' | ' | ' | ' | 2 | ' | ' | |||||
Product revenue | ' | ' | ' | ' | ' | ' | ' | ' | 1,498,070,000 | 1,474,674,000 | 1,319,510,000 | |||||
Service revenue | ' | ' | ' | ' | ' | ' | ' | ' | 668,162,000 | 640,531,000 | 598,998,000 | |||||
Total revenue | ' | ' | ' | ' | ' | ' | ' | ' | 2,166,232,000 | 2,115,205,000 | 1,918,508,000 | |||||
Operating income from continuing operations | 84,681,000 | [1] | 57,196,000 | 39,664,000 | 35,901,000 | -30,844,000 | [2] | 43,218,000 | 49,787,000 | 36,382,000 | 217,442,000 | 98,543,000 | 91,128,000 | |||
Interest and other expense (income), net | ' | ' | ' | ' | ' | ' | ' | ' | 64,110,000 | 47,956,000 | 26,774,000 | |||||
Income from continuing operations before income taxes | 57,816,000 | [1] | 44,856,000 | 26,799,000 | 23,861,000 | -42,740,000 | [2] | 31,346,000 | 38,429,000 | 23,552,000 | 153,332,000 | 50,587,000 | 64,354,000 | |||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | ' | ' | ' | ' | 31,800,000 | ' | ' | ' | -17,600,000 | ' | 67,900,000 | |||||
Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Product revenue | ' | ' | ' | ' | ' | ' | ' | ' | 957,022,000 | 926,733,000 | 761,665,000 | |||||
Service revenue | ' | ' | ' | ' | ' | ' | ' | ' | 252,734,000 | 247,909,000 | 216,227,000 | |||||
Total revenue | ' | ' | ' | ' | ' | ' | ' | ' | 1,209,756,000 | 1,174,642,000 | 977,892,000 | |||||
Operating income from continuing operations | ' | ' | ' | ' | ' | ' | ' | ' | 146,100,000 | [3] | 59,196,000 | [3] | 89,725,000 | [3] | ||
Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Product revenue | ' | ' | ' | ' | ' | ' | ' | ' | 541,048,000 | 547,941,000 | 557,845,000 | |||||
Service revenue | ' | ' | ' | ' | ' | ' | ' | ' | 415,428,000 | 392,622,000 | 382,771,000 | |||||
Total revenue | ' | ' | ' | ' | ' | ' | ' | ' | 956,476,000 | 940,563,000 | 940,616,000 | |||||
Operating income from continuing operations | ' | ' | ' | ' | ' | ' | ' | ' | 97,052,000 | [3] | 111,844,000 | [3] | 108,922,000 | [3] | ||
Corporate [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Operating income from continuing operations | ' | ' | ' | ' | ' | ' | ' | ' | -25,710,000 | [3],[4] | -72,497,000 | [3],[4] | -107,519,000 | [3],[4] | ||
Customer Lists [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | 6,700,000 | ' | ' | |||||
Asset impairment | 6,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Licenses [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,000,000 | |||||
Trade Names And Trademarks [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | 74,200,000 | ' | ' | ' | ' | ' | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | 71,900,000 | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,300,000 | ' | |||||
Trade Names And Trademarks [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 73,400,000 | ' | |||||
Trade Names And Trademarks [Member] | Environmental Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Schedule of Segment Reporting Information, by Segment [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | $700,000 | ' | |||||
[1] | The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2013 also includes pre-tax impairment charges of $6.7 million as the carrying amounts of certain long-lived assets were not recoverable and exceeded their fair value. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statues of limitations and audit settlements. | |||||||||||||||
[2] | The fourth quarter of fiscal year 2012 includes a pre-tax loss of $31.8 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2012 also includes pre-tax impairment charges of $74.2 million as a result of a review of certain trade names within the Company's portfolio as part of a realignment of its marketing strategy. | |||||||||||||||
[3] | Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company recognized a $6.7 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012. The Company recognized a $3.0 million pre-tax impairment charge in the Human Health segment in fiscal year 2011. | |||||||||||||||
[4] | Activity related to the mark-to-market adjustment on postretirement benefit plans have been included in the Corporate operating loss from continuing operations, and together constituted pre-tax income of $17.6 million in fiscal year 2013, a pre-tax loss of $31.8 million in fiscal year 2012, and a pre-tax loss of $67.9 million in fiscal year 2011. |
Industry_Segment_and_Geographi2
Industry Segment and Geographic Area Information Schedule of Depreciation, Amortization and Capital Expenditures (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Schedule of Depreciation, Amortization and Capital Expenditures [Line Items] | ' | ' | ' |
Depreciation and amortization expense | $128,471 | $126,865 | $110,921 |
Human Health [Member] | ' | ' | ' |
Schedule of Depreciation, Amortization and Capital Expenditures [Line Items] | ' | ' | ' |
Depreciation and amortization expense | 100,174 | 101,336 | 81,938 |
Capital expenditures | 20,910 | 24,525 | 16,570 |
Environmental Health [Member] | ' | ' | ' |
Schedule of Depreciation, Amortization and Capital Expenditures [Line Items] | ' | ' | ' |
Depreciation and amortization expense | 25,915 | 23,001 | 27,288 |
Capital expenditures | 16,532 | 14,488 | 12,015 |
Corporate [Member] | ' | ' | ' |
Schedule of Depreciation, Amortization and Capital Expenditures [Line Items] | ' | ' | ' |
Depreciation and amortization expense | 2,382 | 2,528 | 1,695 |
Capital expenditures | 1,549 | 3,395 | 2,007 |
Continuing Operations [Member] | ' | ' | ' |
Schedule of Depreciation, Amortization and Capital Expenditures [Line Items] | ' | ' | ' |
Depreciation and amortization expense | 128,471 | 126,865 | 110,921 |
Capital expenditures | $38,991 | $42,408 | $30,592 |
Industry_Segment_and_Geographi3
Industry Segment and Geographic Area Information Schedule of Total Assets by Segment (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
In Thousands, unless otherwise specified | |||
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | $3,946,712 | $3,901,762 | ' |
Human Health [Member] | ' | ' | ' |
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | 2,698,640 | 2,714,366 | 2,674,243 |
Environmental Health [Member] | ' | ' | ' |
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | 1,213,801 | 1,153,444 | 1,150,015 |
Corporate [Member] | ' | ' | ' |
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | 34,271 | 33,952 | 31,181 |
Net current and long-term assets of discontinued operations [Member] | ' | ' | ' |
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | 0 | 0 | 202 |
Total assets [Member] | ' | ' | ' |
Schedule of Total Assets, by segment [Line Items] | ' | ' | ' |
Assets | $3,946,712 | $3,901,762 | $3,855,641 |
Industry_Segment_and_Geographi4
Industry Segment and Geographic Area Information Schedule of Revenue by Geographic Area (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | $2,166,232 | $2,115,205 | $1,918,508 |
UNITED STATES | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 835,637 | 822,951 | 725,849 |
CHINA | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 254,838 | 216,425 | 164,005 |
UNITED KINGDOM | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 133,611 | 118,611 | 102,366 |
GERMANY | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 99,153 | 105,735 | 113,472 |
FRANCE | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 81,719 | 84,395 | 85,395 |
JAPAN | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 95,676 | 114,300 | 89,977 |
ITALY | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 78,120 | 69,599 | 74,925 |
Other International [Member] | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | 587,478 | 583,189 | 562,519 |
Total international [Member] | ' | ' | ' |
Sales by Geographic Area [Line Items] | ' | ' | ' |
Total sales | $1,330,595 | $1,292,254 | $1,192,659 |
Industry_Segment_and_Geographi5
Industry Segment and Geographic Area Information Schedule of Long-Lived Assets by Geographic Location (Details) (USD $) | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 |
In Thousands, unless otherwise specified | |||
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | $298,240 | $277,707 | $217,397 |
UNITED STATES | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 216,821 | 205,083 | 147,883 |
CHINA | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 30,682 | 30,134 | 22,145 |
FINLAND | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 13,635 | 11,851 | 12,833 |
UNITED KINGDOM | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 9,882 | 2,960 | 2,508 |
SINGAPORE | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 6,812 | 6,366 | 5,663 |
NETHERLANDS | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 4,037 | 3,900 | 4,074 |
ITALY | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 2,735 | 3,303 | 3,288 |
GERMANY | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 2,591 | 2,353 | 2,225 |
BRAZIL | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 1,967 | 1,515 | 1,637 |
JAPAN | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 1,772 | 2,310 | 2,552 |
Other International [Member] | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | 7,306 | 7,932 | 12,589 |
Total international [Member] | ' | ' | ' |
Long-lived assets by Geographic Area [Line Items] | ' | ' | ' |
Total net long-lived assets | $81,419 | $72,624 | $69,514 |
Quarterly_Financial_Informatio2
Quarterly Financial Information (Unaudited) (Details) (USD $) | 3 Months Ended | 12 Months Ended | ||||||||||||||||
Mar. 30, 2014 | Dec. 29, 2013 | Sep. 29, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 30, 2012 | Sep. 30, 2012 | Jul. 01, 2012 | Apr. 01, 2012 | Dec. 29, 2013 | Dec. 30, 2012 | Jan. 01, 2012 | Jan. 02, 2011 | ||||||
Quarterly Financial Data [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Revenue | ' | $593,280,000 | $524,277,000 | $543,297,000 | $505,378,000 | $572,921,000 | $509,604,000 | $521,790,000 | $510,890,000 | $2,166,232,000 | $2,115,205,000 | ' | ' | |||||
Gross profit | ' | 276,278,000 | 233,512,000 | 242,299,000 | 224,885,000 | 261,658,000 | 230,740,000 | 238,794,000 | 232,014,000 | 976,974,000 | 963,206,000 | ' | ' | |||||
Restructuring and contract termination charges, net | ' | 10,215,000 | 1,126,000 | 19,277,000 | 3,310,000 | 4,103,000 | 9,672,000 | 5,203,000 | 6,159,000 | 33,928,000 | 25,137,000 | 13,452,000 | ' | |||||
Operating income from continuing operations | ' | 84,681,000 | [1] | 57,196,000 | 39,664,000 | 35,901,000 | -30,844,000 | [2] | 43,218,000 | 49,787,000 | 36,382,000 | 217,442,000 | 98,543,000 | 91,128,000 | ' | |||
Income from continuing operations before income taxes | ' | 57,816,000 | [1] | 44,856,000 | 26,799,000 | 23,861,000 | -42,740,000 | [2] | 31,346,000 | 38,429,000 | 23,552,000 | 153,332,000 | 50,587,000 | 64,354,000 | ' | |||
Operating income from continuing operations | ' | 68,400,000 | [1] | 40,299,000 | 26,936,000 | 32,289,000 | -16,192,000 | [2] | 28,989,000 | 33,568,000 | 22,076,000 | 167,924,000 | 68,441,000 | 1,172,000 | ' | |||
Net income | ' | 66,873,000 | [1] | 40,198,000 | 27,925,000 | 32,216,000 | -15,856,000 | [2] | 29,594,000 | 33,633,000 | 22,569,000 | 167,212,000 | 69,940,000 | 7,655,000 | ' | |||
Basic earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Continuing operations | ' | $0.61 | [1] | $0.36 | $0.24 | $0.28 | ($0.14) | [2] | $0.25 | $0.30 | $0.20 | $1.50 | $0.60 | $0.01 | ' | |||
Net income | ' | $0.60 | [1] | $0.36 | $0.25 | $0.28 | ($0.14) | [2] | $0.26 | $0.30 | $0.20 | $1.49 | $0.61 | $0.07 | ' | |||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Continuing operations | ' | $0.60 | [1] | $0.36 | $0.24 | $0.28 | ($0.14) | [2] | $0.25 | $0.29 | $0.19 | $1.48 | $0.60 | $0.01 | ' | |||
Net income | ' | $0.59 | [1] | $0.36 | $0.25 | $0.28 | ($0.14) | [2] | $0.26 | $0.29 | $0.20 | $1.47 | $0.61 | $0.07 | ' | |||
Cash dividends per common share | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.28 | $0.28 | ' | ' | |||||
Defined Benefit Plan, Recognized Net Gain (Loss) on Mark-to-Market | ' | ' | ' | ' | ' | 31,800,000 | ' | ' | ' | -17,600,000 | ' | 67,900,000 | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,731,000 | 74,153,000 | 3,006,000 | ' | |||||
Tax Adjustments, Settlements, and Unusual Provisions | ' | -9,200,000 | ' | ' | ' | ' | ' | ' | ' | -24,000,000 | ' | ' | ' | |||||
Tax provision related to repatriation of unremitted foreign earnings | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,700,000 | 65,800,000 | |||||
Unremitted earnings planned to be repatriated | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 350,000,000 | 250,000,000 | |||||
Gain (loss) on disposition of discontinued operations before income taxes | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,810,000 | 2,405,000 | 1,999,000 | ' | |||||
Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Quarterly Financial Data [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Operating income from continuing operations | ' | ' | ' | ' | ' | ' | ' | ' | ' | 146,100,000 | [3] | 59,196,000 | [3] | 89,725,000 | [3] | ' | ||
Illumination And Detection Solutions [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Gain (loss) on disposition of discontinued operations before income taxes | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,800,000 | ' | |||||
November 2011 Caliper Life Sciences [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Tax provision related to repatriation of unremitted foreign earnings | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 79,700,000 | ' | |||||
Customer Lists [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,700,000 | ' | ' | ' | |||||
Asset impairment | ' | 6,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Trade Names And Trademarks [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | 74,200,000 | ' | ' | ' | ' | ' | ' | ' | |||||
Asset impairment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,300,000 | ' | ' | |||||
Trade Names And Trademarks [Member] | Human Health [Member] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Diluted earnings per share: | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Impairment of Intangible Assets (Excluding Goodwill) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $73,400,000 | ' | ' | |||||
[1] | The fourth quarter of fiscal year 2013 includes pre-tax income of $17.6 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2013 also includes pre-tax impairment charges of $6.7 million as the carrying amounts of certain long-lived assets were not recoverable and exceeded their fair value. The fourth quarter of fiscal year 2013 also includes a tax benefit of $9.2 million related to discrete items primarily for lapses in statues of limitations and audit settlements. | |||||||||||||||||
[2] | The fourth quarter of fiscal year 2012 includes a pre-tax loss of $31.8 million as a result of the mark-to-market adjustment on postretirement benefit plans. See Note 1 for a discussion of this accounting policy. The fourth quarter of fiscal year 2012 also includes pre-tax impairment charges of $74.2 million as a result of a review of certain trade names within the Company's portfolio as part of a realignment of its marketing strategy. | |||||||||||||||||
[3] | Pre-tax impairment charges have been included in the Human Health and Environmental Health operating income from continuing operations. The Company recognized a $6.7 million pre-tax impairment charge in the Human Health segment in fiscal year 2013. The Company recognized $73.4 million of pre-tax impairment charges in the Human Health segment and also recognized $0.7 million of pre-tax impairment charges in the Environmental Health segment in fiscal year 2012. The Company recognized a $3.0 million pre-tax impairment charge in the Human Health segment in fiscal year 2011. |